Section |
Name |
Details |
06.04.01.01 |
Continuous combined HRT patch Evorel® Conti |
|
13.05.02 |
5-Methoxypsoralen 20mg tablets |
|
13.05.02 |
8-Methoxypsoralen 10mg tablets |
|
05.03.01 |
Abacavir |
|
05.03.01 |
Abacavir & Lamivudine |
|
05.03.01 |
Abacavir & Lamivudine & Dolutegravir |
|
05.03.01 |
Abacavir & Lamivudine & Zidovudine |
|
10.01.03 |
Abatacept Orencia® |
- Abatacept 250mg injection is approved for:
- Juvenile idiopathic arthritis in patients aged six years and above (licensed) and under six years. It should only be prescribed with informed consent.
- People aged 6 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to other DMARDs, including at least one tumour necrosis factor (TNF) inhibitor in accordance with NICE.
- Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
- Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
- Treatment of severe treatment-resistant morphoea in line with NHS England Clinical Commissioning Policy
- Treating modertae rheumatoid arthritis after conventional DMARDs have failed in line with NICE
- Treating idiopathic inflammatory myopathies in adults and children aged 2 and over in line with NHS England Commissioning Policy
- Abatacept 125mg SC injection (prefilled syringe) is approved for moderate to severe rheumatoid arthritis in accordance with NICE.
|
02.09 |
Abciximab |
|
08.03.04.01 |
Abemaciclib Verzenios® |
- 50mg, 100mg and 150mg tablets
- Approved as an options for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults in line with NICE
- Approved with fulvestrant for treating hormone receptor-positive, HER2 negative advanced breast cancer after endocrine therapy in line with NICE
|
09.06.07 |
Abidec® |
- Drops containing in each 0.6ml dose ascorbic acid 50mg, ergocalciferol
400 units, nicotinamide 5mg, pyridoxine HCL 500micrograms, riboflavin 400 micrograms, thiamine 1mg & vitamin A 1,333 units. To be used in children and adults.
|
08.03.04.02 |
Abiraterone |
- Approved for castration-resistant metastatic prostate cancer in line with NICE.
- Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy.
|
13.05.03 |
Abrocitinib Cibinqo® |
- Approved for the treatment of moderate to severe atopic dermatitis in line with NICE
|
14.04 |
Absorbed Diptheria Low Dose, Tetanus, and Poliomyelitis vaccine |
|
14.04 |
Absorbed Diptheria Low Dose, Tetanus, Pertussis and Poliomyelitis vaccine |
|
14.04 |
Absorbed Diptheria, Tetanus, Pertussis and Poliomyelitis vaccine |
|
08.01.05 |
Acalabrutinib Calquence® |
- 100mg capsules
- Approved for treating chronic lymphocytic leukaemia in adults in line with NICE
|
04.10.01 |
Acamprosate |
- COUNTY DURHAM
acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
|
06.01.02.03 |
Acarbose |
|
02.08.02 |
Acenocoumarol Sinthrome® |
|
04.08.01 |
Acetazolamide |
|
11.06 |
Acetazolamide |
- second line carbonic anhydrase inhibitor for glaucoma
|
12.01.01 |
Acetic Acid 2% spray Earcalm ® |
|
19 |
Acetic acid 5% |
- T o be diluted to 2.5%
- approved for the use in the detection of dysplasia/ neoplasia in Barrett’s oesophagus
|
11.08.02 |
Acetylcholine Chloride |
|
03.07 |
Acetylcysteine |
- 600mg effervescent tablets.
Green for licensed indications.
For use on specialist advice in the treatment of idiopathic pulmonary fibrosis.
- For the prevention of x-ray contrast media induced renal damage
.
|
16 |
Acetylcysteine 2gram in 10ml injection |
Paracetamol overdose
|
11.08.01 |
Acetylcysteine 5% eye drops and preservative free eye drops |
|
11.08.01 |
Acetylcysteine 5% with Hypromellose 0.35% Ilube |
Eye drops: acetylcysteine 5%, hypromellose 0.35% (Ilube®) |
05.03.02.01 |
Aciclovir |
- Tablets: 200mg, 400mg, 800mg
- Dispersible tablets: 200mg, 400mg, 800mg
- Oral suspension (sugar-free available): 200mg/5ml, 400mg/5ml
|
11.03.03 |
Aciclovir |
|
11.03.03 |
Aciclovir |
- 800mg Tablets
- For the treatment of ophthalmic zoster.
|
13.10.03 |
Aciclovir 5% cream |
|
05.03.02.01 |
Aciclovir Injection |
- Injection (for IV infusion): 250mg, 500mg
|
12.03.02 |
Aciclovir tablets and suspension |
see section 05.03.02 |
13.05.02 |
Acitretin Neotigason® |
|
03.01.02 |
Aclidinium Eklira Genuair® |
- 322 microgram/dose (equivalent to aclidinium bromide 375 microgram/dose) inhalation powder (DPI)
|
03.01.04 |
Aclidinium & formoterol Duaklir Genuair® |
- Aclidinium 340 microgram/dose & formoterol 12 microgram/dose (equivalent to aclidinium bromide 396 microgram/dose, formoterol fumarate dihydrate 11.8 microgram/dose) inhalation powder (DPI)
|
18.03.03 |
Acticoat® Flex 3 |
Conformable antimicrobial barrier dressing consisting of polyester core between low adherent silver-coated high density polyethylene mesh.
- Specialist initiation only
|
18.03.03 |
Acticoat® Flex 7 |
Conformable antimicrobial barrier dressing consisting of polyester core between low adherent silver-coated high density polyethylene mesh.
- Specialist initiation only
|
18.10 |
Acti-glide® |
|
13.08.01 |
Actikerall® |
|
18.09.01 |
Actilymph® |
|
18.03.03 |
Actisorb Silver 220 |
Knitted fabric of activated charcoal with one-way stretch, with silver residues, within spun-bound nylon sleeve |
18.06.01 |
ActiV.A.C.® |
|
18.09.01 |
Activa® hosiery |
|
16 |
Activated charcoal Actidose Aqua Advance®, Carbomix® |
- Actidose Aqua Advance® – 50g in 240ml suspension
- Carbomix® - 50g powder supplied in a bottle to which
water is added to prepare a suspension
|
18.02.05 |
ActivHeal Foam |
Polyurethane Foam Film Dressing without Adhesive Border |
18.02.06 |
ActivHeal® Alginate |
Calcium sodium alginate dressing |
18.02.06 |
ActivHeal® Aquafiber |
Non-woven, calcium sodium alginate dressing |
18.02.01 |
ActivHeal® Hydrogel |
|
18.08.02 |
Actiwrap® Latex-free Bandage |
Polyamide and Cellulose Contour Bandage, BP 1988
|
01.05.03 |
Adalimumab |
- Only approved for use in accordance with NICE guidance.
|
10.01.03 |
Adalimumab |
- Adalimumab is approved for:
- The treatment of adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE
- Rheumatoid arthritis after the failure of a TNF inhibitor in accordance with NICE.
- Treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
- Psoriatic arthritis in accordance with NICE.
- As a second-line anti-TNF therapy in children with juvenile idiopathic arthritis and uveitis.
- Children and adults aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose disease has responded inadequately to 1 or more DMARD in accordance with NICE.
- Treating moderate rheumatoid arhritis after conventional DMARDs have failed in line with NICE
|
11.04.02 |
Adalimumab |
- 40mg Injection
- Approved for the treatment of children with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
- Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy (replaces interim policy for adalimumab for adults with severe refractory uveitis from 24th October 2017)
|
13.05.03 |
Adalimumab |
- Approved for psoriasis in line with NICE.
- Approved for the treatment of moderate to severe hidradenitis suppurativa in line with NICE and NHS England Commissioning Policy
- Approved for the treatment of plaque psoriasis in children and young people in line with NICE
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of preferred biosimilar brand. |
13.06.01 |
Adapalene 0.1% gel and cream Differin® |
|
13.06.01 |
Adapalene and benzoyl peroxide Epiduo® Gel |
- adapalene 0.1%/benzoyl peroxide 2.5% & adapelene 0.3%/benzoyl peroxide 2.5%
|
18.02.03 |
Adaptic® Touch |
Non-adherent soft silicone wound Contact Dressing
|
16 |
Adder Snakebite Antiserum |
|
05.03.03.01 |
Adefovir Dipivoxil Hepsera® |
|
02.03.02 |
Adenosine |
- 6mg in 2ml injection
- 25mg in 5ml injection
unlicensed
- 30mg in 10ml injection for infusion - NHCT only
- 130mg in 130ml IV infusion
unlicensed
|
24.01 |
Adenosine injection 1 mg/1 mL, 100 mL, 120 mL, 130 mL |
|
02.07.03 |
Adrenaline (epinephrine) |
- 1 in 1,000 injections in 1ml syringes and 1ml & 10ml ampoules.
- 1 in 10,000 injections in 1ml & 10ml ampoules & syringes.
|
03.04.03 |
Adrenaline / Epinephrine Emerade® |
- Approved for use in the emergency treatment of anaphylaxis for patients with a BMI of >40 or who have required more than one auto-injector previously to control symptoms. Specialist immunologist initiation only
.
- Approved for use by NUTH Community Dental Team in anaphylaxis boxes
.
|
03.04.03 |
Adrenaline / Epinephrine Jext® & Jext Junior® |
|
03.01.05 |
AeroChamber Plus® |
|
03.01.05 |
AeroChamber® Flow-Vu |
|
08.01.05 |
Afatinib |
- Approved as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and they have not had an EGFR-TK inhibitor before NICE and additional NHS England criteria.
|
08.01.05 |
Aflibercept Zaltrap® |
|
11.08.02 |
Aflibercept Eylea® |
- 40mg/1ml & 114.3mg/1ml solution for injection
- Approved for wet age related macular degeneration in line with NICE.
- Approved for macular oedema – central retinal vein occlusion in line with NICE.
- Approved for diabetic macular oedema in line with NICE.
- Approved for treating visual impairment caused by macular oedema after branch retinal vein occlusion in line with NICE.
- Approved as an option for treating visual impairment because of myopic choroidal neovascularisation in adults in line with NICE
|
09.08.01 |
Agalsidase Alfa |
|
09.08.01 |
Agalsidase Beta |
|
04.03.04 |
Agomelatine |
- NETAG approved for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses (as described by NICE and as stated in the BNF).
- Prescribing and monitoring should be initiated by specialist mental health physicians.
- Transfer of prescribing to primary care at around 6 months / when LFT monitoring completed following dose increase
|
02.03.02 |
Ajmaline |
- For use as a diagnostic test of Brugada syndrome.
|
05.05.01 |
Albendazole |
|
16 |
Alcohol (Ethanol) |
|
13.11.01 |
Alcohol hand rub gel |
|
13.11.01 |
Alcohol impregnated wipes |
Containing 70% isopropyl alcohol or methylated spirit (e.g. Clini-wipes®, Alcowipes®) |
11.09 |
Alcon Optifree® Express System |
|
08.01.05 |
Alectinib Alecensa® |
- 150mg capsules
- Approved as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults in line with NICE
|
08.02.03 |
Alemtuzumab |
- Alemtuzumab 30mg in 1ml concentrate for IV infusion is approved for use in, lymphocytic leukaemia & prevention of graft vs. host disease in bone marrow transplant patients, and high-risk kidney and pancreas transplantation.
- Alemtuzumab 12mg in 1.2ml concentrate for IV infusion is approved for treating adults with active relapsing– remitting multiple sclerosis in line with NICE and NHS England commissioning policy.
|
06.06.02 |
Alendronic Acid |
- Approved alendronic acid formulations include:
- 10mg tablets (taken daily)
- 70mg tablets (taken once weekly) – preferred
- 70mg effervescent tablets (Binosto®) - for use only in patients with documented swallowing difficulties
- Alendronic acid is approved for the primary prevention of osteoporosis in postmenopausal women in line with NICE
- Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.
- Approved for the treatment of osteoporosis in line with NICE
|
09.06.04 |
Alfacalcidol |
- 250 nanogram & 1 microgram capsules
- 2 microgram/ml sugar-free oral drops – one drop containing approx. 100 nanograms of alfacalcidol
- 1 microgram in 0.5ml & 2 micrograms in 1ml injections
|
04.07.02 |
Alfentanil |
- Palliative care use
- 500micrograms in 1ml [ST&S], 1mg in 2ml, 5mg in 10ml & 5mg in 1ml injection ampouless - approved for initiation by specialists in palliative care
- All non-palliative care indications
![Red](images/TrafficLightsRedV2.gif)
|
15.01.04.03 |
Alfentanil |
- 500micrograms in 1ml [ST&S], 1mg in 2ml, 5mg in 10ml & 5mg in 1ml injection ampouless - approved for initiation by specialists in palliative care
|
15.01.04.03 |
Alfentanil |
- All non-palliative care indications
|
07.04.01 |
Alfuzosin 2.5mg tablets and 10mg XL tablets |
|
18.03.01 |
Algivon® |
Absorbent, non-adherent calcium alginate dressing impregnated with medical grade manuka honey
|
09.08.01 |
Alglucosidase Alfa Myozyme® |
|
03.04.01 |
Alimemazine |
- Hospital only for the following indications
- Enteral sedation in paediatric ITU setting
- Use in patients where promethazine has failed
- Existing patients can continue to be prescribed in primary care until a treatment review has taken place
|
15.01.04.01 |
Alimemazine |
- 30mg/5ml syrup.
- see section 03.04.01 for other formulations.
|
02.12 |
Alirocumab |
- Only approved for use in accordance with NICE guidance.
|
13.05.01 |
Alitretinoin Toctino® |
- Approved for adults with severe chronic hand eczema that have not responded to potent topical corticosteroids in line with NICE.
|
19 |
Alkaline Nasal Douche |
|
18.02.05 |
Allevyn® Adhesive |
Polyurethane Foam Film Dressing with Adhesive Border
|
18.02.03 |
Allevyn® Gentle |
Soft Polymer Wound Contact Dressing with Polyurethane Foam Film Backing
|
18.02.03 |
Allevyn® Gentle Border |
Silicone gel wound contact dressing, with polyurethane foam film backing
|
18.02.03 |
Allevyn® Gentle Border Lite |
Silicone gel wound contact dressing, with polyurethane foam film backing
|
18.02.03 |
Allevyn® Life |
Soft silicone wound contact dressing, with central mesh screen, polyurethane foam film backing and adhesive border
|
10.01.04 |
Allopurinol |
- An allopurinol 100mg in 5ml suspension (
unlicensed) is also approved for use.
|
10.01.04 |
Allopurinol |
- An allopurinol 100mg in 5ml suspension (
unlicensed) is also approved for use.
|
06.01.02.03 |
Alogliptin |
|
08.03.04.01 |
Alpelisib Piqray® |
- 50mg, 150mg and 200mg tablets
- Approved with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults in line with NICE
|
09.06.05 |
Alpha Tocopherol Vedrop® |
- 50mg in 1ml oral solution - approved for the treatrment of children with vitamin E deficiency due to fat malabsorption syndromes.
|
09.06.05 |
Alpha Tocopheryl Acetate |
- 500mg in 5ml suspension
- 134mg (200 unit) capsules
|
09.06.05 |
Alpha Tocopheryl Acetate Injection |
Injection: 100mg/2ml |
07.04.05 |
Alprostadil Vitaros® & Muse® |
- Vitaros® 3mg/g cream
- Muse® 500microgram, and 1mg.
Treatment with alprostadil cream (Vitaros®) is NOT approved for use in County Durham and Tees Valley |
07.04.05 |
Alprostadil Caverject® & Viridal Duo® |
- Approved as the second choice intracavernosal injection option.
- Caverject® 10 & 20 microgram injections (Caverject® dual chamber injections are easier to use and less expensive than the vials).
- Viridal Duo® 10, 20 and 40 microg starter pack and dual chamber injection (approved for use whilst supply issues surrounding Caverject® are ongoing).
- Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)
|
02.10.02 |
Alteplase |
- 10mg, 20mg, and 50mg injections.
- Also approved for stoke in accordance with NICE guidance.
- 2mg in 2ml injection - approved for unblocking intravenous lines, mainly in paediatric dialysis patients.
|
11.08.02.04 |
Alteplase intravitreal injection |
|
18.09.01 |
Altiform® Hosiery |
|
18.09.01 |
Altipress® |
|
13.12 |
Aluminimum Chloride Driclor®, Anhydrol Forte® |
- Aluminium chloride hexahydrate 20% solution in an alcoholic basis
|
04.09.01 |
Amantadine |
- For use on the advice of neurologists.
|
02.05.01 |
Ambrisentan |
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
|
05.01.04 |
Amikacin |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
- Approved for the treatment of non-tuberculous mycobacterial pulmonary diseases caused by Mycobacterium Avium Complex (MAC) that is refractory to current treatment options (adults and post pubescent children) in line with NHSE Specialised Commissioning Policy
![](images/NHSE.gif)
|
02.02.03 |
Amiloride Hydrochloride |
|
02.11 |
Aminocaproic acid |
- Approved for the use in paediatric patients undergoing extracorporeal membrane oxygenation (ECMO).
|
03.01.03 |
Aminophylline Injection |
- 250mg/10ml injection
- COPD: intravenous aminophylline of limited benefit.
- Injection used in hospital for acute asthma not responding to steroids and continuous inhaled bronchodilators.
- Plasma levels need to be checked before administration if patient has previously taken theophylline/ aminophylline.
|
02.03.02 |
Amiodarone |
- 100mg & 200mg tablets
![Amber](images/TrafficLightsAmberV2.gif)
- 50mg in 5ml suspension is also approved
unlicensed
- 150mg/3ml & 300mg/10ml injection
![Red Traffic Light](images/TrafficLightsRedV2.gif)
NHS England (June 2019) advises that prescribers should not initiate amiodarone in primary care for any new patient.
in exceptional circumstances, where there is a clinical need for amiodarone to be prescribed, this should be undertaken in a cooperation arrangement with a multi-disciplinary team and/or other healthcare professional. Amiodarone has an important place in the treatment of severe cardiac rhythm disorders where other treatments either cannot be used or have failed. It has potential major toxicity and its use requires monitoring both clinically and via laboratory testing.
MHRA Drug Safety Update (Mar 2022): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision |
04.02.01 |
Amisulpride |
|
04.03.01 |
Amitriptyline |
|
04.07.03 |
Amitriptyline |
|
04.07.04.02 |
Amitriptyline |
|
06.01.05 |
Amitriptyline |
|
07.04.02 |
Amitriptyline |
- 10mg, 25mg and 50mg tablets
- 25mg in 5ml sugar-free oral solution is also approved for use.
Green plus for the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products.Should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis
|
02.06.02 |
Amlodipine |
- Preferred calcium channel blocker for treating hypertension.
- If a 10mg dose is not tolerated e.g. due to leg/ankle
oedema, consider reducing dose before changing to an alternative such as lercanidipine.
|
05.01.01.03 |
Amoxicillin |
- 250mg, 500mg & 1g injections
![Red](images/TrafficLightsRedV2.gif)
|
05.02.03 |
Amphotericin |
- 50mg injection (Fungizone®)
- 50mg liposomal injection (Ambisome®)
|
11.03.02 |
Amphotericin B Preservative-free |
|
08.01.05 |
Amsacrine |
|
09.01.04 |
Anagrelide |
- For the treatment of thrombocythemiaas a 2nd line agent in patients poorly/non-responsive tohydroxycarbamide therapy.
|
10.01.03 |
Anakinra Kineret® |
- Approved for:
- Juvenile Idiopathic Arthritis (JIA) in line with NICE and NHS England Clinical Commissioning Policy: E03/P/d
- Periodic Fevers and Autoinflammatory conditions in line with NHS England Clinical Commissioning Policy: 170062P
- Adult‑onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older in line with NICE
- Cryopyrin Associated Periodic Syndrome in line with NHSE Service Specification.
- The treatment of severe gout in patients who have not responded to other treatment and for patients with pseudogout who have failed to respond to conventional treatment or unable to tolerate conventional treatment.
- Chronic Infantile Neurocutaneous Arthritis (CINCA) and Muckle-Wells Syndrome (
unlicensed indications).
- Islet cell transplantation as part of a protocol including alemtuzumab and etanercept to improve outcomes (i.e. insulin dependance)
- Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages
|
08.03.04.01 |
Anastrozole |
|
02.08.02 |
Andexanet alfa Ondexxya® |
- 200mg powder for solution for infusion
- Approved for reversing anticoagulation from apixaban and rivaroxaban in adults with life-threatening or uncontrolled bleeding in line with NICE
|
18.08.08 |
AndoFlex® TLC |
|
18.08.08 |
AndoFlex® UBZ |
|
05.02.04 |
Anidulafungin |
|
01.01.02 |
Antacid with oxetacaine |
- Used to relieve symptoms in patients who have had radiotherapy and may be of value in some patients with acute oesophagitis. Not for routine use as an antacid.
|
11.04.02 |
Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® |
|
13.08.01 |
Anthelios Sunscreen Lotion |
|
14.05.03 |
Anti-D (Rh0) Immunoglobulin Rhophylac® |
- Approved for the prevention of RhoD sensitisation in
women in line NICE.
- Approved for use by haematologists in appropriate patients with immune thrombo-cytopenia. The 1,500 and 5,000 unit vials (WinRho) are much more expensive than the other formulations and should only be used on advice from haematologists. It is the only formulation licensed for use in immune thrombocytopaenia.
|
14.05.03 |
Anti-D (Rh0) Immunoglobulin WinRho SDF® |
- Approved for the prevention of RhoD sensitisation in
women in line NICE.
- Approved for use by haematologists in appropriate patients with immune thrombo-cytopenia. The 1,500 and 5,000 unit vials (WinRho) are much more expensive than the other formulations and should only be used on advice from haematologists. It is the only formulation licensed for use in immune thrombocytopaenia.
|
02.11 |
Antithrombin III Kybernin® |
|
08.02.02 |
Antithymocyte immunoglobulin (horse) Thymoglobuline® |
- NETAG approved for aplastic anaemia in adults (
unlicensed).
|
08.02.02 |
Antithymocyte immunoglobulin (rabbit) Thymoglobuline® |
- Used in the management of transplant rejection.
|
01.07.01 |
Anusol ® |
- Cream and Suppositories
Self Care Medicine: Advise that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
|
01.07.02 |
Anusol®HC |
Self Care Medicine: Advise CCGs that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
- Topical corticosteroids are suitable for occasional short-term use (no more than 7 days) after exclusion of infections
|
08.03.04.02 |
Apalutamide Erleada® |
- 60mg tablets
- Approved for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults in line with NICE
- Approved for treating hormone-sensitive metastatic prostate cancer in adults in line with NICE, only if:
- docetaxel is not suitable
|
02.08.02 |
Apixaban |
- Only approved for use in accordance with NICE guidance.
|
04.09.01 |
Apomorphine |
- 5mg/1ml (20ml) solution for infusion for infusion pumps & 10mg/1ml (3ml) solution for injection cartridges (Dacepton®) - NEW PATIENTS
- 30mg/3ml solution for injection (APO-go®) - Patients commenced on treatment prior to July 2022 can continue on APO-go® (including 50mg/10ml solution for infusion pre-filled syringes for infusion pumps)
- Apomorphine 10mg lozenges are also approved (RVI)
Unlicensed
|
18.07.02 |
Appeel® Single Use Wipes |
|
11.08.02 |
Apraclonidine |
- 0.5% and 1% ophthalmic solution.
|
10.01.03 |
Apremilast Otezla® |
- Approved for the treatment of psoriatic arthritis in line with NICE
|
13.05.03 |
Apremilast Otezla® |
- 10mg, 20mg & 30mg tablets
- To be used in accordance with NICE guidance
|
04.06 |
Aprepitant |
- For the prevention of chemotherapy induced nausea and vomiting (CINV) in high risk patients in accordance with North of England Cancer Network: CINV Guidelines in adult oncology and haematology patients
|
02.11 |
Aprotinin |
- For limited use in cardiothoracic surgery.
|
A2.03.01 |
Aptamil |
|
18.03.03 |
Aquacel® Ag Extra |
|
18.02.04 |
Aquacel® Extra |
Soft sterile non-woven pad containing hydrocolloid fibres.
- Provides greater tensile strength compared to aquacel
|
18.02.04 |
Aquacel® Foam |
Soft non-woven pad containing hydrocolloid-fibres with foam layer, without adhesive border |
18.02.04 |
Aquacel® Foam Border |
Soft non-woven pad containing hydrocolloid-fibres with foam layer, with adhesive border |
18.02.04 |
Aquacel® Surgical cover dressing |
- Not to be prescribed on FP10
|
13.02.01 |
AquaGel lubricating jelly |
- Approved for the relief of dryness of the nose, lips and face when a patient is using oxygen via nasal prongs, CPAP masks etc
|
13.02.01 |
Aqueous Cream BP |
- Due to the SLS content to be used as a soap substitute only.
|
01.06.03 |
Arachis Oil |
|
02.08.01 |
Argatroban |
- For use on advice of haematologists in patients with heparin induced thrombocytopenia.
|
09.08.01 |
Arginine |
|
06.05.02 |
Argipressin 20units in 1ml injection |
|
04.02.01 |
Aripiprazole |
- Approved for schizophrenia in people aged 15 to 17 years in line with NICE.
- Approved for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder NICE.
- Aripriprazole 10mg & 15mg orodispersible tablets are approved for doses over 5mg for those patients who have difficulty swallowing.
- Aripiprazole 1mg in 1ml oral solution is only for doses of 5mg or less, or when titrating patients on doses of increments of less than 5mg, in patients who have difficulty swallowing tablets.
- To be used in accordance with NICE criteria.
- Note: Aripiprazole 7.5mg/ml IM Injection is approved for use in rapid tranquilisation in patients with acute psychosis.
NTW use only.
|
04.02.02 |
Aripiprazole Abilify Maintena® |
CNTW
TEWV
- Approved for the treatment of psychosis and schizophrenia in line with NICE guidance
|
08.01.05 |
Arsenic Trioxide |
- NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL).
|
05.04.01 |
Artesunate |
- Approved for severe malaria in in line WHO guidance.
|
15.02 |
Articaine Hydrochloride with Adrenaline |
- Articaine 4% & adrenaline 1 in 100,000 injection
- approved for mandibular procedures in patients in whom nerve blocks are contraindicated.
|
12.03.05 |
Artificial Saliva |
- Use cheapest
- Available products include
- AS Saliva Orthana®
- Biotene Oralbalance® gel
- BioXtra® Glandosane® spray
- Malic acid Salivix®
- Oralieve® Moisturising Spray & Gel
- Patients should be advised of self-care measures and signposted to purchase over the counter remedies where appropriate.
|
11.08.01 |
Artificial Tears Minims |
Hydroxyethylcellulose Artifical Tears Minims 4.4mg per mL Minims Eye Drops |
08.01.05 |
Asciminib Scemblix® |
- 20mg and 40mg tablets
- Approved as an option for treating chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia without a T315I mutation after 2 or more tyrosine kinase inhibitors in adults, in line with NICE
|
09.06.03 |
Ascorbic Acid Vitamin C |
- 50mg, 100mg, 200mg & 500mg tabs
- 500mg in 5ml injection
unlicensed
|
11.08.02.04 |
Ascorbic acid 10% Preservative-free eye drops |
|
09.08.01 |
Asfotase alfa Strensiq® |
- 40mg/ml & 100mg/ml solution for injection
- Approved for the treatment of paediatric-onset and juvenile-onset hypophosphatasia in line with NICE and NHS England Commissioning Policy
|
18.03.03 |
Askina® Calgitrol 15g Paste |
|
02.09 |
Aspirin |
- 75mg dispersible tablets
- Note: 75mg e/c tablets – no longer recommended for use.
|
04.07.01 |
Aspirin |
|
04.07.04.01 |
Aspirin |
|
07.01.04 |
Aspirin |
- Dispersible tablets: 75mg
|
02.09 |
Aspirin 500mg in 5ml injection |
- For specialist use in the endovascular treatment of cerebral
aneurysms
|
10.02.01 |
Ataluren Translarna® |
- Approved as an option for treating Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene in people 2 years and over who can walk - in line with NICE HST22.
|
05.03.01 |
Atazanavir |
- For limited use as part of triple therapy where other protease inhibitors are unsuitable
|
05.03.01 |
Atazanavir sulfate and cobicistat |
To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614). |
02.03.02 |
Atenolol |
|
02.04 |
Atenolol |
|
02.04 |
Atenolol Injection |
|
08.01.05 |
Atezolizumab |
- 840mg/14ml & 1200mg/20m concentrate for solution for infusion (IV)
- 1875mg/15ml solution for injection (S/C)
- Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour).
- Approved in combination with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE
- Approved for the treatment of advanced non-small-cell lung cancer in line with NICE
- Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
- Approved for for adjuvant treatment of resected non-small-cell lung cancer in adults in line with NICE
- Approved with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults in line with NICE
- Approved with nab‑paclitaxel for triple-negative, unresectable, PD‑L1‑positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
- Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
|
19 |
Atidarsagene autotemcel Libmeldy® |
- Atidarsagene autotemcel is recommended, within its marketing authorisation, as an option for treating metachromatic leukodystrophy with mutations in the arylsulphatase A (ARSA) gene:
- for children who have late infantile or early juvenile types, with no clinical signs or symptoms
- for children who have the early juvenile type, with early clinical signs or symptoms, and who can still walk independently and have no cognitive decline.
|
04.04 |
Atomoxetine |
- 10mg, 18mg, 25mg, 40mg, 60mg, 80mg & 100mg capsules
- 4mg/1ml oral solution - approved for patients with more complex needs e.g. younger patients and those with swallowing difficulties.
|
02.12 |
Atorvastatin |
- 10mg, 20mg, 40mg & 80mg tablets
|
02.12 |
Atorvastatin Chewable |
- 10mg and 20mg chewable tablets
- Note: atorvastatin 10mg and 20mg chewable tablets should be used instead of simvastatin suspension where solid dosage forms cannot be used.
|
07.01.03 |
Atosiban |
- Approved formulations include:
- 6.75mg in 0.9ml injection
- 37.5mg in 5ml (7.5mg/ml) concentrate for IV infusion.
|
05.04.08 |
Atovaquone |
- Approved for use in patients intolerant of co-trimoxazole
|
15.01.05 |
Atracurium |
- 25mg in 2.5ml
- 50mg in 5ml
- 250mg in 25ml injection
|
18.01.01 |
Atrauman |
|
01.02 |
Atropine |
- 500microgram in 5ml mixture (
unlicensed).
|
15.01.03 |
Atropine 600microgram injection |
|
15.01.03 |
Atropine pre-filled syringes minijet® |
- 1mg in 5ml and 3mg in 30ml injections in prefilled syringes used in cardiac resuscitation.
|
16 |
Atropine sulphate |
|
11.05 |
Atropine Sulphate Single Use Minims® |
|
10.01.05 |
Autologous chondrocyte implantation |
Commissioning: NHS England
Overview | Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | Guidance | NICE |
10.01.05 |
Avacopan Tavneos® |
- an option for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults - in line with NICE TA825
|
09.08.01 |
Avalglucosidase alfa Nexviadyme® |
- 100mg powder for concentrate for solution for infusion
- Approved for treating Pompe disease in line with NICE
|
09.01.04 |
Avatrombopag Doptelet® |
- Approved for the treatment of severe thrombocytopenia in people with chronic liver disease needing a planned invasive procedure in line with NICE
- Approved for treating primary chronic immune thrombocytopenia in adults in line with NICE
|
13.02.01 |
Aveeno® Cream |
|
08.02.03 |
Avelumab Bavencio® |
- Approved for for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults in line with NICE
- as an option for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease in line with NICE
|
07.04.05 |
Aviptadil 25microgram/phentolamine 2mg solution for injection Invicorp® |
- 25microgram/phentolamine 2mg solution for injection.
- Approved as first choice intracavernosal injection option.
- Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)
|
08.01.05 |
Axicabtagene ciloleucel |
- 0.4 – 2 × 108 cells dispersion for infusion
|
08.01.05 |
Axitinib Inlyta® |
- Approved as treatment for adults with advanced renal cell carcinoma when tyrosine kinase inhibitors or cytokines have not worked in line with NICE.
|
08.01.03 |
Azacitidine |
- Approved for myelodysplastic syndromes, CLL and AML - in line with NICE guidance.
|
01.05.03 |
Azathioprine |
|
08.02.01 |
Azathioprine |
- For Transplant indications
unless from a Trust/speciality that hasn't formaly repatriated it's patients or for patients who require weekly scripts for MDS boxes .
- An azathioprine 50mg in 5ml suspension (
unlicensed) is also available.
|
10.01.03 |
Azathioprine |
|
13.06.01 |
Azelaic Acid |
- 15% (Finacea®) and 20% (Skinoren®) gel
|
12.02.01 |
Azelastine and fluticasone Dymista® |
|
12.02.01 |
Azelastine Hydrochloride 140microgram nasal spray Rhinolast® |
|
11.03.01 |
Azithromycin Azyter® |
|
05.01.05 |
Azithromycin Injection |
- 500mg powder vial for infusion
|
05.01.05 |
Azithromycin Oral Preparations |
- Tablets: 250mg, 500mg
- Capsules: 250mg
- Oral suspension: 200mg/5ml
|
05.01.02.03 |
Aztreonam |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
05.01.02.03 |
Aztreonam nebuliser solution Cayston® |
- To be used in accordance with NHS England Commissioning Policy
|
10.02.02 |
Baclofen |
- The following baclofen intrachecal injections (
unlicensed) are also approved; 36mg in 12ml, and 72mg in 12ml intrathecal injections.![Red Traffic Light](images/TrafficLightsRedV2.gif)
|
19 |
Baclofen Intrathecal |
|
11.08.01 |
Balanced Salt Solution |
- Sterile solution containing sodium chloride 0.64%, sodium acetate 0.39%, sodium citrate 0.17%, calcium chloride 0.048%, magnesium chloride 0.03%, potassium chloride 0.075% in 15ml bottles and 500ml bags.
- For intra-ocular or topical irrigation during surgical procedures.
|
13.02.01 |
Balneum® Plus cream |
|
01.05.01 |
Balsalazide Sodium |
Alternatives |
10.01.03 |
Baricitinib Olumiant® |
- Approved for the treatment of moderate to severe rheumatoid arthritis in adults in line with NICE.
- Approved for use in monogenic interferonopathis in adults and children 2 years and over in line with NHS England Clinical Commissioning Policy.
|
13.05.03 |
Baricitinib Olumiant® |
- Approved for treating moderate to severe atopic dermatitis in adults in line with NICE.
|
17 |
Barium sulfate E-Z-HD® |
|
17 |
Barium sulfate Polibar® |
|
13.02.02 |
Barrier preparation Cavilon®Film |
|
08.02.02 |
Basiliximab |
- Approved for limited use in adult renal transplant patients with high risk of acute organ rejection.
- Approved for severe graft versus host disease post haematopoietic stem cell transplantation.
- Approved for induction therapy in renal transplantation in children and adolescents in with combinations that include ciclosporin in line with NICE.
|
11.09 |
Bausch & Lomb contact lens solution Boston® |
|
11.09 |
Bausch & Lomb saline Salette® |
|
08.02.04 |
BCG 81mg vial (connaught) |
|
14.04 |
BCG vaccine |
(BCG Vaccine, Dried/Tub/BCG) 1ml multidose vials containing freeze dried powder for preparing intradermal injections |
03.02 |
Beclometasone Qvar® |
- QVAR® CFC-free MDI: 50mcg, 100mcg per puff
- QVAR® breath-actuated MDI: 50mcg, 100mcg per puff
- N.B. CFC-free beclometasone must be prescribed by brand name.
- 50mcg QVAR is equivalent to 100mcg for a conventional beclometasone inhaler and 100mcg is equivalent to 250mcg conventional beclometasone.
|
03.02.03 |
Beclometasone and formoterol Fostair® |
- Beclomethasone dipropionate 100 microgram/dose & formoterol 6 microgram/dose pressurised metered dose inhaler (pMDI)
- Beclomethasone dipropionate 200 microgram/dose & formoterol 6 microgram/dose pressurised metered dose inhaler (pMDI)
|
03.02.03 |
Beclometasone and formoterol Fostair NEXThaler® |
- Beclomethasone 100 microgram/dose & formoterol 6 microgram/dose dry powder inhaler (DPI)
- Beclomethasone 200 microgram/dose & formoterol 6 microgram/dose dry powder inhaler (DPI)
|
03.02.03 |
Beclometasone and formoterol Luforbec® |
- Beclomethasone dipropionate 100 microgram/dose & formoterol 6 microgram/dose pressurised metered dose inhaler (pMDI)
- Additional treatment option
|
03.02 |
Beclometasone dipropionate Clenil Modulite® |
- 50 / 100 / 200 / 250 microgram/dose pressurised metered dose inhaler (pMDI) - Clenil Modulite®
|
12.02.01 |
Beclometasone Dipropionate 50 microgram nasal spray |
|
03.02.03 |
Beclometasone, formoterol & glycopyrronium Trimbow® |
- Beclometasone 87 microgram/dose, formoterol 5 microgram/dose & glycopyrronium 9 microgram/dose pressurised metered dose inhaler (pMDI)
- Beclometasone 172 microgram/dose, formoterol 5 microgram/dose & glycopyrronium 9 microgram/dose pressurised metered dose inhaler (pMDI)
|
03.02.03 |
Beclomethasone, formoterol & glycopyrronium Trimbow NEXThaler® |
- Beclomethasone 88 microgram/dose, formoterol 5 microgram/dose & glycopyrronium 9 microgram/dose dry powder inhaler (DPI)
|
05.01.09 |
Bedaquiline |
- To be used in accordance with NHS England Commissioning Policy
|
03.04.02 |
Bee and Wasp Allergen Extracts Pharmalgen® |
- For use in adults and children by adult and paediatric immunologists only. Only approved for use in accordance with NICE guidance.
|
10.01 |
Belimumab |
Approved for the treatment of active autoantibody-positive systemic lupus erythematosus in line with NICE. |
10.01.03 |
Belimumab Benlysta® |
- Approved for treating active autoantibody-positive systemic lupus erythematosus in line with NICE
|
08.02.02 |
Belumosudil Rezurock® |
- 200mg tablets
- Approved for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments in line with NICE
|
02.12 |
Bempedoic acid Nilemdo® |
- 180mg tablets
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults in line with NICE and following the statin intensification pathway outlined in NEELI
|
02.12 |
Bempedoic acid with ezetimibe Nustendi® |
- Bempedoic acid 180mg & ezetimibe 10mg tablets
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults in line with NICE and following the statin intensification pathway outlined in NEELI
|
08.01.01 |
Bendamustine |
- Approved for the first line treatment of CLL (Binet stage B or C) in, patients for whom fludarabine combination chemotherapy is not appropriate in line with NICE.
- NECDAG approved for use in combination with rituximab for patients with CLL not fit for FCR chemotherapy and not fit for alemtuzumab.
- Approved for Low Grade Non-Hodgkins Lymphoma in line with NICE - not recommended for (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen NICE.
|
02.02.01 |
Bendroflumethiazide 2.5mg tablets |
- Current patients should continue on bendroflumethiazide
- Bendroflumethiazide 5mg tablets are available but not recommended for general use.
|
04.02.01 |
Benperidol |
- Approved for the control of deviant antisocial sexual behaviour
|
03.04.02 |
Benralizumab Fasenra® |
- 30mg/1ml solution for injection (pre-filled devices)
- Approved for treating severe eosinophilic asthma in adults in line with NICE and NHS England Commissioning Policy.
|
10.01.04 |
Benzbromarone |
Tablets: 100mg
Special order product |
13.06.01 |
Benzoyl Peroxide 5% Gel Acnecide® |
|
13.06.01 |
Benzoyl Peroxide 5% with Clindamycin 1% Duac® |
|
12.03.01 |
Benzydamine Mouthwash & Spray Difflam® |
|
05.01.01.01 |
Benzylpenicillin |
|
11.03.01 |
Benzylpenicillin 0.3% Eye drops |
|
05.01.01.01 |
Benzylpenicillin Benzathine |
|
03.05.02 |
Beractant Survanta® |
- 25mg/ml suspension for intratracheal administration
|
02.11 |
Beriplex - P/N® |
- Approved for reversing the effects of oral anticoagulants in patients with life or limb threatening bleeding in accordance with a regional protocol.
|
03.04.03 |
Berotralstat Orladeyo® |
- 150mg capsule
- Approved for preventing recurrent attacks of hereditary angioedema in people 12 years and older in line with NICE
|
04.06 |
Betahistine Dihydrochloride |
|
09.08.01 |
Betaine |
|
07.01.04 |
Betamethasone |
|
12.03.01 |
Betamethasone |
- Soluble tablets 500 micrograms
- Used as mouth gargle
|
13.04.01 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 2% Diprosalic® |
|
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic® |
|
13.04 |
Betamethasone (as Valerate) 0.025% Betnovate-RD® |
|
13.04 |
Betamethasone (as Valerate) 0.1% |
- Cream, ointment & scalp application
|
13.04 |
Betamethasone (as Valerate) 0.1% with Clioquinol 3% Betnovate C® |
|
13.04 |
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® |
|
13.04 |
Betamethasone (as valerate) medicated plasters Betesil® |
- 2.25mg medicated plasters
|
13.09 |
Betamethasone 0.05%, salicylic acid 2% Diprosalic ® |
|
12.01.01 |
Betamethasone 0.1% Betnovate® Scalp Application |
unlicensed
|
13.09 |
Betamethasone 0.1% |
|
12.01.01 |
Betamethasone 0.1% ear/eye/nose drops |
- First choice corticosteroid ear drops.
|
11.04.01 |
Betamethasone 0.1% eye drops |
|
12.02.01 |
Betamethasone 0.1% eye/ear/nose drops |
|
12.01.01 |
Betamethasone 0.1% with neomycin 0.5% ear drops Betnesol N® |
- Alternative choice compound antibacterial/corticosteroid ear drop.
|
11.04.01 |
Betamethasone 0.1% with Neomycin 0.5% eye drops |
|
06.03.02 |
Betamethasone 4mg in 1ml |
|
12.02.01 |
Betamethasone Sodium Phosphate 0.1% eye/ear/nose drops |
|
08.01.05 |
Bevacizumab Avastin® |
|
11.08.02 |
Bevacizumab 1.25mg/0.5ml intravitreal injection |
- NETAG approved for use in the management of macular oedema
secondary to retinal vein occlusion. This is considered a more cost effective treatment option in RVO compared with ranibizumab.
- NTAG approved for age related macular degeneration.
|
08.01.05 |
Bexarotene Targretin® |
|
02.12 |
Bezafibrate |
|
18.02.03 |
Biatain® Silicone |
Silicone gel wound contact dressing, with polyurethane foam film backing
|
18.02.03 |
Biatain® Silicone Lite |
Silicone gel wound contact dressing, with polyurethane foam film backing
|
08.03.04.02 |
Bicalutamide |
Initiate with specialist advice. |
11.06 |
Bimatoprost eye drops |
|
11.06 |
Bimatoprost with Timolol eye drops |
- For use as a second/third-line agent in patients insufficiently responsive
to monotherapy with a prostaglandin analogue or beta blocker
|
10.01.03 |
Bimekizumab Bimzelx® |
- 160mg/1ml solution for injection - pre-filled pen and syringes
- Approved for the treatment of active psoriatic arthritis in line with NICE
- Approved fofr the treatment of axial spondyloartritis in line with NICE
|
13.05.03 |
Bimekizumab Bimzelx® |
- 160mg/ml solution pre-filled pen/syringe
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
19 |
BioGaia® |
|
19 |
Biotin 5mg tablets |
|
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
- Approved NovoMix® 30 formulations include:
- 5x3ml cartridges (for use with Novopen® and Novopen® Penmate injection devices)
- 5x3ml Flexpen® pens.
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix 25 amd Mix 50 |
- Approved formulations of Humalog® Mix 25 and Mix 50 include:
- 5x3ml cartridges
- 5x3ml Kwikpen®
|
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
- Approved Humulin®M3 formulations include:
- 10ml vials;
- 5x3ml cartridges;
- 5x3ml pens.
|
01.06.02 |
Bisacodyl |
|
19 |
Bisacodyl 0.274% rectal soln |
|
12.02.03 |
Bismuth Subnitrate and Iodoform (B.I.P.P.) |
1.25cm x 100cm & 2.5cm x 100cm impregnated gauze |
13.10.05 |
Bismuth Subnitrate and Iodoform (B.I.P.P.) Paste |
- For use in ENT surgery & epistaxis
1.25cm x 100cm & 2.5cm x 100cm impregnated gauze
|
02.04 |
Bisoprolol |
- 5mg & 10mg tablets.
- 1.25mg, 2.5mg, 3.75mg & 7.5mg tablets - for use in the treatment of heart failure only. The 5mg and 10mg tablets should be used where possible - cheaper than other strengths.
|
02.08.01 |
Bivalirudin |
- Approved for preventing thrombosis in patients undergoing percutaneous coronary artery interventions.
- For use instead of abciximab in some low risk patients.
- Approved in combination with aspirin and clopidogrel for the treatment of adults with ST segment elevation MI undergoing percutaneous coronary intervention, in accordance with NICE guidance.
|
08.01.02 |
Bleomycin |
- Also approved for use in intralesional sclerotherapy in the treatment of low-flow vascular lesions.
unlicensed indication
|
08.02 |
Blinatumomab Blincyto® |
- Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NICE and NHS England Commissioning Policy.
- Approved for the treatment of acute lymphoblastic leukaemia in remission with minimal residual disease activity in line with NICE
- Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm
|
13.11.06 |
Bonney's Blue Paint |
- For limited use in some operating theatres only.
|
12.02.03 |
Boric Acid & Povidone Iodine |
|
12.01.01 |
Boric acid (insufflation) |
|
08.01.05 |
Bortezomib |
- Approved for:
- Relapsed multiple myeloma in line with in line with NICE.
- Combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE.
- Induction therapy for multiple myeloma in line with NICE.
- Treatment of adults with mantle cell lymphoma that has not been treated before, if haemotopoietic stem cell transplantation is not suitable, in line with NICE.
|
02.05.01 |
Bosentan |
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
- Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
|
08.01.05 |
Bosutinib Bosulif® |
- Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatanib are not appropriate in line with NICE.
|
01.10 |
Botulinum A toxin |
- Approved for use in the repair of complex hernia
|
01.07.04 |
Botulinum toxin type A |
- Approved for use by specialists as an alternative to surgery in patients failing other treatments. Also approved for use in paediatrics but there must be documented informed consent from patients/carers.
|
04.07.04.02 |
Botulinum Toxin Type A |
- Only approved for use in accordance with NICE guidance.
|
04.09.03 |
Botulinum Toxin Type A Botox® |
- Botox also approved for use in paediatric patients with severe bladder over- activity and neuropathic bladder who have not responded to other treatment.
- Prescribe by brand name.
|
04.09.03 |
Botulinum Toxin Type A Vistabel® |
- Restricted to use in private patients receiving aesthetic treatment.
- Prescribe by brand name.
|
04.09.03 |
Botulinum Toxin Type A Dysport® |
|
13.12 |
Botulinum toxin type A |
|
04.09.03 |
Botulinum Toxin Type A injection Xeomin ® |
- 50, 100 & 200 unit powder for solution for injection
- Approved for the treatment of chronic sialorrhoea in line with NICE
- Similar potency to Botox®, and may be less expensive (depending on price agreements/ contracts), but not licensed for the full range of indications.
- Prescribe by brand name.
|
04.09.03 |
Botulinum Toxin Type B NeuroBloc® |
|
14.04 |
Botulism antitoxin |
1 vial of Botulism antitoxin trivalent (equine) A B& E 5000 units injection |
08.01.05 |
Brentuximab vedotin Adcetris® |
- 50mg powder for concentrate for solution for infusion
- Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
- Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
- if they have already had autologous stem cell transplant
- if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable.
![CDF](images/CDF.gif)
- Approved for the treatment of CD30-positive cutaneous T-cell lymphoma in line with NICE
- Approved in combination with cyclophosphamide, doxorubicin and prednisone for untreated systmic anaplastic large cell lymphoma in adults in line with NICE
|
08.01.05 |
Brexucabtagene autoleucel Tecartus® |
- 0.4 – 2 × 108 cells dispersion for infusion
|
08.01.05 |
Brigatinib Alunbrig® |
- Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE.
- Approved for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in line with NICE
|
13.06.01 |
Brimonidine Tartate 0.33% gel Mirvaso® |
- For specialist initiation for the treatment of severe rosacea. Following specialist review of effectiveness, primary care can continue supply.
|
11.06 |
Brimonidine Tartrate 0.2% eye drops |
|
11.06 |
Brinzolamide |
|
11.06 |
Brinzolamide 1% with Timolol 0.5% Azarga® |
|
11.06 |
Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza® |
- Approved as a third line agent as an “add-on” in patients at the very end of medical management.
|
04.08.01 |
Brivaracetam |
- Approved for use as adjunctive therapy in patients with severe/intractable partial onset seizures e.g. a sezuire frequency of 1 per week following failure of first-line adjunctive therapy. Response must be assessed within 3-6 months before transferring prescribing to primary or stopping treatment, as appropriate.
|
13.05.03 |
Brodalumab Kyntheum® |
- 210mg/1.5ml solution for injection in pre-filled syringes.
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
11.08.02 |
Brolucizumab Beovu® |
- 19.8mg/0.165mL solution for injection (pre-filled syringes)
- Approved for treating wet age-related macular degeneration in adults in line with NICE
|
04.09.01 |
Bromocriptine |
|
06.07.01 |
Bromocriptine 2.5mg tablets |
|
01.05.02 |
Budesonide |
- Alternative
- Budenofalk® (3mg capsules enclosing e/c pellets)
- Entocort® (3mg capsules enclosing e/c m/r pellets)
- For use on consultant gastroenterologist advice only
- Oral Viscous Budesonide
unlicensed
- For the treatment of eosinophilic oesophagitis.
- 0.5mg or 1mg nebule is added to 13ml of syrup and this is then mixed and swallowed.
- Orodispersible tablet (Jorveza®)
- For the treatment of eosinophilic oesophagitis in adults in line with NICE
![Red](../images/TrafficLightsRedV2.gif)
- Approved for the maintenance of eosinophilic oesophagitis in line with NTAG
- 9mg MR tablet (Cortiment®)
- For induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.
- 8 week course to be provided by secondary care.
- 4mg modified-release capsules (Kinpeygo®)
- Approved for treating primary IgA nephropathy in line with NICE
|
01.05.02 |
Budesonide |
- 2mg foam enema
- Equal first choice with hydrocortisone foam enema
|
03.02 |
Budesonide |
- 100 microgram/dose dry powder inhaler - Easyhaler® (DPI)
- 100 microgram/dose dry powder inhaler - Turbohaler® (DPI)
- 500 microgram/2ml & 1mg/2ml nebuliser liquid
|
03.02.03 |
Budesonide and formoterol DuoResp Spiromax® |
- Budesonide 160 microgram/dose & formoterol 4.5 microgram/dose (equivalent to budesonide 200 microgram/dose & formoterol fumarate dihydrate 6 microgram/dose) dry powder inhaler (DPI)
- Budesonide 320 microgram/dose & formoterol 9 microgram/dose (equivalent to budesonide 400 microgram/dose & formoterol fumarate dihydrate 12 microgram/dose) dry powder inhaler (DPI)
|
03.02.03 |
Budesonide and formoterol Symbicort Turbohaler® |
- Budesonide 200 microgram/dose & formoterol 6 microgram/dose inhalation powder (DPI)
- Budesonide 400 microgram/dose & formoterol 12 microgram/dose inhalation powder (DPI)
|
03.02.03 |
Budesonide and formoterol Fobumix® |
- Budesonide 80 microgram/dose & formoterol 4.5 microgram/dose (equivalent to budesonide 100 microgram/dose & formoterol fumarate dihydrate 6 microgram/dose) dry powder inhaler - Easyhaler (DPI)
- Budesonide 160 microgram/dose & formoterol 4.5 microgram/dose (equivalent to budesonide 200 microgram/dose & formoterol fumarate dihydrate 6 microgram/dose) dry powder inhaler - Easyhaler (DPI)
- Budesonide 320 microgram/dose & formoterol 9 microgram/dose (equivalent to budesonide 400 microgram/dose & formoterol fumarate dihydrate 12 microgram/dose) dry powder inhaler - Easyhaler (DPI)
|
03.02.03 |
Budesonide, formoterol & glycopyrronium Trixeo Aerosphere® |
- Formoterol 5 microgram/dose, glycopyrronium 7.2 microgram/dose & budesonide 160 microgram/dose pressurised metered dose inhaler (pMDI)
|
05.03.03.02 |
Bulevirtide Hepcludex® |
- 2mg powder for solution for injection
- Approved as an option for treating chronic hepatitis D in adults with compensated liver disease in line with NICE and NHSE Specialised Commissioning Policy only if:
- there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above) and
- their hepatitis has not responded to peginterferon alfa‑2a (PEG‑IFN) or they cannot have interferon-based therapy
- Only available from:
- The Newcastle Upon Tyne Hospitals NHS Foundation trust
|
02.02.02 |
Bumetanide |
|
15.02 |
Bupivacaine Hydrochloride |
- 0.25% & 0.5% injection 10ml
- 0.25% & 0.5% + adrenaline 1 in 200,000 inj. 10ml
- 0.5% in glucose 8% injection (Marcain Heavy)
- 0.1% & 0.125%
unlicensed in sodium chloride 0.9% infusions
|
04.07.02 |
Buprenorphine |
- 200microgram sublingual tablets
- 300microgram in 1ml injection
- Buprenorphine patches (Preferred brand - Butec®) are approved for use in palliative care when fentanyl 12 microgram/hr transdermal patches exceed the patient’s analgesic requirements.
|
04.10.03 |
Buprenorphine Buvidal® |
- 8mg/0.16ml 16mg/0.32ml, 24mg/0.48ml, 32mg/0.64ml, 64mg/0.18ml, 96mg/0.27ml, 128mg/0.36ml 160mg/0.45ml prolonged-release solution for injection (pre-filled syringes).
- Approved for the treatment of opioid dependance in adults and adolescents aged 16 years and over, by substance misuse service providers, in line with NTAG and RMOC guidance.
|
04.10.03 |
Buprenorphine 400 microgram, 2mg, and 4mg sublingual tablets |
- Only approved for use in accordance with NICE guidance.
- In the treatment of substance misuse the 400microgram strength should be prescribed as Subutex® to avoid a product licensed for pain relief being supplied
|
04.10.03 |
Buprenorphine and Naloxone Suboxone® |
|
04.10.02 |
Bupropion Hydrochloride |
- For smoking cessation - RAG status as per local commissioning arrangements
- Resistant depression
![Green plus](images/TrafficLightsGreenPlus.gif)
- MHRA Drug Safety Update (Nov 2020): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs
|
06.06.02 |
Burosumab Crysvita® |
- 10mg, 20mg & 30mg solution for injection
- Approved for treating X-linked hypophosphataemia in children and young people in accordance with NICE
|
08.03.04.02 |
Buserelin |
- Approved formulations include:
- 5mg in 5ml injection;
- 150 microgram metered dose nasal spray.
|
06.04.04 |
Buserelin 150microgram Nasal Spray Suprecur® |
- 150 micrograms per spray; 268 dose spray
|
06.07.02 |
Buserelin 150microgram nasal spray |
|
04.01.02 |
Buspirone Hydrochloride |
|
08.01.01 |
Busulfan |
- Approved formulations include:
- 2mg tablets;
- 25mg capsules (
unlicensed);
- 60mg in 10ml injection.
|
03.04.03 |
C1 Esterase Inhibitor |
- Approvded for the treatment and pre-procedure prevention of angioedema attacks in patients with hereditary angioedema (HAE).
- Approvded for the routine prevention of angioedema attacks in adults and adolescents years old with severe and recurrent attacks of HAE.
|
08.01.05 |
Cabazitaxel |
- Approved for the treatment of hormone relapsed metastatic prostate cancer treated with with docetaxel in line with NICE.
|
04.09.01 |
Cabergoline |
|
06.07.01 |
Cabergoline 500microgram and 1mg tablets |
|
05.03.01 |
Cabotegravir Vocabria® |
- 30mg tablet
- 600mg/3ml prolonged-release suspension for injection
- Approved in combination with rilpivirine (Rekambys) for treating HIV-1 in adults in line with NICE
|
08.01.05 |
Cabozantinib Cometriq® |
- Approved for use in the treatment of renal cell carcinoma in line with NICE and NHS England Commissioning Policy
- Approved for the treatment of medullary thyroid cancer in line with NICE and NHS England Commissioning Policy
- Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy
|
03.05.01 |
Caffeine Citrate |
- 50mg in 5ml injection (equivalent to 25mg caffeine base in 5ml).
- 50mg in 5ml oral solution.
|
13.05.02 |
Calcipotriol 50mcg/g Dovonex® |
- 0.005% Cream and ointment
- 0.005% scalp application
|
13.09 |
Calcipotriol 50micrograms in 1ml |
|
13.05.02 |
Calcipotriol with Betamethasone |
- Calcipotriol 50mcg/1g and betamethasone (as betamethasone dipropionate) 500mcg/1g
- Gel and ointment (Dovobet®)
- approved for the treatment of scalp and mild to moderate non scalp plaque psoriasis vulgaris in adults.
- 60g cutaneous spray (Enstilar®)
- Approved for the treatment of plaque psoriasis
- Cream (Wynzora®)
|
09.05.01.02 |
Calcitonin Salmon® |
- 400 units in 2ml injection
|
06.06.01 |
Calcitonin 400units in 2ml |
|
09.06.04 |
Calcitriol |
Capsules: 0.25 micrograms, 0.5 micrograms |
16 |
Calcium chloride |
|
09.05.02.02 |
Calcium Acetate Phosex®, Renacet® |
- Phosex® 1g tablets (containing 250mg, 6.2mmol of calcium)
- Renacet® 475mg (containing 120.25mg, 3mmol of calcium) &
950mg tablets (containing 240.5mg, 6mmol of calcium)
|
09.06.04 |
Calcium and Ergocalciferol Tablets |
- Calcium lactate 300mg, calcium phosphate 150mg (Ca 97mg, 2.4 mmol) & ergocalciferol 10 micrograms (400 units).
|
09.05.01.01 |
Calcium Carbonate |
- 1.25g chewable tablets (500mg, 12.6 mmol calcium).
- 2.5g chewable tablets (1g, 25 mmol calcium).
- 500mg in 5ml suspension
unlicensed.
|
09.05.02.02 |
Calcium Carbonate |
- 1.25g & 2.5g chewable tablets (Calcichew)
(Other formulations e.g. Remegel, Rennies, Rennie Soft gel and Settler’s. Tums are also stocked at the RVI for use in paediatric renal patients)
|
09.06.04 |
Calcium Carbonate and Colecalciferol |
- Accrete®
- Film coated tablet containing calcium carbonate 1.5g and colecalciferol 10 micrograms (400 units)
- Adcal D3®
- Chewable tablet containing calcium carbonate 1.5g and colecalciferol 400 units (contains soya and sucrose)
- Effervescent tablet containing calcium carbonate 1.5g and colecalciferol 400 units
- Cacit D3®
- Effervescent granule sachet containing calcium carbonate 1.25g and colecalciferol 440 units
- Calcichew D3 Forte®
- Chewable table containing calcium carbonate 1.25g and colecalciferol 400 units
- Evacal®
- Chewable tablet containing calcium carbonate 1.5g and colecalciferol 400 units
- approved as chewable option and also to be used in patients with peanut and soya allergy
|
09.05.01.01 |
Calcium Chloride |
- Injection:10% equivalent to calcium 6.8 mmol/10 mL
|
08.01 |
Calcium Folinate |
- Approved for methotrexate-induced mucositis and myelosuppression. The following formulations are approved:
- 15mg tablets.
- 3mg, 15mg, 30mg, and 300mg injections
- A calcium folinate 1mg per ml mouthwash can be prepared if needed.
unlicensed
|
16 |
Calcium folinate (Folinic Acid) |
|
09.05.01.01 |
Calcium Gluconate |
- Injection: 10%, equivalent to calcium 2.25 mmol/10 mL
|
16 |
Calcium gluconate |
|
16 |
Calcium gluconate gel |
|
09.08.01 |
Calcium Levomefolate Prefolic |
|
09.02.01.01 |
Calcium Resonium® |
- Powder (Calcium polystyrene sulphonate)
|
13.02.01 |
Calmurid® emollient |
|
A2.04.01.02 |
Calogen® |
|
09.05.01.01 |
Calvive 1000® |
- Calvive 1000 tablets [2263 mg of calcium lactate gluconate and 1750 mg of calcium carbonate (equivalent to 1000 mg or 25 mmol of calcium)]
|
06.01.02.03 |
Canagliflozin |
- Only approved for use in accordance with NICE guidance.
|
02.05.05.02 |
Candesartan |
|
02.09 |
Cangrelor Kengrexal® |
- 50mg powder for concentrate for solution for injection/infusion
- Approved for bridging therapy in patients who have recently had a coronary stent but require urgent elective surgery
|
04.06 |
Cannabidiol Epidyolex® |
- 100mg/1mL oral solution
- Approved for use in combination with clobazam for treating seizuires associated with Dravet syndrome in people aged 2 years and older
- Approved for use in combination with clobazam for treating seizures associated with Lennox-Gastaut syndrome
|
04.08.01 |
Cannabidiol Epidyolex® |
- 100mg/1mL oral solution
- Approved for use in combination with clobazam for treating seizuires associated with Dravet syndrome in people aged 2 years and older
- Approved for use in combination with clobazam for treating seizures associated with Lennox-Gastaut syndrome
- Approved as an add-on treatment option for seizures caused by tuberous sclerosis complex in people aged 2 years and over - in line with NICE TA873.
|
10.02.02 |
Cannabis extract Sativex® |
- cannabidiol 2.5mg/dronabinol 2.7mg per dose oromucosal spray
- approved to treat moderate to severe spasticity in adults with multiple sclerosis in line with NICE
![Amber](images/TrafficLightsAmberV2.gif)
|
13.09 |
Capasal® |
|
08.01.03 |
Capecitabine |
- Only approved for use in accordance with NICE guidance.
- Approved in combination with gemcitabine following surgery for pancreatic cancer in line with NHS England Clinical Commissioning Policy
|
12.03.01 |
Caphosol® |
- For limited use in patients having chemo-radiotherapy or radiotherapy to malignancies of the oral cavity, hypopharynx and oro-pharynx.
- Trusts encouraged to prescribe enough between chemotherapy and radiotherapy appointments in secondary care in anticipation of mucositis developing.
|
09.01.04 |
Caplacizumab Cablivi ® |
- 10mg solution for injection
- Approved with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg in line with NICE
|
05.01.09 |
Capreomycin |
- Infectious diseases, microbiology or respiratory advice only Only in patients with MDR-TB intolerant of other medication
|
04.07.03 |
Capsaicin |
- Qutenza® cutaneous patch approved for the treatment of neuropathic pain as fourth line agent for neuropathic pain and in line with the attached regionally agreed pathway.
![Red](images/TrafficLightsRedV2.gif)
- 0.075% cream (Axsain®) approved for post hepatic neuralgia and peripheral diabetic neuropathy
![Green plus](../images/TrafficLightsGreenPlus.gif)
|
10.03.02 |
Capsaicin |
- 0.025% cream
- approved for use as an adjunct to core treatment for knee and hand osteoarthritis as per NICE
|
02.05.05.01 |
Captopril |
- Treatment should only be on the advice of a hospital paediatrician.
- 5mg in 5ml suspension are also approved for use.
- 2mg capsules are also approved for use
unlicensed.
|
04.02.03 |
Carbamazepine |
|
04.07.03 |
Carbamazepine |
- Restricted use in treatment of trigeminal neuralgia only.
|
04.08.01 |
Carbamazepine |
- Carbamazepine 200mg and 400mg MR tablets (Tegretol® retard) are available on consultant request for those in whom conventional carbamazepine has been shown to be unsuitable
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
|
04.08.01 |
Carbamazepine Suppositories |
|
17 |
Carbex® granules |
|
06.02.02 |
Carbimazole |
|
03.07 |
Carbocisteine |
- 375mg capsules.
- 750mg/10ml oral solution in sachets: first choice liquid preparation for adult patients.
- 250mg in 5ml syrup.
|
11.08.01 |
Carbomer 980 eye drops |
- Viscotears® eye drops
- GelTears® single unit dose eye drops
|
08.01.05 |
Carboplatin |
|
07.01.01 |
Carboprost 250microgram in 1ml |
|
08.01.05 |
Carfilzomib Kyprolis® |
- Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
- Approved in combination with dexamethasone and lenalidomide for previously treated multiple myeloma in line with NICE
|
09.08.01 |
Carglumic Acid Carbaglu® |
|
11.08.01 |
Carmellose sodium |
|
08.01.01 |
Carmustine |
- Approved formualtions include 100mg injection and 7.7mg implants.
- Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
|
09.08.01 |
Carnitine |
- 30% oral solution
- 1g in 5ml injection
|
12.04 |
Carnoy’s solution |
Unlicensed
- 10ml bottle
|
A2.05.02 |
Carobel, Instant® |
|
02.04 |
Carvedilol |
- For use in the treatment of heart failure only.
|
05.02.04 |
Caspofungin |
|
07.05 |
Catheter Care Products |
|
07.04.04 |
Catheter Patency Solutions |
- Chlorhexidine 0.02% (1 in 5,000) solution in 100ml sachets.
|
07.04.04 |
Catheter Patency Solutions |
- Sodium chloride 0.9% solution in 100ml sachets.
|
07.04.04 |
Catheter Patency Solutions Urotainer Twin Suby G® |
- Solution G 2 x 30ml sachets (citric acid 3.23%, magnesium oxide 0.38%,
sodium bicarbonate 0.7%, disodium edetate 0.01%)
|
07.04.04 |
Catheter Patency Solutions Urotainer Twin Solution R® |
- Solution R 2 x 30ml sachets (citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%)
|
05.01.02.01 |
Cefalexin |
|
05.01.02.01 |
Cefazolin |
- 1g and 2g vials
- Approved as an alternative to flucloxacillin in patients with non-immediate penicillin allergy or in those who cannot tolerate flucloxacillin or alternatives
- To be used on the advice of microbiology and ID physicians only.
|
05.01.02.01 |
Cefiderocol Fetcroja® |
- 1g powder for concentrate for solution for infusion
- approved for the treatment of infections with gram negative aerobic bacteria in patients with limited treatment options. Only to be used on the advice of mricbiology and ID physicians
|
05.01.02.01 |
Cefixime |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
- 200mg tablets
- 100mg in 5ml paediatric suspension: also approved for the prevention of irinotecan induced diarrhoea, specialist use only
.
|
05.01.02.01 |
Cefotaxime |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
05.01.02.01 |
Ceftaroline |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
05.01.02.01 |
Ceftazadime / avibactam Zavicefta ® |
- 2.5g injection
- Approved for use only on the advice of Microbiology/Infectious Diseases for the treatment of infections with carbapenemase-producing organisms for which treatment options are very limited, toxic and not particularly effective.
|
05.01.02.01 |
Ceftazidime |
|
05.01.02.01 |
Ceftobiprole |
- Approved for the treatment of hospital acquired pneumonia and other infections on the advice of microbiology/infectious disease physicans.
|
05.01.02.01 |
Ceftolozane & tazobactam |
- Approved for use in multiple antibiotic resistant strains of enterobacteriaceae, pseudomonas and acinetobacters on the advice of microbiology/infectious disease physicians.
|
05.01.02.01 |
Ceftriaxone |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Approved for use in primary care (i.e. care homes) to treat patients with conditions such as UTIs and pneumonia, at risk of sepsis in line with local guidance and microbiology input
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
|
05.01.02.01 |
Cefuroxime |
|
11.03.01 |
Cefuroxime 5% eye drops |
|
10.01.01 |
Celecoxib |
|
02.04 |
Celiprolol Hydrochloride |
- For specialist use in the treatment of patients who cannot tolerate other beta-blockers. Treatment should only be intiated on the advice of a cardiologist.
|
08.01.05 |
Cemiplimab Libtayo® |
- Approved for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults in line with NICE
|
04.08.01 |
Cenobamate Ontozry® |
- 12.5mg, 25mg, 50mg, 100mg, 150mg and 200mg tablets
- Approved for treating focal onset seizure in epilepsy in line with NICE
- Patients will be stabilised by the epilepsy specialist prior to transfer to the GP for continuation. This will usually be after 3 months of treatment.
|
08.01.05 |
Ceritinib |
- Approved for use in previously treated anaplastic lymphoma kinase positive non-small-cell-lung cancer in line with NICE and NHS England Commissioning Policy.
- Approved for untreated ALK-positive non-small-cell lung cancer in line with NICE and NHS England Commissioning Policy
|
10.01.03 |
Certolizumab Pegol Cimzia® |
- Approved for:
- Adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
- Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor in accordance with NICE.
- Severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
- Psoriatic arthritis in accordance with NICE.
|
13.05.03 |
Certolizumab pegol |
|
03.04.01 |
Cetirizine |
|
13.02.01 |
Cetraben® |
|
06.07.02 |
Cetrorelix |
|
08.01.05 |
Cetuximab |
- Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy - as per NICE).
- NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan.
- Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE.
- Approved for previously untreated metastatic colorectal cancer in line with NICE.
- Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
- Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.
|
09.08.01 |
Chenodexoycholic acid Xenbilox® |
- 250mg capsules
- Approved for the treatment of inborn errors of bile acid synthesis (all ages) in line with NHS England Commissioning Policy
- Approved for the treatment of Cerebrotendinous Xanthomatosis in line with NHS Commissioning Policy. NHS England will commission this drug for patients who are currently being treated (April 2017)
|
04.01.01 |
Chloral Hydrate |
|
04.01.01 |
Chloral Hydrate 500mg in 5ml mixture |
|
08.01.01 |
Chlorambucil |
|
05.01.07 |
Chloramphenicol |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
12.01.01 |
Chloramphenicol |
|
11.03.01 |
Chloramphenicol 0.5% eye drops & ointment |
- Preservative-free eye drops are also approved for use:
- 0.5% preservative-free Minims® - first choice.
- 0.5% preservative-free eye drops
unlicensed - approved only for patients who are unable to use Minims®due to dexterity problems
|
12.01.01 |
Chloramphenicol 5% and 10% ear drops |
|
04.01.02 |
Chlordiazepoxide |
|
04.10.01 |
Chlordiazepoxide |
- COUNTY DURHAM
acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
|
11.03.02 |
Chlorhexidine |
|
12.03.04 |
Chlorhexidine |
- 0.2% mouthwash.
- 0.2% mint flavoured spray.
- 1% dental gel.
- Dental products should only be prescribed by dentists and GPs should not accept requests to prescribe medicines that the dentist could reasonably prescribe themselves, nor accept requests from patients to issue FP10 prescriptions for items prescribed on a private prescription by their dentist.
- 2% oral gel
unlicensed ![Red](images/TrafficLightsRedV2.gif)
- For hospital use in the prevention of ventilator-associated pneumonia in adult patients who are ventilated (for >48 hours).
|
13.11.02 |
Chlorhexidine 0.015% with Cetrimide 0.15% |
|
13.11.02 |
Chlorhexidine Gluconate |
- 0.05% solutions, 25ml & 100ml sachets
- 0.5% solution in 70% methylated spirit (pink, colourless & red staining)
- 2.5% in 70% methylated spirit wipes
- 0.5% hand rub (contains 70% isopropyl alcohol + emollients)
- 4% surgical scrub
- 2% in 70% isopropyl alcohol wipes (Clinell®)
- Skin swabs & skin cleanser
- 3ml & 10.5ml applicators (Chloraprep®)
- 1% Obstetric cream
|
12.02.03 |
Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® |
|
19 |
Chlorhexidine impregnated sponge Biopatch® |
|
08.01.05 |
Chlormethine Gel |
160 micrograms/g gel
Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:
• Overview | Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | Guidance | NICE
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm. |
08.01.01 |
Chlormethine hydrochloride Ledaga® |
- 160micrograms/g gel
- Approved for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma in line with NICE
|
15.02 |
Chloroprocaine hydrochloride Ampres® |
- 50mg/5ml ampoules & 400mg/20ml vials.
- Approved for spinal nerve and peripheral blocks. To be reviewed in April 2022.
|
05.04.01 |
Chloroquine |
- 200mg tablets (=150mg chloroquine base)
Not NHS.
- 68mg in 5ml syrup (=50mg in 5ml chloroquine)
Not NHS 272.5mg in 5ml injection (=200mg in 5ml chloroquine) unlicensed .
|
02.02.01 |
Chlorothiazide 250mg in 5ml suspension |
- Treatment should only be on advice from paediatric cardiology or nephrology specialists
|
03.04.01 |
Chlorphenamine |
|
04.02.01 |
Chlorpromazine |
|
01.09.01 |
Cholic acid |
- Approved for the treatment of inborn errors of bile acid synthesis (all ages) in line with NHS England Commissioning Policy
|
12.03.01 |
Choline Salicylate Bonjela® Adult |
|
07.04.04 |
Chondroitin sulfate Gepan Instill® |
- Approved the treatment of:
- Interstitial cystitis/painful bladder syndrome
- Radiation cystitis
- Recurring bacterial cystitis
- Overactive bladder
|
06.05.01 |
Choriogonadotropin Alfa Ovitrelle® |
- Fertility treatment
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Hypogonadism
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
|
01.05.03 |
Ciclosporin |
- Capsules: 10mg, 25mg, 50mg, 100mg
- Oral solution: 100mg/ml
- Must be prescribed by brand name
- Brands include Capimune, Capsorin, Deximune, Neoral, Sandimmun, Vanquoral
- 50mg/1ml continuous infusion
![Red](images/TrafficLightsRedV2.gif)
|
08.02.02 |
Ciclosporin Sandimmun® |
|
08.02.02 |
Ciclosporin |
- Approved formulations include:
- 10mg, 25mg, 50mg, and 100mg capsules;
- 100mg in 1ml sugar free oral solution (oily).
- Should be prescribed by brand for transplant indications
- For Transplant indications
unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes .
|
10.01.03 |
Ciclosporin |
|
13.05.03 |
Ciclosporin |
- Capsules & SF Solution
See section 8.2.2
|
11.04.02 |
Ciclosporin 0.1% (1mg/1ml) Eye Drops |
- Ikervis® - Approved for the treatment of dry eye disease in adults that has not improved despite treatment with artificial tears in line with NICE
- Verkazia® - Approved for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents
|
05.03.02.02 |
Cidofovir infusion |
- For use in the prevention and treatment of cytomegalovirus infection.
- For limited use by ENT Surgeons in the treatment of selected
patients with respiratory papillomatosis ( unlicensed)
|
01.03.01 |
Cimetidine |
|
09.05.01.02 |
Cinacalcet |
- Approved for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance haemodialysis where parathyroid gland surgery has failed or is inappropriate.
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Also for short term use to control symptoms prior to a second attempt at more definitive surgery.
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Approved for patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated based on serum calcium levels, symptoms and end organ damage, but in whom parathyroidectomy is either not clinically appropriate or is contraindicated. It is not normally commissioned if serum calcium concentration is <2.85mmol/L
![Amber](images/TrafficLightsAmberV2.gif)
|
04.06 |
Cinnarizine |
|
09.08.01 |
Cipaglucosidase alfa (CIPA) Pombiliti® |
- 105mg powder for concentrate for solution for infusion vials
- Approved with with miglustat (Opfolda) for treating late-onset Pompe disease in adults in line with NICE and NHSE Specialised Commissioning guidance
For information only - as there are no providers within the North East & Cumbria area that are commissioned to provide this service
|
11.03.01 |
Ciprofloxacin |
Eye drops: 0.3% Eye ointment (preservative-free): 0.3% |
12.01.01 |
Ciprofloxacin & dexamethasone Ciprodex® |
- Ciprofloxacin 0.3% and dexamethasone 0.1% ear drops
|
12.01.01 |
Ciprofloxacin 0.2% ear drops |
- 2mg/ml (0.2%) ear drops (0.25ml unit dose)
|
05.01.12 |
Ciprofloxacin Infusion |
- 100mg & 200mg, 400mg intravenous infusions
|
05.01.12 |
Ciprofloxacin Oral Preparations |
- 250mg, 500mg & 750mg tablets
- 250mg in 5ml suspension
|
15.01.05 |
Cisatracurium Nimbex® |
- 20mg in 10ml (2mg/ml) injection
- 150mg in 30ml (5mg/ml) injection
|
08.01.05 |
Cisplatin |
|
04.03.03 |
Citalopram |
- Please note maximum doses
|
19 |
Citrasate® |
|
19 |
Citric Acid |
- 0.6mmol/L solution
- Approved for use to assist in the identification of silent aspiration in stroke patients.
- Temporary approval subject to evaluation being carried out after 6 months
|
08.01.03 |
Cladribine |
- 10mg in 10ml solution for preparing infusions; 2mg in 1ml subcutaneous injection
- Approved for Hairy cell leukaemia only.
- 10mg tablets
- Approved for treating highly active multiple sclerosis in adults in line with NICE
|
05.01.05 |
Clarithromycin Injection |
- Injection (for IV infusion): 500mg
|
05.01.05 |
Clarithromycin Oral Preparations |
- Tablets: 250mg, 500mg
- Oral suspension: 125/5ml, 250mg/5ml
|
11.09 |
Clens 100® |
|
13.06.01 |
Clindamycin Dalacin T® |
- 1% topical solution (alcohol – water basis)
- 1% lotion (aqueous)
|
07.02.02 |
Clindamycin 2% vaginal cream |
|
05.01.06 |
Clindamycin Injection |
- Injection: 300mg/2ml, 600mg/4ml
|
05.01.06 |
Clindamycin Oral Preparations |
- 150mg capsules.
- 75mg in 5ml suspension
unlicensed
|
04.08.01 |
Clobazam |
|
13.09 |
Clobetasol 0.05% |
|
13.04 |
Clobetasol Propionate 0.05% Dermovate® |
- Cream, ointment & scalp application
|
13.04 |
Clobetasol Propionate with neomycin and nystatin Dermovate-NN® |
|
13.04 |
Clobetasone Butyrate 0.05% Eumovate® |
- Cream, ointment & scalp application
|
13.04 |
Clobetasone butyrate with nystatin and oxytetracycline Trimovate® |
- Clobetasone butyrate 500mcg/1g, nystatin 100000iu/1g, oxytetracycline (as oxytetracycline calcium) 30mg/1g
|
08.01.03 |
Clofarabine Evoltra® |
|
05.01.10 |
Clofazimine |
- 50mg and 100mg capsules
- Approved for the treatment of non-tuberculous mycobacterial (NTM) infections, on the advice of microbiology and Infectious Diseases (ID) physicians
|
04.01.01 |
Clomethiazole |
- Alcohol withdrawal - chlordiazepoxide is preferred in the management of alcohol withdrawal.
|
06.05.01 |
Clomifene Citrate |
|
07.05.01.01 |
Clomiphene |
|
04.03.01 |
Clomipramine |
|
04.08.01 |
Clonazepam |
- Clonazepam 500microgram in 5ml sugar-free oral solution is also approved
unlicensed
|
04.08.02 |
Clonazepam |
- For initiation by neurologists only.
|
04.07.04.02 |
Clonidine |
- Clonidine is not generally recommended for migraine prophylaxis; may aggravate depression/cause insomnia.
|
02.05.02 |
Clonidine 100 microgram tablets |
- Treatment should be on the advice of a cardiologist/nephrologist.
|
02.05.02 |
Clonidine 150 microgram in 1ml injection |
- For use in paediatric cardiac ITU and in adult ITU patients with delerium and agitation, often around extubation
unlicensed.
|
19 |
Clonidine Intrathecal Injection |
|
02.09 |
Clopidogrel |
- Approved for use in cardiac patients being fitted with stents/acute coronary syndromes and where aspirin is contraindicated/not tolerated, despite its use in combination with acid suppressants e.g. omeprazole.
- Approved ischaemic stroke; in peripheral arterial/multivascular disease; or after MI only if aspirin not suitable in line with NICE.
- The North of Tyne APC recommends the use of generic 75mg clopidogrel tablets in all the approved indications for clopidogrel.
- Care should be taken to ensure that the brand supplied is suitable if it is to be packed into monitored dosage systems.
|
02.09 |
Clopidogrel 75mg in 5ml suspension |
- Approved for use in paediatric patients with Berlin Heart devices.
|
07.02.02 |
Clotrimazole |
|
13.10.02 |
Clotrimazole 1% cream |
|
12.01.01 |
Clotrimazole 1% solution |
|
04.02.01 |
Clozapine |
- First choice in patients with treatment-resistant schizophrenia.
|
13.05.02 |
Coal tar 2% and salicylic acid 2% ointment |
|
13.09 |
Coal Tar Extract 5% shampoo Alphosyl 2 in 1® |
|
13.05.02 |
Coal tar in emulsifying ointment solution |
- 1%
unlicensed
- 2%
unlicensed
- 5%
unlicensed
|
13.05.02 |
Coal tar lotion 1% Exorex® |
|
05.01.01.03 |
Co-Amoxiclav Injection |
- Injection: 500/100 (600mg), 1000/200 (1.2g)
|
05.01.01.03 |
Co-Amoxiclav Oral Preparations |
- Tablets: 250/125, 500/125
- Oral suspension (sugar-free available): 125/31, 250/62, 400/57
|
18.08.07 |
Coban® 2 Comfort Foam Layer |
- Used in lymphoedema
- Specialist use
|
18.08.07 |
Coban® 2 Compression Layer |
- Used in lymphoedema
- Specialist use
|
18.08.08 |
Coban® 2 Layer |
|
18.08.08 |
Coban® 2 Layer Lite |
|
04.09.01 |
Co-Beneldopa |
|
05.03.01 |
Cobicistat Tybost® |
|
11.07 |
Cocaine |
unlicensed P/F eye drops: 4% |
15.02 |
Cocaine |
- 4% nasal solution (drops)
unlicensed 25% paste (1g syringe pack) unlicensed
|
12.04 |
Cocaine 5% Nasal Spray |
|
15.02 |
Cocaine with Adrenaline |
- 4% solution with adrenaline
unlicensed
|
04.09.01 |
Co-Careldopa |
|
04.09.01 |
Co-Careldopa and Entacapone |
|
19 |
Co-Careldopa liquid |
|
13.05.02 |
Cocois® |
|
07.03.01 |
Co-Cyprindiol 2000/35 - cyproterone Acetate 2mg with ethinylestradiol 35micrograms |
- Co-cyprindiol should be reserved for those women requiring treatment for the androgenic conditions such as severe acne or moderately severe hirsutism. It is recommended that treatment be withdrawn 3 to 4 cycles after the androgenic condition(s) has/have completely resolved and that it is not continued solely to provide oral contraception. Venous thromboembolism occurs more frequently in women taking co-cyprindiol than those taking a low-dose combined oral contraceptive. Repeat courses may be given if the androgen-dependent condition(s) recur.
- Note: generic co-cyprindiol is much cheaper than Dianette®
|
13.06.02 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) |
- Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms
– generic co-cyprindiol is much cheaper than Dianette®
|
13.06.02 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) |
- Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms.
- Note: generic co-cyprindiol is much cheaper than Dianette®
|
13.09 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) |
- Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms.
- Note: generic co-cyprindiol is much cheaper than Dianette®
|
01.06.02 |
Co-danthramer |
- Note: Co-danthramer and Co-danthrusate are generally restricted to use in the treatment of constipation in terminally ill patients. A combination of Senna and Docusate is normally preferred.
|
01.06.02 |
Co-danthrusate |
- Note: Co-danthramer and Co-danthrusate are generally restricted to use in the treatment of constipation in terminally ill patients. A combination of Senna and Docusate is normally preferred.
|
01.04.02 |
Codeine |
|
03.09.01 |
Codeine |
- Codeine linctus 15mg/5ml
- Approved for cough suppression in palliative care patients unable to take tablets
|
04.07.02 |
Codeine |
First line
Second line
The following codeine preparations are unlicensed and approved for use:
- 30 mg suppositories.
- codeine 2mg, 3mg, 6mg, 15mg;
- codeine 30mg in 1ml injection
![CD](images/CD.jpg)
|
19 |
Codeine Phosphate Suppositories |
|
10.01.04 |
Colchicine |
|
09.06.04 |
Colecalciferol |
- 20 microgram (800 units) capsules or tablets
- For first line use in the long term maintenance treatment of patients with documented vitamin D deficiency following high strength therapy and also for use in patients with symptoms and insufficient levels.
- 80 microgram (3,200 units) capsules
- For use in patients with malabsorption such as patients who have had bariatric surgery and require higher maintenance doses
- 500 microgram (20,000 units) capsules.
- For use in patients requiring high strength therapy for vitamin D deficiency.
- 2740iu/ml oral solution (Fultium®-D3 Drops)
- 1000iu and 3000iu buccal spray (DLux®)
unlicensed ![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Approved for use in paediatric parenteral nutrition patients with short bowel syndrome and adults with metabolic bone disease who have vitamin D deficiency despite previous treatment.
|
09.06.04 |
Colecalciferol 25,000 unit liquid Invita D3® |
|
01.09.02 |
Colesevelam |
- Approved for second line use (after Colestyramine) for the treatment of bile malabsorption that results in diarrhoea.
|
02.12 |
Colesevelam |
- For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
|
01.09.02 |
Colestyramine |
- Also approved for the treatment for leflunomide toxicity
![Red Traffic Light](images/TrafficLightsRedV2.gif)
|
02.12 |
Colestyramine |
- For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
- Also approved for the treatment of leflunomide toxicity
.
|
05.01.07 |
Colistimethate |
- 1 million-unit & 2 million-unit vial for nebulisation/intravenous injection
- Nebulised therapy for bronchiectasis
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
- Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis
![Green plus](images/TrafficLightsGreenPlus.gif)
- To be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.
- Nebulised therapy for CF
.
- Intravenous therapy
.
- Dry powder for inhalation (Colobreath®)
.
|
13.10.05 |
Collodion Flexible BP |
- 2.5% castor oil & colophony 2.5% in a collodion base.
|
01.01.01 |
Co-magaldrox Maalox® |
- Mucogel is first choice in the community due to cost.
|
01.01.01 |
Co-magaldrox Mucogel® |
- First choice in the community due to cost.
|
06.04.01.01 |
Combined cyclical HRT tablet Elleste Duet® |
- Pack of 16 x 1mg estradiol tablets + 12 x 1mg estradiol and 1mg norethisterone tablets
|
06.04.01.01 |
Combined cyclical HRT tablet Femoston® |
- Femoston® 1/10 Tablets:
- Pack of 14 x 1mg estradiol tablets + 14 tablets containing estradiol 1mg and dydrogesterone 10mg
- Femoston® 2/10 Tablets:
- Pack of 14 x 2mg estradiol tablets + 14 tablets containing estradiol 2mg and dydrogesterone 10mg
|
07.03.01 |
Combined Hormonal Contraceptive - patch Evra |
- Evra® are self-adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin/24 hours.
- Approved for use by a small number of women with gastrointestinal absorption problems or with compliance issues.
|
07.03.01 |
Combined Hormonal Contraceptives - oral |
- Logynon®
- Logynon® ED
- Tri-Regol®
|
07.03.01 |
Combined Hormonal Contraceptives - oral |
First Choice
- Rigevidon® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)
Alternatives
- Cilique® (ethinylestradiol 35 microgram/norgestimate 250microgram)
- Femodene® (ethinylestradiol 30 microgram/gestodene 75 microgram)
- Femodene® ED (ethinylestradiol 30 microgram/gestodene 75 microgram)
- Gedarel 30/150® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
- Levest® (ethinylestradiol 35 microgram/norgestimate 250microgram)
- Lizinna® (ethinylestradiol 35 microgram/norgestimate 250 microgram)
- Loestrin 30® (ethinylestradiol 30 microgram/ norethisterone 1.5mg)
- Lucette® (ethinylestradiol 30 microgram/drospirenone 3mg)
- Marvelon® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
- Microgynon® 30 (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
- Microgynon® ED (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
- Millinette 30/75® (ethinylestradiol 30 microgram/ gestodene 75 microgram)
- Ovranette® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)
- Ovysmen® (ethinylestradiol 35 microgram/norethisterone 500 microgram
|
03.04.03 |
Conestat Alfa Ruconest® |
- Vials: 2,100 units (as dry powder)
|
06.04.01.01 |
Continuous combined HRT tablets Elleste-duet Conti, Kliofem, Kliovance, Femosten Conti, Premique-low dose |
|
09.08.01 |
Copper histidinate |
- Subcutaneous copper histidinate injections
- Approved for presymptomatic neonates with classical Menkes disease in line with NHSE Specialised Commissioning Policy
- The following providers are commissioned to provide this service within North East:
- The Newcastle upon Tyne Hospitals NHS Trust
|
01.01.01 |
Co-simalcite Altacite plus® |
|
18.01.02 |
Cosmopor E® |
Absorbent Perforated Dressing with Adhesive Border |
05.04.08 |
Co-trimoxazole |
|
05.01.08 |
Co-trimoxazole Infusion |
- 480mg in 5ml ampoules for IV infusion
|
05.04.08 |
Co-trimoxazole Infusion |
|
05.01.08 |
Co-trimoxazole Oral Preparations |
- 480mg tablets, 960mg tablets
- 240mg in 5ml & 480mg in 5ml suspensions.
|
18.08.03 |
Cotton Stockinette Bleached BP 1988 Comfi-gauz® |
|
14.04 |
COVID-19 vaccines |
- Comirnaty® Original / Omicron BA.4-5
- Comirnaty® 10 Concentrate for children
- Comirnaty® 3 (THREE) Concentrate
- VidPrevtyn Beta®
- Spikevax® Original/Omicron BA.4-5
|
08.01.05 |
Crisantaspase Erwinase |
|
08.01.05 |
Crizotinib |
- Approved in accordance with NICE and NHS England Commissioning Policy.
|
13.03 |
Crotamiton Eurax® |
|
13.11.06 |
Crystal Violet 0.5% Paint |
- For limited use in some operating theatres/critical care areas only.
|
04.06 |
Cyclizine |
|
11.05 |
Cyclopentolate Eye drops |
|
11.05 |
Cyclopentolate Single Use Minims® |
|
11.05 |
Cyclopentolate with phenylephrine |
|
08.01.01 |
Cyclophosphamide |
|
05.01.09 |
Cycloserine |
- 250mg capsules Infectious diseases
- microbiology or respiratory advice only
|
16 |
Cyproheptadine hydrochloride Periactin® |
|
08.03.04.02 |
Cyproterone |
|
06.04.04 |
Cyproterone Acetate |
|
06.04.02 |
Cyproterone Acetate 50mg and 100mg tablets |
- Approved for use on the advice of a urologist.
|
08.01.03 |
Cytarabine |
- A cytarabine 50mg vial - intrathecal injection (cytarabine encapsulated in liposomes) is also approved for use.
|
02.08.02 |
Dabigatran |
- Only approved for use in accordance with NICE guidance.
|
08.01.05 |
Dabrafenib Tafinlar® |
- Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE
- Approved for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC) in line with NHSE Specialised Commissioning Policy
- Approved with trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults in line with NICE
|
08.01.05 |
Dacarbazine |
|
05.03.03.02 |
Daclatasvir |
- Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
|
08.02.04 |
Daclizumab Zinbryta® |
- 150mg subcutaneous injection
- Approved for the treatment of highly active relapsing-remitting mutiple sclerosis that has failed to respond to other treatment in adults in line with NICE and NHS England Commissioning Policy.
- Subject to restricted use by EMA
|
08.01.05 |
Dacomitinib Vizimpro® |
- Approved as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults in line with NICE
|
08.01.02 |
Dactinomycin |
|
05.01.07 |
Dalbavancin Xydalba ® |
- 500mg injection
- approved for the treatment of significant deep soft tissue infections such as joint, discitis and spinal infection, on the advice of infectious disease physicians or microbiology.
|
09.06.07 |
Dalivit® |
- Drops containing in each 0.6ml dose ascorbic acid 50mg, ergocalciferol
400 units, nicotinamide 5mg, pyridoxine HCl 500 micrograms, riboflavin 400 micrograms, thiamine 1mg & vitamin A 5,000 units)
- Dalivit drops are to be retained for use in patients requiring a full supplement of vitamin A.
|
02.08.01 |
Danaparoid |
- For use on advice from haematologists in patients who develop thrombocytopenia with heparins - cross reactivity with heparin antibodies is thiought to be <10%.
|
03.04.03 |
Danazol |
- For use on the advice of an immunologist in the prophylaxis, treatment hereditary angioedema associated with C1-esterase inhibitor deficiency.
|
06.07.02 |
Danazol 100mg and 200mg capsules |
|
10.02.02 |
Dantrolene |
|
15.01.08 |
Dantrolene Sodium Dantrium Intravenous® |
|
16 |
Dantrolene sodium |
|
02.15 |
Dapafliflozin Forxiga® |
- 5mg and 10mg tablets
- Approved for treating chronic heart failure with reduced ejection fraction in line with NICE
- Approved for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults in line with NICE
|
06.01.02.03 |
Dapagliflozin Forxiga® |
- 5mg and 10mg tablets
- Approved for treating type 2 diabetes in adults
- Approved for the treatment of chronic kidney disease in adults in line with NICE and NTAG
![Green](images/TrafficLightsGreenV2.gif)
|
05.01.10 |
Dapsone |
- Used in the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists).
|
05.01.07 |
Daptomycin |
|
08.01.05 |
Daratumumab Darzalex® |
- Approved in combination with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable in line with NICE
- Approved as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment in line with NICE
- Approved with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable in line with NICE and NHSE Specialised Commissioning guidance
- Approved in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis in line with NICE and NHSE Specialised Commissioning Guidance
|
09.01.03 |
Darbepoetin Alfa Aranesp® |
- 10, 15, 20, 30, 40, 50, 60, 80, 100, 150 & 300 microgram injections in prefilled syringes
- 20, 40, 60, 80, 100 & 300 microgram Sureclick® pens - approved for management of cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer
- Monitoring: monitoring of erythropeoetin (darbepoetin) in adult patients can be undertaken by GPs under a shared care arrangement
![Amber](images/TrafficLightsAmberV2.gif)
|
04.01.01 |
Daridorexant Quviviq® |
- 25mg and 50mg tablets
- Approved for the treatment long-term insomnia in line with NICE via NHS Sleep Clinic at
- South Tees Hosptials NHS Foundation Trust; and
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
- First 3 months treatment to be provided by secondary care followed by a review and a further 1 month supply if appropriate before prescribing is handed over to primary care
|
07.04.02 |
Darifenacin |
|
08.03.04.02 |
Darolutamide Nubeqa® |
- 300mg tablets
- Approved for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease in line with NICE
- Approved with andorgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer in line with NICE and NHSE Specialised Commissioning guidance
|
05.03.01 |
Darunavir |
|
05.03.01 |
Darunavir and Cobicistat |
To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614). |
08.01.05 |
Dasatinib Sprycel® |
- Approved for use in accordance with NICE and NHS EnglandCommissioning Policy
|
08.01.02 |
Daunorubicin |
- The following formualtions are approved:
- 20mg injection;
- 10mg, 15mg, 35mg;
- 40mg prefilled syringes.
|
08.01.03 |
Daunorubicin/cytarabine Vyxeos® |
- Daunorubicin 44mg/cytarabine 100mg powder for solution for infusion
- Approved for untreated acute myeloid leukaemia in line with NICE
|
19 |
DC beads |
|
18.05 |
Debrisoft® |
Polyester fibres with bound edges and knitted outer surface coated with polyacrylate
- Specialist initiation only
|
13.02.02 |
Deegan's ointment |
|
19 |
Deep Heat® Max Strength |
- Approved to arterialise earlobe capillary blood to facilitate capillary blood testing
|
09.01.03 |
Deferasirox |
- Approved for iron chelation in patients with myelodysplastic syndromes (MDS) - (as per NECN Haematology Group Guidelines) and recommended for use in patients when treatment with desferrioxamine is no longer considered to be appropriate due to progressive iron overload despite maximally tolerated doses of desferrioxamine.
- Approved for the treatment of iron overload for trasnfused and non-tranfused patients with chronic inherited anaemias (all ages) in line with NHSE Specialised Commissioning Policy
|
09.01.03 |
Deferiprone Ferriprox® |
|
02.08 |
Defibrotide |
- Approved for use in severe veno-occlusive disease following stem cell transplant - in accordance with NHS England commissioning policy.
|
08.03.04.02 |
Degarelix |
- Approved formulations include 80mg and 120mg vials (with diluent).
- Approved for the first line treatment of advanced hormone dependant prostate cancer with a PSA > 20ng/l at presentation
- -approved as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases in line with NICE.
|
04.12 |
Dehydrated alcohol 100% BP for Injection |
- Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients
|
09.06.07 |
DEKAs® Essentials multivitamins |
- Approved for adult patients requiring multivitamin and mineral supplementation with Cystic Fibrosis
|
09.06.07 |
DEKAs® Plus multivitamins |
- Approved for adult patients requiring multivitamin and mineral supplementation with Cystic Fibrosis
|
19 |
Del Nido Cardioplegia Solution |
- Approved for use at Newcastle in paediatric and adult congenital cardiac surgery.
|
05.01.12 |
Delafloxacin |
- 300mg powder for concentrate for solution for infusion
- approved for the treatment of acute bacterial skin and skin structure infections where other antibiotics are inappropriate either due to resistant organisms or intolerance/allergy
|
05.01.09 |
Delamanid |
- To be used in accordance with NHS England Commissioning Policy
|
06.05.02 |
Demeclocycline |
- 150mg capsules
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Treatment to be intitated by specialist.
|
06.06.02 |
Denosumab Xgeva® |
- Denosumab 70mg in 1ml (120mg) vial is approved for the prevention of skeletal-related events in adults with bone metastases from solid tumours in line with NICE
- Note: denosumab is not approved for therapy induced bone loss in non- metastatic prostate cancer (NICE).
- North Cumbria only
- New patients
![Red](images/TrafficLightsRedV2.gif)
- Exisiting patients
![Green plus](images/TrafficLightsGreenPlus.gif)
|
06.06.02 |
Denosumab Prolia® |
- Denosumab 60mg in 1ml solution in prefilled syringe is approved for use in the treatment of postmenopausal osteoporosis in line with NICE. Also approved for male patients who dont tolerate bisphosphonates or strontium ranelate.
- NOTE: Denosumab will remain as
in most localities until a shared care guideline has been produced.
|
18.04.02 |
Dermatix® 15g Gel |
Silicone gel
- Burns Team and scar clinic initiation only
|
13.02.01 |
Dermol® |
|
13.02.01 |
Dermol® 500 Lotion |
|
16 |
Desferrioxamine |
- 500mg vials (for preparing injection & oral solution)
|
09.01.03 |
Desferrioxamine Mesilate |
- Approved for the treatment of iron overload for trasnfused and non-tranfused patients with chronic inherited anaemias (all ages) in line with NHSE Specialised Commissioning Policy
|
03.04.01 |
Desloratadine |
|
06.05.02 |
Desmopressin |
- The following desmopressin formualtions are approved for use:
- 10 microgram/dose nasal spray.
- 2.5 & 150 microgram/dose nasal sprays
( unlicensed).
- 100 microgram & 200 microgram tablets.
- 120 microgram sublingual tablets.
- 4 microgram in 1ml injection and 15 microgram in 1ml injection
![Red Traffic Light](images/TrafficLightsRedV2.gif)
|
07.04.02 |
Desmopressin |
- The following formulations are approved:
- 100microgram and 200 microgram tablets;
- 120 microgram sublingual tablets.
- Note: nasal formulations no longer licensed for treating nocturnal
enuresis (see section 6.5.2 for other formulations).
|
07.04.02 |
Desmopressin Noqdirna® |
- Oral lyophilisates: 25microgram, 50 microgram
|
13.05.03 |
Deucravacitinib Sotyktu |
- 6mg tablets
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
06.03.02 |
Dexamethasone |
- 500microgram & 2mg tablets
- 500microgram soluble tablets
- 2mg in 5ml oral solution and 5mg in 5ml oral solution is also approved.
unlicensed
- 20mg/5ml oral solution
![Red](images/TrafficLightsRedV2.gif)
- Approved for use in patients requiring high dose to reduce pill burden
|
12.01.01 |
Dexamethasone 0.05% with framycetin 0.5% ear drops Sofradex® |
- Alternative choice compound antibacterial/corticosteroid ear drop.
|
11.04.01 |
Dexamethasone 0.05%, framycetin sulf. 0.5%, gramicidin 0.005% eye drops Sofradex |
|
11.04.01 |
Dexamethasone 0.1% eye drops Maxidex® |
- Preservative-free eye drops are also approved.
- 0.1% Minims® - first choice.
- 0.1% preservative free eye drops
unlicensed - approved only for patients who are unable to use Minims®due to dexterity problems.
|
11.04.01 |
Dexamethasone 0.1% Preservative-free |
First choice
Unit dose vials (Minims®)
Alternative
Eye drops (unlicensed) - only for patients who are unable to use Minims® due to dexterity problems |
12.01.01 |
Dexamethasone 0.1% with neomycin 0.5% spray Otomize® |
- Alternative choice compound antibacterial/corticosteroid ear drop.
|
06.03.02 |
Dexamethasone 3.3mg in 1ml and 6.6mg in 2ml |
- Note: there are two different strength preparations of dexamethasone injection available in the UK (3.8mg/ml and 3.3mg/ml) where traditionaly a 4mg/ml preparation was available and prescribed as such. To avoid confusion the 3.3mg/ml strength is the preparation of choice in the acute Trusts. Where previously a 4mg dose would have prescribed it is appropriate to prescribe a 3.3mg dose (or multiples thereof). This is because the range of doses given in clinical practice varies widely and subsequent doses tend to be adjusted to reflect clinical response. If 4mg is required please ensure that the appropriate volume of 3.3mg/ml is (e.g. 1.2ml) prescribed (or mulitples thereof).
|
11.04.01 |
Dexamethasone 700 microgram intravitreal implant Ozurdex® |
- Approved for macular oedema following central retinal vein occlusion
in line with NICE.
- Approved for treating diabetic macular oedema in line with NICE.
- Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy
Note: The Northern (NHS) Treatment Advisory Group recommends the sequential pharmacological management of MO secondary to RVO as per the North East Retina Group (NERG) RVO treatment pathway. |
10.01.02.02 |
Dexamethasone Phosphate |
Injection: 3.3 mg/1 mL, 4 mg/1 mL, 6.6 mg/2 mL, 8 mg/2 mL |
11.04.01 |
Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® |
- Eye drops and eye ointment
|
04.04 |
Dexamfetamine |
- 5mg, 10mg and 20mg tablets
- ADHD
- Narcolepsy
- Doses up to 60mg daily
|
06.01.06 |
Dexcom ONE+® |
- Recommended for use only as per NTAG advice and NHS England Guidance.
|
06.01.06 |
Dexcom One® |
- Recommended for use only as per NTAG advice and NHS England Guidance.
|
15.01.04.04 |
Dexmedetomidine Dexdor® |
- 100 micrograms in 1ml injection approved for use in patients:
- with traumatic brain injury, have no respiratory problems but require prolonged ventilatory support due to severe agitation, confusion and requirement for propofol/midazolam; and
- who are difficult to sedate e.g. with overdose of MDMA/PMA/”legal highs” or who have pre-existing drug or alcohol dependence or who have failed conventional methods of treatment.
- Paediatric patients undergoing cardiac surgery with a high risk of post-operative Junctional Ectopic Tachyarrhythmia (JET) or those suitable for fast-track surgery.
- 100 micgrograms in 1ml injection (intranasal)
unlicensed route
- approved for pre-operative sedation in anxious children at risk of respiratory depression in whom midazolam is contraindicated or those who have failed pre-operative sedation with other agents.
|
08.01 |
Dexrazoxane Savene® |
- For use in line with NECN extravasation.
|
09.02.02.02 |
Dextran 40/Sodium Chloride |
|
04.07.02 |
Diamorphine |
Unlicensed intranasal diamorphine is approved for use in children for the relief of severe pain due to clinically suspected limb fractures, burns and significant fingertip injuries. Appropriate risk assessments are to be conducted by each organisation in order to determine formulation of choice (e.g. ampoules or intranasal spray).
- Note: intranasal diamorhine
|
04.01.02 |
Diazepam |
- Diazepam 2mg tablets: are the preferred strength in primary care.
- Diazepam 10mg tablets: should no longer be used.
- Diazepam 10mg in 2ml injection: only approved for use in epilepsy (see section 4.8.2).
- Diazepam 2 mg/5ml oral solution: swallowing difficulties
|
04.08.02 |
Diazepam |
|
10.02.02 |
Diazepam |
- Note: diazepam 10mg tablets are no longer on the formulary.
|
15.01.04.01 |
Diazepam |
- 2mg, 5mg tablets – 10mg tablets should no longer be used.
- 2mg in 5ml oral solution.
- 10mg in 2ml injection (plain & emulsion)
.
- For use in epilepsy see section 4.8.2 and use in anxiety see
section 4.1.2.
|
16 |
Diazepam (emulsion) |
|
02.05.01 |
Diazoxide |
|
06.01.04 |
Diazoxide |
- Diazoxide suspensions can be obtained/prepared if needed.
unlicensed
|
19 |
Dibotermin Alfa Inductos® |
|
04.07.01 |
Diclofenac |
- Oral diclofenac is restricted to short-term use for post operative pain.
- If long-term use is required diclofenac is only approved for 4th line treatment (see below):
- Ibuprofen low dose – first line treatment.
- Naproxen low dose – second line treatment.
- Naproxen high dose – third line treatment.
- Diclofenac – fourth line treatment.
|
04.07.04.01 |
Diclofenac |
|
10.01.01 |
Diclofenac |
Tablets: 25mg, 50mg
The use of oral diclofenac is restricted. It can be used short-term for post operative pain, or as a fourth line choice for long-term use.
- Topical formulations are NOT on the formulary
|
11.08.02 |
Diclofenac |
- 0.1% eye drops and unit dose eye drops.
- For post-operative inflammation limited to patients where corticosteroids are unsuitable.
|
13.08.01 |
Diclofenac 3% in sodium hyaluronate (Solaraze) |
|
15.01.04.02 |
Diclofenac 75mg/1ml injection |
- Mainly for use in post-operative analgesia - see section 10.01.01 for other formulations
|
10.01.01 |
Diclofenac Sodium |
Injection: 75 mg/3 ml |
10.01.01 |
Diclofenac Suppositories |
Diclofenac: new contraindications and warnings - GOV.UK (www.gov.uk) |
16 |
Dicobalt edetate |
|
01.02 |
Dicycloverine |
|
05.03.01 |
Didanosine |
|
08.03.01 |
Diethylstilbestrol |
- Should be initiated with specialist advice.
|
13.14.07 |
Difelikefalin Kapruvia® |
- 50mcg/1ml solution for injection
- Approved for pruritus in adults with chronic kidney disease having haemodialysis in line with NICE
|
02.01.01 |
Digoxin |
- 62.5, 125 & 250 microgram tablets
.
- 50 microgram per ml elixir
.
- 500 microgram in 2ml injection
.
- 100 microgram in 1ml injection
unlicensed .
|
02.01.01 |
Digoxin specific antibody fragments Digifab® |
For the treatment of life threatening digoxin toxicity only, requests must be cleared by an appropriate clinician.
|
05.04.01 |
Dihydroartemisinin / piperaquine phosphate Eurartesim® |
- 160mg/20mg & 320mg/40mg tablets
- Approved for the treatment for plasmodium falciparum malaria in line with current UK and WHO guidelines.
- Only available from Newcastle Hospitals (RVI)
|
04.07.02 |
Dihydrocodeine |
- Note: the use of dihydrocodeine 30mg tablets & 10mg in 5ml oral solution is no longer recommended for regular use. Codeine is the preferred weak opioid analgesic.
- Dihydrocodeine is only approved for use in breast feeding mothers immediately postdelivery/ c-section where adequate pain relief has not been achieved using paracetamol and NSAIDs. Patients requiring continuation of dihydrocodeine following discharge (post delivery/c-section) can have dihydrocodeine prescribed in primary care (for short-term use only).
|
05.04.02 |
Diloxanide |
|
02.06.02 |
Diltiazem |
- Preferred calcium channel blocker for angina.
- Zemtard® is the formulary brand of choice for starting new patients on long acting diltiazem.
|
01.07.04 |
Diltiazem 2% |
- The most effective formulation is to be prescribed
|
16 |
Dimercaprol |
|
08.02.04 |
Dimethyl fumarate Tecfidera® |
- Approved as a option for treating adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis NICE and NHS England Commissioning Policy.
|
13.05.03 |
Dimethyl fumarate Skilarence® |
- 120mg tablets
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
13.02.02 |
Dimeticone Siopel® |
|
13.10.04 |
Dimeticone 4% lotion Hedrin® |
|
07.01.01 |
Dinoprostone |
- The following formulations are approved:
- 0.75mg in 0.75ml injections;
- 3mg vaginal tablets;
- 10mg pessaries.
|
08.01.05 |
Dinutuximab beta Qarziba® |
- 20mg/4.5mL concentrate for solution for infusion
- Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE
|
09.02.01.02 |
Dioralyte® Oral Rehydration Salts |
|
19 |
Diphencyprone in acetone |
|
13.05.02 |
Diprosalic ointment |
|
02.09 |
Dipyridamole |
- Only approved for use in accordance with NICE guidance.
- 50mg in 5ml sugar free suspension alos avialable
unlicensed.
|
08.02.04 |
Diroximel fumarate Vumerity® |
- 231mg capsules
- Approved for treating relapsing-remitting multiple sclerosis in line with NICE
|
11.08.02.04 |
Disodium edetate 0.37% solution |
|
09.05.01.02 |
Disodium Pamidronate |
|
06.06.02 |
Disodium Pamidronate 30mg injection |
|
02.03.02 |
Disopyramide |
|
04.10.01 |
Disulfiram |
- COUNTY DURHAM
acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
|
13.05.02 |
Dithranol in Full Strength Lassar's Paste BP |
- 0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6% & 8%.
|
13.05.02 |
Dithranol pomade |
- 0.2%, 0.4% & 0.6%
unlicensed
|
13.05.02 |
Dithranol with salycyclic acid 0.5% |
- 0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6%, 8% & 16%in emulsifying base.
|
02.07.01 |
Dobutamine |
|
08.01.05 |
Docetaxel |
- Approved for early node-positive breast cancer in line with NICE.
- Approved for hormone refractory metastatic prostate cancer in line with NICE.
|
01.06.02 |
Docusate sodium |
|
05.03.01 |
Dolutegravir |
|
05.03.01 |
Dolutegravir Sodium & Lamivudine Dovato® |
- Film-coated tablet containing dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine
|
05.03.01 |
Dolutegravir Sodium & Rilpivirine Hydrochloride Juluca® |
- Film-coated tablets containing dolutegravir sodium (equivalent to 50 mg dolutegravir) and rilpivirine hydrochloride (equivalent to 25 mg rilpivirine)
|
01.02 |
Domperidone |
Tablets - 10mg Suspension - 5mg/5ml
MHRA Drug Safety Alert (May 2014): Domperidone: risk of cardiac side effects MHRA Drug Safety Update (Dec 2019): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents |
04.06 |
Domperidone |
- Approved for use as a galactagogue to re-establish breastfeeding on specialist advice and following a cardiovascular risk assessment in light of MHRA advice.
|
04.11 |
Donepezil |
- Only approved for use in accordance with NICE guidance.
|
02.07.01 |
Dopamine |
|
03.07 |
Dornase Alfa |
|
11.06 |
Dorzolamide |
- 2% eye drops.
- 2% unit dose eye drops.
|
11.06 |
Dorzolomide 2% with Timolol 0.5% |
- Eye drops and unit dose eye drops
- Approved for use in patients with confirmed allergy presenting as
conjunctival changes or skin allergy. To be initiated by ophthalmologists only. The ophthalmologists must clearly document that signs and symptoms of preservative allergy have been demonstrated in their patient prior to initiation.
|
08.01.05 |
Dostarlimab Jemperli |
|
13.02.01 |
DoubleBase®gel |
|
03.05.01 |
Doxapram |
|
15.01.07 |
Doxapram |
- 100mg in 5ml injection
- 2mg/ml 500ml intravenous infusion in glucose 5%
see section 03.05.01
|
02.05.04 |
Doxazosin |
|
07.04.01 |
Doxazosin 1mg, 2mg and 4mg tablets |
- MR formulations are not approved
|
08.01.02 |
Doxorubicin |
- Doxorubicin 50mg injection - includes use with DC Beads for use in transcatheter arterial chemoembolisation (TACE) therapy in patients with hepatocellular cancer.
- Doxorubicin 20mg & 50mg pegylated liposomal injection - approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE.
- Approved for the treatment of recurrent ovarian cancer in line with NICE.
|
05.01.03 |
Doxycycline |
- 50mg and 100mg capsules
![Green](images/TrafficLightsGreenV2.gif)
- 100mg/5ml injection
unlicensed
- approved as sclerosing agent for lymphatic malformations in children
|
11.03.01 |
Doxycycline |
SR capsules 40 mg
Specialist indication: drug of choice for ocular rosacea |
13.06.02 |
Doxycycline |
|
12.03.01 |
Doxycycline 20mg tablets |
- Treatment of periodontitis.
|
13.02.02 |
Drapolene® |
|
13.10.05 |
Drapolene® cream |
|
18.02.07 |
DrawTex® |
Super absorbent hydroconductive dressing with absorbent, cross-action structures of viscose, polyester and cotton |
18.07.01 |
Dressit® |
Contains vitrex gloves, large apron, disposable bag, paper towel, soft swabs, absorbent pad and sterile field.
|
02.03.02 |
Dronedarone |
- Approved for patients who are unsuitable for or not tolerant of amiodarone. Treatment should be initiated by a cardiologist.
|
04.06 |
Droperidol |
|
06.01.02.03 |
Dulaglutide Trulicity® |
- 0.75mg, 1.5mg, 3mg and 4.5mg prefilled syringes
- Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy.
- This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist
|
04.03.04 |
Duloxetine |
- For use on advice of psychiatrists as a third-line antidepressant - but only for use in patients who cannot tolerate high-dose (>150mg daily) venlafaxine, or patients with hypertension, established CHD or other cardiovascular risk factors which would make the use of high-dose venlafaxine undesirable.
- Also approved for third-line use (after drugs such as the tricyclic antidepressants and gabapentin) in the treatment of neuropathic pain on the advice of pain specialists.
|
04.07.03 |
Duloxetine |
- For third-line use (after drugs such as the tricyclic antidepressants and gabapentin) in the treatment of neuropathic pain on the advice of pain specialists.
|
07.04.02 |
Duloxetine |
- Capsules: 20mg, 40mg
- Moderate to severe stress incontinence in combination with supervised pelvic floor excercises only
|
06.01.05 |
Duloxetine 30mg and 60mg capsules |
|
A2.04.01.02 |
Duocal® Super Soluble |
|
18.02.04 |
DuoDERM® Extra Thin |
Semi-permeable hydrocolloid dressing |
11.08.01 |
Duolube® eye ointment |
UNDER REVIEW
- Please note
The brand name will soon change to Sooth Night-time and Duolube will be unable to be ordered
|
11.08.02 |
Duovisc® Injection |
- Injection for use in cataract surgery containing VisCoat (1% sodium hyaluronate) and ProVisc (3% sodium hyaluronate, 4% chondroitin sulphate).
|
03.04.02 |
Dupilumab Dupixent® |
- 200mg/1.14ml & 300mg/2ml solution for injection
- Approved for or treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over in line with NICE
|
13.05.03 |
Dupilumab Dupixent® |
- 200mg/1.14ml & 300mg/2ml solution for injection
- Approved for treating moderate to severe atopic dermatitis in adults in line with NICE
|
08.01.05 |
Durvalumab Imfinzi® |
- Approved for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults in line with NICE.
- Approved in combination with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer in line with NICE and NHS England Specialised Commissioning Policy.
|
06.04.02 |
Dutasteride |
|
07.04.01.02 |
Dutasteride |
|
13.02.01 |
E45® |
|
18.05 |
Eakin® Wound Pouches |
|
18.01.02 |
Eclyspe® adherent |
Soft silicone wound contact layer with absorbent pad and film-backing
- Specialist initiation only
|
09.01.03 |
Eculizumab |
- 300mg/30ml solution for infusion
- Approved treating atypical haemolytic uraemic syndrome in adults and children in line with NICE
Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:
- King’s College Hospital NHS Foundation Trust, London - London and South East
- Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom
|
02.08.02 |
Edoxaban |
- Only approved for use in accordance with NICE guidance.
|
15.01.06 |
Edrophonium |
|
10.02.01 |
Edrophonium Chloride |
|
05.03.01 |
Efavirenz Sustiva® |
|
13.09 |
Eflornithine 11.5% cream Vaniqa® |
- **UNDER REVIEW**
- Approved for use as a second-line treatment of facial hirsutism in patients where co-cyprindiol is ineffective, contra-indicated or considered inappropriate. Treatment should be initiated by or on the specific advice of an appropriate specialist - endocrinologist (or gynaecologist).
|
18.08.03 |
Elasticated Tubular Bandages BP 1993 Comfigrip® |
|
18.08.03 |
Elasticated Viscose Stockinette Comfifast® range |
|
18.08.03 |
Elasticated Viscose Stockinette Clinifast® range |
|
05.03.03.02 |
Elbasvir & grazoprevir Zepatier® |
- Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
|
A2.01.01.02 |
Elemental 028® Extra |
|
09.08.01 |
Elosulfase alfa |
- 5mg/5ml concentrate for solution for infusion:
- treating mucopolysaccharidosis type 4A in people of all ages
|
09.01.04 |
Eltrombopag |
- For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.
|
02.15 |
Empagliflozin Jardiance® |
- 10mg and 25mg tablets
- Approved for the treatment of chronic heart failure with reduced ejection fraction in adults in line with NICE
- Approved for the treatment of chronic heart failure with preserved or mildly reduced ejection fraction in line with NICE
|
06.01.02.03 |
Empagliflozin |
- Approved in combination therapy for treating type 2 diabetes in line with NICE
- Approved for the treatment of type 2 diabetes in line with NICE
- Approved for treating chronic kidney disease in line with NICE
|
05.03.01 |
Emtricitabine |
|
05.03.01 |
Emtricitabine & Elvitegravir & Cobicistat & Tenofovir alafenamide Genvoya® |
- Tablet: 200mg / 150 mg / 150 mg / 10 mg
- To be used in accordance with NHS England Clinical Commissioning Policy.
|
05.03.01 |
Emtricitabine & Rilpivirine & Tenofovir alafenamide Odefsey® |
- Film coated tablets containing rilpivirine 25mg, emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
- To be used in accordance with NHS England Clinical Commissioning Policy.
|
05.03.01 |
Emtricitabine & Rilpivirine & Tenofovir disoproxil Eviplera® |
- Tablets: 200 mg / 25 mg / 245 mg
|
05.03.01 |
Emtricitabine & Tenofovir alafenamide Descovy® |
- Film coated tablets containing:
- emtricitabine 200mg & tenofovir alafenamide (as fumarate) 10mg
- emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
- To be used in accordance with NHS England Clinical Commissioning Policy.
|
05.03.01 |
Emtricitabine & Tenofovir Disoproxil |
- Tablets: Emtricitabine 200 mg and Tenofovir disoproxil (as fumarate) 245 mg
- Use generic preparation in preference to the branded product (Truvada®)
|
13.02.01 |
Emulsifying Ointment BP |
|
02.05.05.01 |
Enalapril |
- For use in breastfeeding mothers only. Breastfeeding mothers should be converted to ramipril when they are no longer breastfeeding.
|
13.10.05 |
Enbucrilate |
- See 13.10.05 skin tissue adhesives (Liquiband®, Liquiband Optima®, IndermilX-Fine, Histoacryl Blue®)
|
08.01.05 |
Encorafenib Braftovi® |
- Approved in combination with binimetinib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults in line with NICE
- Approved in combination with cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment
|
05.03.01 |
Enfuvirtide |
|
02.08.01 |
Enoxaparin Inhixa® |
- Use during pregnancy and for pre-operative bridging therapy
.
|
02.01.02 |
Enoximone |
- As per licensed indication
- Injection given orally. Approved for the treatment of severe heart failure in adults and children to wean from IV milrinone as a bridge to transplant and to reduce the need for ventricular assist devices (VADs)
unlicensed
|
04.09.01 |
Entacapone |
|
05.03.03.01 |
Entecavir |
|
15.01.02 |
Entonox® |
50% nitrous oxide and 50% oxygen mixture used for analgesia |
08.01.05 |
Entrectinib Rozlytrek® |
- Approved for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors in line with NICE
|
08.03.04.02 |
Enzalutamide |
- Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
- Approved for treating hormone-sensitive metastatic prostate cancer in line with NICE
|
13.02.01 |
Epaderm® emollient |
- Hydromol® Ointment is made to the same formula and is more cost effective.
|
08.01.05 |
Epcoritamab Tepkinly® |
- 4mg/0.8ml & 48mg/0.8ml solution for injection
- Approved for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE
|
02.07.02 |
Ephedrine |
- 30mg in 1ml injection
- 30mg in 10ml syringe
unlicensed.
- 15mg tablets.
|
12.02.02 |
Ephedrine |
|
03.01.01.02 |
Ephedrine Hydrochloride |
|
13.02.01 |
Epimax® |
|
08.01.02 |
Epirubicin |
- Note: epirubicin 100mg injection is
unlicensed.
|
02.02.03 |
Eplerenone |
- For use in post-acute myocardial infarction patients with left ventricular dysfunction and heart failure. Only to be used in patients who are unable to tolerate the estrogenic side effects of spironolactone. Treatment should only be on advice from a cardiologist.
|
09.01.03 |
Epoetin alfa Eprex® |
- Prefilled syringes (various strengths)
- Approved for management of cancer treatment-induced anaemia in
women receiving platinum-based chemotherapy for ovarian cancer
- No longer regularly used in NUTH
|
09.01.03 |
Epoetin beta NeoRecormon® |
- Cartridges for use in RecopensPrefilled syringes
- Approved for management of cancer treatment-induced anaemia
in women receiving platinum-based chemotherapy for ovarian cancer.
- No longer regularly used in NUTH.
- Monitoring: monitoring of erythropeoetin (epoetin beta) in adult patients can be undertaken by GPs under a shared care arrangement
![Amber](images/TrafficLightsAmberV2.gif)
|
09.01.03 |
Epoetin delta |
|
09.01.03 |
Epoetin theta |
|
09.01.03 |
Epoetin zeta |
|
02.05.01 |
Epoprostenol |
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
|
02.08.01 |
Epoprostenol |
- For pulmonary hypertension see section 2.5.1
|
04.07.04.02 |
Eptinezumab Vyepti® |
- 100mg/1ml concentrate for solution for infusion
- Approved for the prevention of chronic migraine in adults in line with NICE only if
- they have 4 or more migraine days a month
- at least 3 preventative drug treatments have failed
|
19 |
Eptotermin alfa Osigraft® |
|
04.07.04.02 |
Erenumab Aimovig® |
- 70mg/1ml and 140mg/1ml solution for injection (pre-filled pens)
- Approved for the prevention of chronic migraine in adults in line with NICE only if
- they have 4 or more migraine days a month
- at least 3 preventative drug treatments have failed
|
09.06.04 |
Ergocalciferol |
- 250 microg. (10,000 units) & 1.25mg (50,000 units) tablets.
- A 3000 units in 1ml suspension (
unlicensed) may be supplied if colecalciferol oral solution is not available.
- 7.5mg (300,000 units) in 1ml injection.
|
07.01.01 |
Ergometrine Maleate |
- Injection: 500 micrograms in 1ml
|
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
- Injection: ergometrine maleate 500micrograms and oxytocin 5 units
|
08.01.05 |
Eribulin Halaven® |
- Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens in accordance with NICE and NHS England Commissioning Policy
|
08.01.05 |
Erlotinib |
- Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
- Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
- Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
|
05.01.02.02 |
Ertapenem |
|
06.01.02.03 |
Ertugliflozin |
- Approved as monotherapy or with metformin for the treatment of type 2 diabetes in line with NICE
|
11.03.01 |
Erythromycin 0.5% Eye ointment |
|
13.06.01 |
Erythromycin 40mg with Zinc Acetate 1.2% topical solution Zineryt® |
|
05.01.05 |
Erythromycin Injection |
- Injection for infusion: 1g vial*
|
05.01.05 |
Erythromycin Oral Preparations |
- Tablets: 250mg, 500mg
- Oral suspension (sugar-free available): 125mg/5ml, 250mg/5ml, 500mg/5ml
|
04.03.03 |
Escitalopram |
|
04.08.01 |
Eslicarbazepine |
- Approved for use by specialists only in those patients for whom intolerance of carbamazepine is a major concern and when use of this agent is more cost effective than alternatives available.
|
02.04 |
Esmolol |
|
01.03.05 |
Esomeprazole |
|
06.04.04 |
Estradiol 1mg and 2mg tablets |
|
06.04.01.01 |
Estradiol patches/gel/spray |
- Twice weekly matrix patches releasing approximately 25, 37.5 (Estradot® only), 50, 75 & 100 microgram/24 hours (Estradot®,Evorel®, Estraderm® MX);
- Weekly matrix patches releasing approximately 25, 50, 75 & 100 microgram/24 hours (Femseven®);
- Once weekly matrix patches releasing approx. 50 & 100 microgram estradiol/24 hours (Progynova TS®)
- Estradiol 0.1% gel (Sandrena®)
- Estradiol 0.06% gel (Oestrogel®)
- Approved for use in gender dysphoria therapy
![Green plus](images/TrafficLightsGreenPlus.gif)
- Approved for use as hormone replacement therapy
- Estradiol 1.53mg/spray transdermal spray (Lenzetto®)
- Approved as an alternative to patches and gels for patients who have issues with absorption, find patch adhesive irritating or the gel messy
|
06.04.01.01 |
Estradiol tablets |
|
06.04.01.01 |
Estradiol vaginal tablet |
- 10mg vaginal tablet
- Vagifem® 10mg vaginal tablets
- Vagirux® 10mg vaginal tablets (alternative)
|
07.03.01 |
Estradiol valerate plus dienogest Qlaira® |
|
08.01.01 |
Estramustine Phosphate |
|
07.02.01 |
Estriol |
- The following topical estriol formulations are approved:
- 0.01% cream (Gynest®) 80g;
- 0.1% cream (Ovestin®)
|
10.01.03 |
Etanercept |
Prescribe by brand name.
- Approved formulations include 10mg (Enbrel®) 25mg injection (Enbrel®, Benepali® & Erelzi®), 50mg injection (Enbrel®, Benepali® & Erelzi®).
- Approved for:
- Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in line with NICE.
- Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
- Psoriatic arthritis in accordance with NICE.
- Treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
- The treatment of juvenile idiopathic arthritis (JIA) in people 2 years or older whose disease has responded inadequately to, or who are intolerant of methotrexate in line with NICE.
- Treatment of Juvenile Scleroderma (Its use will be subject to informed consent and specialists using etanercept in this indication should collect data on patient outcomes. If after a six month trial, treatment were found to be beneficial, it would be continued for two years. If unsuccessful after six months, treatment should be discontinued).
- People aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to, or who are intolerant of methotrexate in line with NICE.
- Treating moderate rheumatoid arthritis after conventional DMARDs have failed in line with NICE
|
13.05.03 |
Etanercept Enbrel®, Benapali® & Erelzi® |
- Approved for psoriasis in line with NICE
- Approved for the treatment of plaque psoriasis in children and young people in line with NICE
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of preferred biosimilar brand. |
09.05.01.02 |
Etelcalcetide Parsabiv® |
- 2.5mg/0.5ml, 5mg/1ml & 10mg/2ml solution for injection
- Approved for the treatment of secondary hyperparathyroidism in line with NICE and NHS England Commissioning Policy
|
05.01.09 |
Ethambutol |
|
11.08.02 |
Ethanol 20% eye drops. |
- For use in the debridement of the corneal epithelium in patients with
recurrent corneal erosion syndrome.
|
02.13 |
Ethanolamine Oleate |
|
06.04.01.01 |
Ethinylestradiol |
- Note: ethinylestradiol 2microgram tablets are
unlicensed.
|
07.03.01 |
Ethinylestradiol and drospirenone Eloine® |
- 20mcg ethinylestradiol and 3mg drospirenone
|
04.08.01 |
Ethosuximide |
|
15.02 |
Ethyl Chloride Spray |
|
10.01.01 |
Etodolac |
- Capsules: 300mg
- MR tablets: 600mg
|
15.01.01 |
Etomidate 20mg/10ml injection |
|
07.03.02.02 |
Etonorgestrel 68mg implant Nexplanon® |
- Replaces Implanon® and differs in that it is impregnated with radio opaque material.
|
08.01.04 |
Etoposide |
- The following formulations are approved for use:
- 50mg capsules & 100mg capsules;
- 100mg in 5ml injections;
- 500mg in 25ml injections.
|
10.01.01 |
Etoricoxib |
- Tablets: 30mg, 60mg, 90mg, 120mg
|
01.05.03 |
Etrasimod Velsipity® |
- 2mg tablet
- Approved for treating moderately to severely active ulcerative colitis in people aged 16 and over in line with NICE
|
05.03.01 |
Etravirine Intelence® |
|
13.09 |
Eucerin 5% Dry Scalp Shampoo |
|
08.01.05 |
Everolimus Afinitor®, Votubia® |
- 2.5mg, 5mg & 10mg tablets (Votubia®)
- Approved for the treatment of angiomyolipomas associated with tuberous sclerosis in accordnace with NHS England Commissioning Policy.
- Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy.
- 5mg & 10mg tablets (Afinitor®)
- Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE.
- Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
- Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE.
- Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
|
02.12 |
Evolocumab |
- Approved for use in accordance with NICE guidance for treating primary hypercholesterolaemia.
- Approved for the treatment of homozygous familial hypercholesterolaemia in line with NHS England Commissioning policy.
|
08.03.04.01 |
Exemestane |
|
06.01.02.03 |
Exenatide |
- 5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.
- Only approved for use in accordance with NICE guidance Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.
- 2.5mg/0.85ml prolonged-release suspension for injection
- temporarily approved due to supply issues with semaglutide and dulaglutide (please refer to linked advice below)
|
02.12 |
Ezetimibe |
- Only approved for use in accordance with NICE guidance.
- For further information refer to NEELI.
|
02.11 |
Factor IX |
|
02.11 |
Factor VIIa |
|
02.11 |
Factor VIII |
|
02.11 |
Factor VIII |
|
02.11 |
Factor XIII |
|
05.03.02.01 |
Famciclovir |
- 125mg, 250mg and 500mg tablets
|
01.03.01 |
Famotidine |
|
11.08.02 |
Faricimab Vabysmo® |
- 120mg/1ml solution for injection
- Approved for the treatment of diabetic macular oedema in adults in line with NICE
- Approved for the treatment of wet age-related macular degeneration in line with NICE
|
10.01.04 |
Febuxostat Adenuric® |
- Approved for patients where allopurinol is not tolerated or contraindicated in line with NICE.
|
08.01.05 |
Fedratinib |
|
02.06.02 |
Felodipine |
- M/R tablets: 2.5mg, 5mg, 10mg
|
04.08.01 |
Fenfluramine Fintepla® |
Oral solution: 2.2mg/mL |
02.12 |
Fenofibrate |
For initiation in lipid clinic only in patients with combined hyperlipidaemias and severe hypertriglycerideamia. |
04.07.02 |
Fentanyl |
- 12, 25, 50, 75 & 100 microgram/hour transdermal patches
- Prescribe by brand. Mezolar® has replaced Matrifen® as the first choice brand. Patients who currently use Matrifen® can continue to do so if managing well.
- Fentanyl sublingual tablets (Abstral®) NoTGhdNC
only for patients experiencing incident pain during radiotherapy, restricted to palliative care use only
- Fentanyl sublingual tablets (Abstral®) CD&TV
for breakthrough / rescue pain relief in palliative care
- nasal spray
- approved for use in children during diamorphine shortage with appropriate local governance arrangements
|
15.01.04.03 |
Fentanyl |
- 100 microgram in 2ml & 500 microgram in 10ml injections
- 2.5mg in 50ml (50 micrograms/ml) syringe
unlicensed
|
09.01.01.02 |
Ferric Carboxymaltose 100ml in 2ml & 500mg in 10ml injections Ferinject® |
- For use as an alternative to iron dextran or iron sucrose. Approved for
use by renal physicians, gastroenterologists and haematologists.
- Unlicensed for use in children under 14 years of age. If used in this age-group, use should only be on the advice of a consultant with the informed consent of the patient and/or his/her parents/carers.
|
09.01.01.01 |
Ferric maltol 30mg hard capsules Ferracru® |
- For the treatment of iron deficiency anemia in patients with or without inflammatory bowel disease.
- To be initiated by specialist in inflammatory bowel disease or iron deficiency anaemia
|
19 |
Ferric Subsulphate (Monsel’s Soln) 50ml |
|
09.01.01.01 |
Ferrous Fumarate |
- First Choice oral liquid iron preparation - 140mg in 5ml syrup (45mg iron/5ml).
- 210mg tablets (68mg iron/tablet).
|
09.01.01.01 |
Ferrous Gluconate |
300mg tablets (35mg iron) |
09.01.01.01 |
Ferrous Sulphate |
- 200mg tablets (65mg iron).
|
07.04.02 |
Fesoterodine |
|
03.04.01 |
Fexofenadine |
|
13.10.05 |
Fibrin sealant (Artiss®) |
- 2ml, 4ml & 10ml prefilled syringe.
- For use in plastic surgery to close dead spaces, adhere skin graft, close simple wounds and stabilise bone grafts.
|
13.10.05 |
Fibrin sealant (Bioglue®) |
- For use in neurosurgery and vascular surgery.
|
13.10.05 |
Fibrin sealant (Evicel® Human Fibrin Glue) |
2ml and 5ml kit |
13.10.05 |
Fibrin sealant (Floseal® Matrix sealant) |
|
13.10.05 |
Fibrin sealant (Tisseel Lyo® Fibrin Glue) |
- 2ml, 4ml & 10ml kit
- Also approved for use in the treatment of mesh fixation in hernia repair.
|
02.11 |
Fibrinogen |
|
05.01.07 |
Fidaxomicin Dificlir® |
- 200mg tablets
- Fidaxomicin 40mg/ml granules for oral suspension
- Approved for use in the treatment of C. difficile. To be initiated on the recommendation of a consultant microbiologist.
|
01.05.03 |
Filgotinib Jyseleca® |
- 100mg and 200mg tablets
- Approved for the treatment of moderate to severe active ulcerative colitis in line with NICE
|
10.01.03 |
Filgotinib Jyseleca® |
- Approved for treating moderate to severe rheumatoid arthritis in line with NICE
|
09.01.06 |
Filgrastim (G-CSF) Neupogen®, Ratiograstim® |
- Available as Neupogen (original brand) and Ratiograstim – a
biosimilar product.
|
07.04.01.02 |
Finasteride |
|
06.04.02 |
Finasteride 5mg tablets |
|
06.04.04 |
Finasteride 5mg tablets |
|
02.02.03 |
Finerenone Kerendia® |
- Approved as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults - in line with NICE TA877:
- add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
- angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
- sodium–glucose cotransporter‑2 (SGLT2) inhibitors and
- the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more.
|
08.02.04 |
Fingolimod |
- Approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE and NHS England Commissioning Policy.
- Approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line with NHS EnglandClinical Commissioning Policy.
|
01.03 |
First choice regimen - eradication H.Pylori |
- The most current H.Pylori guidance and treatment regimens can be found here
|
18.03.04 |
Flaminal ® Hydro Gel |
Alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds |
18.03.04 |
Flaminal® Forte Gel |
Alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds |
02.03.02 |
Flecainide |
- 50mg & 100mg tablets
- 5mg in 1ml liquid
unlicensed.
|
02.03.02 |
Flecainide Injection |
|
13.04 |
Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N® |
|
05.01.01.02 |
Flucloxacillin Injection |
- Injection: 250mg, 500mg, 1g
|
05.01.01.02 |
Flucloxacillin Oral Preparations |
|
07.02.02 |
Fluconazole |
|
05.02.01 |
Fluconazole Infusion |
- IV infusion: 50mg/25ml, 200mg/100ml
|
05.02.01 |
Fluconazole Oral Preparations |
- Capsules: 50mg, 150mg, 200mg
- Oral solution: 50mg/5ml, 200mg/5ml
|
05.02.05 |
Flucytosine |
- 500mg tablets
unlicensed.
- 2.5g in 250ml IV infusion.
|
08.01.03 |
Fludarabine Phosphate |
- Approved for the second line therapy of B-cell CLL in line with NICE.
- Note: fludarabine is not approved for monotherapy in the first line treatment of CLL - this is in line with NICE.
|
06.03.01 |
Fludrocortisone |
|
13.04 |
Fludroxycortide Haelan® |
|
15.01.07 |
Flumazenil |
- 500 microgram in 5ml injection
|
16 |
Flumazenil |
|
12.01.01 |
Flumetasone 0.02% with Clioquinol 1% ear drops |
- Alternative choice compound antibacterial/corticosteroid ear drop.
|
11.04.01 |
Fluocinolone 190 microgram intravitreal implant |
- Recommended as a possible treatment for people with chronic diabetic macular oedema who have an artificial lens in their eye if the implant is used in the eye with the artificial lens and their diabetic macular oedema has not got better with other treatments - in line with NICE.
- Approved for the treatment of recurrent non-infectious uveitis in line with NICE
- Approved for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy in line with NICE
- Approved for treating chronic diabetic macular oedema in line with NICE
|
13.04 |
Fluocinolone Acetonide 0.025% Synalar® |
|
13.04 |
Fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® |
|
11.08.02 |
Fluorescein |
- 2% minims eye drops
- 1mg ophthalmic strips
- Fluorets
- 10% 5ml & 20% 5ml injections
unlicensed
|
11.04.01 |
Fluorometholone 0.1% Eye drops FML® |
- For use in patients who experience ocular hypertension with other corticosteroids – treatment to be initiated with the advice of an ophthalmologist.
|
08.01.03 |
Fluorouracil |
- A fluorouracil 10mg in 0.4ml subconjunctival injection (
unlicensed) is also approved for use.
- FOLFIRINOX is approved for the management of selected patients with inoperable pancreatic cancer in patients with performance status 0-1.
|
13.08.01 |
Fluorouracil Efudix® |
- For the treatment of superficial malignant and premalignant skin lesions.
|
04.03.03 |
Fluoxetine |
- 20mg capsules
- 20mg dispersible tablets
- first choice for patients unable to use the capsules
- 20mg/5ml oral solution
|
04.02.01 |
Flupentixol |
|
04.02.02 |
Flupentixol Decanoate |
CNTW
TEWV
|
10.01.01 |
Flurbiprofen |
|
08.03.04.02 |
Flutamide |
|
03.02.03 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
- Fluticasone 22 microgram/dose & vilanterol 92 microgram/dose dry powder inhaler (DPI): Licensed for COPD and asthma.
- Fluticasone 22 microgram/dose & vilanterol 184 microgram/dose dry powder inhaler (DPI): Licensed for asthma only.
|
12.02.01 |
Fluticasone furoate 27.5microgram/dose nasal spray Avamys® |
- Note: take care to avoid confusion with fluticasone propionate.
|
03.02 |
Fluticasone propionate Flixotide® |
- 50mcg/inhalation
- Approved for asthma in children only
|
12.02.01 |
Fluticasone Propionate 400microgram/dose nasal drops Flixonase Nasule® |
- Note: take care to avoid confusion with fluticasone furoate.
|
12.02.01 |
Fluticasone Propionate 50microgram/dose nasal spray Nasofan® |
- Note: take care to avoid confusion with fluticasone furoate.
|
03.02 |
Fluticasone propionate and formoterol Flutiform® |
- 50/5mcg per puff
- 125/5mcg per puff
- 250/10mcg per puff
|
03.02 |
Fluticasone propionate and salmeterol Sereflo® |
|
03.02 |
Fluticasone propionate and salmeterol Combisal® |
- Fluticasone 50microgram & salmeterol 25 microgram; fluticasone 125microgram & salmeterol 25 microgram; & fluticasone 250microgram & salmeterol 25 microgram (pMDI)
- Approved for asthma in children only
|
03.02 |
Fluticasone propionate and salmeterol Seretide® |
|
03.02 |
Fluticasone propionate and salmeterol Sirdupla® |
|
03.02.03 |
Fluticasone, umeclidinium & vilanterol Trelegy Ellipta® |
- Fluticasone 92 microgram/dose, umeclinidium 65 microgram/dose & vilanterol 22 microgram/dose dry powder inhaler (DPI)
|
09.01.02 |
Folic Acid |
- 400 microgram and 5mg tablets
- 2.5mg in 5ml sugar-free syrup
- 15mg in 1ml injection
unlicensed
- 30mg in 2ml injection
|
06.05.01 |
Follitropin Alfa |
|
06.05.01 |
Follitropin delta Rekovelle® |
- Approved for patients at risk of ovarian hyper stimulation syndrome (OHSS).
|
16 |
Fomepizole |
- 100mg in 20ml injection
unlicensed
|
02.08.01 |
Fondaparinux |
- Approved for high risk orthopaedic surgery pateints and as an alternative to enoxaparin in accordance with NICE guidance.
|
09.06.07 |
Forceval® |
- Capsules
- For limited use as a vitamin and mineral supplement in patients with phenylketonuria The capsules are also approved as an oral supplement in burns patients with malnutrition or alcohol dependency and patients with major burns after discontinuation of IV therapy, and have also been approved for use in patients with severe anorexia nervosa. Treatment initiated with specialist advice.
- Soluble
- Approved for short term use in patients who are unable to swallow
Forceval capsules.
|
13.07 |
Formaldehyde |
|
03.01.01.01 |
Formoterol |
- 6 mcg & 12 mcg/puff breath actuated dry powder inhaler (DPI) - Turbohaler®
|
A2.02.01.02 |
Fortijuce® |
|
A2.01.03.03 |
Fortini |
|
A2.02.02.03 |
Fortisip |
|
05.03.01 |
Fosamprenavir |
|
04.06 |
Fosaprepitant |
- For the prevention of chemotherapy induced nausea and vomiting (CINV) in high risk patients in accordance with North of England Cancer Network: CINV Guidelines in adult oncology and haematology patients
|
05.03.02.02 |
Foscarnet Sodium |
|
05.01.07 |
Fosfomycin |
- 500mg capsules
unlicensed ![Red Traffic Light](images/TrafficLightsRedV2.gif)
- 4g injections
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- 3g sachets: sachets can be initiated in primary care for the treatment of UTIs caused by multi-resistant organisms following advice from microbiology only. Most cost effective option to be used
![Green](images/TrafficLightsGreenV2.gif)
|
04.09.01 |
Foslevidopa/foscarbidopa Produodopa® |
- foslevidopa 240mg/foscarbidopa 12mg in 1ml solution for infusion
- Approved for the treatment advanced Parkinson’s with motor symptoms in adults in line with NICE and NHSE Specialised Commissioning Policy
|
08.01.05 |
Fostamatinib |
100mg and 150mg film-coated tablets
Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:
• NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm |
05.03.01 |
Fostemsavir Rukobia® |
- 600mg MR tablets
- Approved for the treatment of multi-drug resistant HIV-1 infection in adults
|
18.08.08 |
Four layer systems |
- Profore® Kit
- Profore® Lite Kit
|
06.01.06 |
Freestyle Libre 2 Plus® |
- Flash Blood Glucose Monitoring System
- Recommended for use only as per NTAG advice and NHS England Guidance.
|
06.01.06 |
Freestyle Libre 2® |
- Flash Blood Glucose Monitoring System
- Recommended for use only as per NTAG advice and NHS England Guidance.
|
06.01.06 |
Freestyle Libre 3® |
- Flash Blood Glucose Monitoring System
- Freestyle Libre 3 is not to be prescribed by primary care. Use is limited to type 1 diabetes patients only with a compatible insulin pump. It is to be prescribed/supplied by secondary care diabetes teams only.
|
04.07.04.02 |
Fremanezumab Ajovy® |
- 225mg/1.5ml solution for injection (Pre-filled pens/syringes)
- Approved for the prevention of chronic migraine in adults in line with NICE only if
- they have 4 or more migraine days a month
- at least 3 preventative drug treatments have failed
|
04.07.04.01 |
Frovatriptan |
|
08.03.04.01 |
Fulvestrant Faslodex® |
|
13.05.02 |
Fumaric acid esters |
|
02.02.02 |
Furosemide |
|
11.03.01 |
Fusidic Acid Fucithalmic® |
|
13.10.01.02 |
Fusidic Acid 2% |
|
04.07.03 |
Gabapentin |
- For use in the treatment of neuropathic pain
- Gabapentin is also approved for hospital use as an adjunct to other treatment in the management of peri/post-operative pain.
unlicensed
- GPs should not be asked to prescribe gabapentin for this unlicensed indication.
- Approved for intractable itch with severe burns
![Green plus](images/TrafficLightsGreenPlus.gif)
|
04.08.01 |
Gabapentin |
- Note: gabapentin 250mg in 5ml is also approved
unlicensed.
|
06.01.05 |
Gabapentin |
- Also approved for hospital use as an adjunct to other treatment in
the management of peri/post-operative pain. ![Red](images/TrafficLightsRedV2.gif)
- GPs should not be asked to prescribe gabapentin for this
unlicensed indication.
|
19 |
Gadobenate dimeglumine Multihance ® |
- for use in the differential diagnosis of liver disease
|
19 |
Gadobutrol Gadovist® |
- Gadolinium based MRI Contrast medium for use as an alternative to Magnevist®. One of the safer gadolinium contrast media with regard to the potential risk of nephrogenic systemic fibrosis.
|
17 |
Gadobutrol Gadovist® |
|
19 |
Gadofosveset Vasovist® |
- Gadolinium (MRI) contrast agent that binds to albumin for use
in MRI angiograms
|
17 |
Gadoxetate Primovist® |
|
19 |
Gadoxetic acid Primovist® |
- Gadolinium based MRI Contrast medium for use in:
The assessment of hepatic vascular structures and biliary system of potential living, related liver donors. The detection and characterisation of focal liver lesions using MRI, when standard imaging with other agents has been inconclusive.
- The detection and characterisation of focal liver lesions which
potentially communicate with the biliary system e.g. large liver cysts.
|
04.11 |
Galantamine |
- Only approved for use in accordance with NICE guidance.
- The oral solution is only approved for limited short-term use in the management of hospital patients who are unable to swallow tablets/ capsules. It is not for use in patients whose dementia is so severe that they can no longer swallow tablets.
|
04.07.04.02 |
Galcanezumab Emgality® |
- 120mg/1ml injection
- Approved for the prevention of chronic migraine in adults in line with NICE only if
- they have 4 or more migraine days a month
- at least 3 preventative drug treatments have failed
|
09.08.01 |
Galsulfase Naglazyme® |
|
05.03.02.02 |
Ganciclovir |
|
11.03.03 |
Ganciclovir Virgan® |
|
19 |
Gastrografin |
- A contrast medium for the radiological examination of the gastrointestinal tract
|
01.01.02 |
Gaviscon Infant |
- Note: each half of the dual-sachet is identified as ‘one dose'.
To avoid errors prescribe as ‘dual-sachet' with directions in terms of ‘dose'
|
08.01.05 |
Gefitinib |
- Approved for first line use in locally advanced or metastatic NSCLC in line with NICE.
|
09.02.02.02 |
Gelatin Isoplex® |
- 4%succinylated gelatin infusion in a balanced electrolyte solution containing Na+ 145 mmol, K+ 4 mmol, Mg2+ 0.9 mmol, Cl- 105 mmol, lactate 25 mmol/litre.
- Mainly for use in critical care areas and other situations where the perceived advantages of a balanced electrolyte plasma substitute are likely to be clinically important. Note Not yet cleared for use in NUTH.
|
09.02.02.02 |
Gelatin Volplex® or Gelofusine® |
- 4% succinylated gelatin infusion in sodium chloride 0.9% (500ml bags)
|
12.03.01 |
Gelclair® |
- Trusts encouraged to prescribe enough between chemotherapy and radiotherapy appointments in secondary care in anticipation of mucositis developing.
|
08.01.03 |
Gemcitabine |
- Approved in combination with paclitaxel for metastatic breast cancer in line with NICE.
- NECDAG approved for the second line treatment of women with partially platinum – sensitive, platinum resistant or platinum refractory advanced ovarian cancer (To be used when liposomal doxorubicin [Caelyx] is unavailable).
- Approved for pancreatic cancer in line with NICE.
- Approved for the treatment of recurrent ovarian cancer in line with NICE.
- Approved in combination with capecitabine following surgery for pancreatic cancer in line with NHS England Clinical Commissioning Policy
|
07.01.01 |
Gemeprost 1mg pessaries |
|
08.01.05 |
Gemtuzumab ozogamicin Mylotarg® |
- Approved for untreated acute myeloid leukaemia in line with NICE
|
19 |
Gentafleece® |
|
05.01.04 |
Gentamicin |
- Approved for
- For long term therapy in non-cystic fibrosis bronchiectasis usually in patients having > 3 exacerbations per annum with an organism identified as being sensitive to gentamicin.
- Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis
|
05.01.04 |
Gentamicin |
- 80mg in 2ml & 20mg in 2ml IV/IM injections
- 5mg in 1ml intrathecal injection
- bone cement & beads (for use in orthopaedic surgery)
unlicensed.
|
11.03.01 |
Gentamicin 0.3% ear/eye drops |
- 1.5% eye drops with and with out preservative are also approved -
unlicensed and ![Red Traffic Light](images/TrafficLightsRedV2.gif)
|
12.01.01 |
Gentamicin 0.3% ear/eye drops |
|
11.03.01 |
Gentamicin 15mg/ml |
|
13.11 |
Gigasept PA |
|
08.01.05 |
Gilteritinib Xospata® |
- Approved for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults in line with NICE
|
09.08.02 |
Givosiran Givlaari® |
- Approved for treating acute hepatic porphyria (AHP) in adults and young people aged 12 and older in line with NICE, only if:
- they have clinically confirmed severe recurrent attacks (4 attacks or more within 12 months) and
- the company provides it according to the commercial arrangement.
|
08.02.04 |
Glatiramer Acetate |
- Approved for treating multiple sclerosis in line with NICE and NHS Engand commissioning policy.
|
05.03.03.02 |
Glecaprevir & Pibrentasvir Maviret® |
- Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
|
06.01.02.01 |
Gliclazide |
- 40mg & 80mg tablets
- 30mg MR tablets
- *Not to be prescribed for new patients*
- Exisiting patients can continue until clinically appropriate to change in line with switch policy
|
06.01.02.01 |
Glimepiride |
|
06.01.02.01 |
Glipizide |
|
08.01.05 |
Glofitamab Columvi® |
- 2.5mg and 10mg concentrate for solution for infusion
- Approved for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning guidance
|
06.01.04 |
Glucagon |
- GlucaGen® Hypokit - 1mg powder and solvent for solution for injection
![Green](images/TrafficLightsGreenV2.gif)
- Ogluo® - 500mcg/0.1ml & 1mg/0.2ml solution for injection (pre-filled pens)
- To be used in accordance with Medicine Supply Notification (MSN/2023/051U) due to supply issues with GlucaGen® Hypokit
|
16 |
Glucagon GlucaGen® Hypokit |
|
08.01 |
Glucarpidase |
- Approved for the urgent treatment of methotrexate-induced renal
dysfunction.
|
09.02.02.01 |
Glucose |
- 5% IV infusion (100ml, 250ml, 500ml & 1000ml)
- 10% IV infusion (500ml & 1000ml)
- 20% IV infusion (500ml)
- 50% Injection (50ml)
|
A2.07 |
Glucose |
|
06.01.04 |
Glucose 5%, 10%, 25% & 50% |
|
06.01.04 |
Glucose 40% Oral Gel GlucoGel® |
|
13.07 |
Glutaraldehyde 10% paint Glutarol® |
|
A2.06.01 |
Gluten Free Products |
|
01.06.02 |
Glycerol (Glycerin) |
|
02.06.01 |
Glyceryl Trinitrate |
- 400 microgram/metered dose spray
. 5mg & 10mg/day patches - for use in cardiothoracic critical care unit. .
|
07.01.04 |
Glyceryl trinitrate |
- Spray: 400micrograms/dose
|
16 |
Glyceryl Trinitrate |
|
01.07.04 |
Glyceryl Trinitrate 0.4% ointment Rectogesic® |
- 0.2% also available
unlicensed.
|
02.06.01 |
Glyceryl Trinitrate Injection |
- 5mg in 5ml , 50mg in 10ml & 50mg in 50ml injections
|
07.04.04 |
Glycine 1.5% solution |
- 1.5% large volume solutions (up to 3 litres).
|
19 |
Glycopyrrolate 0.5% in Cetomacrogol A |
|
13.12 |
Glycopyrrolate 1% cream |
- To be initiated by specialist.
|
03.01.02 |
Glycopyrronium Seebri Breezhaler® |
- 44microgram (equivalent to 55 micrograms of glycopyrronium bromide) powder capsule with device (DPI)
|
03.01.04 |
Glycopyrronium & formoterol Bevespi Aerosphere® |
- Glycopyrronium 7.2 microgram/dose & formoterol 5 microgram/dose (equivalent to Glycopyrronium (as Glycopyrronium bromide) 7.2 microgram /dose & formoterol fumarate dihydrate 5 microgram/dose) pressurised metered dose inhaler - (pMDI)
|
01.02 |
Glycopyrronium bromide |
- 1mg/5mL oral solution sugar free
- Approved for the first line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation patients who have cognitive impairment.
- Approved for second line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation patients who have failed other treatment options such as hyoscine patches or who have intolerance to other agents.
- 2mg/5ml oral solution (Sialanar®)
- approved for the treatment of severe sialorrhoea in children and adolescents with chronic neurological disorders.
|
15.01.03 |
Glycopyrronium injection |
|
03.01.04 |
Glycopyyronium & indacaterol Ultibro Breezhaler® |
- Glycopyrronium 43 microgram/dose & indacaterol 85 microgram/dose (equivalent to glycopyrronium bromide 54 microgram/dose & indacaterol maleate 85 microgram/dose) inhalation powder capsules (DPI)
|
01.05.03 |
Golimumab |
- Only approved for use in accordance with NICE guidance.
|
10.01.03 |
Golimumab Simponi® |
- Approved for:
- Rheumatoid arthritis in accordance with NICE.
- Psoriatic arthritis in accordance with NICE.
- The treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
- Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
- The treatment of non-radiographic axial spondyloarthritis in accordance with NICE
|
06.05.01 |
Gonadorelin 100microgram in 1ml |
|
06.07.02 |
Goserelin |
- The following goserelin formulations are approved for use 3.6mg & 10.8mg injections (also see section 8.3.4.2).
- Note: leuprorelin is now substantially less expensive than goserelin
|
08.03.04.02 |
Goserelin |
- Approved formulations include 3.6mg and 10.8mg implants.
|
06.04.04 |
Goserelin 3.6mg injection |
|
04.06 |
Granisetron |
|
03.04.02 |
Grass and Tree Pollen Extract Pollinex Quattro® |
- For use in adults and children by adult and paediatric immunologists only.
- Less injections than with conventional Pollinex®
|
03.04.02 |
Grass and Tree Pollen Extract Pollinex® |
- For use in adults and children by adult and paediatric immunologists only.
|
03.04.02 |
Grass pollen extract Grazax® |
|
05.02.05 |
Griseofulvin |
- For very limited use where terbinafine is contraindicated.
|
09.04 |
Growth Faltering in Primary Care |
|
04.04 |
Guanfacine Intuniv® |
- 1mg, 2mg, 3mg & 4mg prolonged release tablets
- Approved for use in children and adolescents when 1st line stimulants and atomoxetine are contraindicated or ineffective.
- Can also be prescribed in primary care by GPs in adults who started treatment in childhood and wish to continue, for whom stimulants are not suitable, not tolerated or have been shown to be ineffective under specialist supervision
|
10.01.03 |
Guselkumab Tremfya |
- 100 mg/1 mL as a pre-filled syringe
- Approved (alone or with methotrexate) for treating active psoriatic arthritis after inadequate response to DMARDs in line with NICE
Overview | Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | Guidance | NICE |
13.05.03 |
Guselkumab Tremfya® |
- 100mg/1mL solution for injection
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
13.12 |
Haem-agglutinin complex |
- For limited use as an alternative to surgery in some patients.
|
14.04 |
Haemophilus influenzae type B |
|
14.04 |
Haemophilus Influenzae type b & Meningococcal Group C Conjugate vaccine |
|
01.07.01 |
Haemorrhoid relief ointment |
Self Care Medicine: Advise that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
|
04.02.01 |
Haloperidol |
Palliative Care
|
04.02.02 |
Haloperidol Decanoate |
CNTW
TEWV
|
09.02.02.01 |
Hartmann’s solution (compound sodium lactate) |
|
15.01.02 |
Heliox21® |
|
02.08.01 |
Heparin |
|
02.08.01 |
Heparin |
- 50 units in 5ml & 200 units in 2ml – for flushing cannulae
|
14.04 |
Hepatitis A vaccine |
|
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Twinrix® |
|
14.05.02 |
Hepatitis B immunoglobulin Hepatect CP® |
|
14.05.02 |
Hepatitis B immunoglobulin HBIG |
- 200 international units - for infant use
|
14.04 |
Hepatitis B vaccine |
|
11.03.01 |
Hexamidine |
UNLICENSED |
12.03.04 |
Hexetidine 0.1% mouthwash |
|
13.10.05 |
Histoacryl Blue® |
|
11.08.02.04 |
Holoclar® |
- Approved for treating limbal stem cell deficiency after eye burns in line with NICE and NHS England Commissioning Policy as of 14 November 2017
|
18.08.02 |
Hospilite® |
Cotton, Polyamide and Elastane Bandage |
03.04.02 |
House dust mite allergen immunotherapy Acarizax® |
- 12 SQ-HDM oral lyophilisates
- Approved for the treatment of house dust mite allergy.
- Licensed alternative to Oralvac®
|
09.02.02.02 |
Human Albumin Solution |
- 4.5% (50ml, 100ml & 500ml)
- 20% (50ml & 100ml)
|
09.08.02 |
Human Arginate |
|
14.04 |
Human papilloma virus (HPV) vaccine |
|
07.02.01 |
Hyalofemme® water-based intimate lubricant |
- For restricted use for the relief of symptoms of atrophic vaginitis, in women who have had treatment for gynaecological malignancyand where topical estriol is not a treatment option
|
12.03.01 |
Hyaluronan |
- 0.2% gel and 0.025% mouthwash.
- For limited second-line use on specialist advice in the treatment of
orofacial granulomatosis, severe oral ulceration and mucositis secondary to immunosuppression where conventional treatments are unsuitable or have failed.
|
19 |
Hyaluronic Acid Hydrafil Softline Max® |
|
19 |
Hyaluronic Acid - Perlane Restylane Perlane® |
|
19 |
Hyaluronic Acid - Sub Q Restylane Sub Q ® |
|
10.03.01 |
Hyaluronidase Hyalase® |
|
02.05.01 |
Hydralazine |
|
02.05.01 |
Hydralazine Injection |
|
06.03.02 |
Hydrocortisone |
|
06.03.02 |
Hydrocortisone |
- 10mg and 20mg tablets
![Green](images/TrafficLightsGreenV2.gif)
- 2.5mg buccal tablets
![Green](images/TrafficLightsGreenV2.gif)
- 10mg in 5ml suspension
unlicensed.![Green](images/TrafficLightsGreenV2.gif)
|
10.01.02.02 |
Hydrocortisone acetate 25mg in 1ml injection |
|
06.03.02 |
Hydrocortisone sodium phosphate Efcortesol® |
- 100mg/ml solution for injection
- As an additional option to hydrocortisone sodium succinate for patients who are steroid dependent (pituitary or adrenal cause and occasionally non-endocrine reasons for long term steroid use) to manage sick day rules to avoid an Addisonian crisis.
- Paraesthesia and pain may follow intravenous injection.
|
06.03.01 |
Hydrocortisone sodium succinate |
|
13.04 |
Hydrocortisone 0.5%, 1% & 2.5% |
|
12.01.01 |
Hydrocortisone 1% Neomycin 0.439% & Polymixin B sulphate 10,000iu/ml ear drops Otosporin® |
- Alternative choice compound antibacterial/corticosteroid ear drop.
|
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
- Cream 30g
- 15g available Over the Counter.
|
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® |
- Cream 30g (15g available Over the Counter) and Ointment 30g
|
13.04 |
Hydrocortisone 1%, Oxytetracycline 3% Terra-Cortril ® |
|
06.03.01 |
Hydrocortisone 10 mg, and 20mg tablets |
- Hydrocortisone 10mg in 5ml suspension is also approved for use.
unlicensed
|
12.03.01 |
Hydrocortisone 2.5mg Lozenges |
|
13.04 |
Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® |
|
12.01.01 |
Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC |
- First choice compound antibacterial/corticosteroid ear drop.
|
13.04 |
Hydrocortisone Butyrate 0.1% cream Locoid® |
|
06.03.02 |
Hydrocortisone Granules Alkindi® |
0.5mg, 1mg, 2mg & 5mg
- approved for treatment of adrenal insufficiency in infants, children and adolescents
- patients should be transitioned onto tablets once they are able to take them
|
18.02.02 |
Hydrofilm® Plus |
|
13.11.06 |
Hydrogen Peroxide Solution BP |
- 10 volume (3%) & 20 volume (6%) solutions.
|
13.02.01.01 |
Hydromol® bath and shower |
- For inpatient use only as per Trust Moisture-Associated Tissue Damage (MASD) guidelines
|
13.02.01 |
Hydromol® ointment |
- This product is also known locally as ‘Emulsifying Ointment RVI
Formula’. It is softer than emulsifying ointment BP. Epaderm ointment is made to the same formula, but is more expensive.
|
04.07.02 |
Hydromorphone |
|
13.02.01 |
Hydrous® ointment |
|
16 |
Hydroxocobalamin Cyanokit® |
|
09.01.02 |
Hydroxocobalamin 1mg in 1ml injection |
|
08.01.05 |
Hydroxycarbamide |
- 100mg tablets
- 500mg capsules
- 500mg in 5ml suspension (
unlicensed) is also approved
- When used to treat non-malignant conditions in accordance with shared care protocol
|
10.01.03 |
Hydroxychloroquine |
|
13.05.03 |
Hydroxychloroquine |
|
03.04.01 |
Hydroxyzine |
|
11.08.01 |
Hylo Night® |
- Eye ointment (containing retinol palmitate (vitamin A) 250iu/g, white soft paraffin, light liquid paraffin, liquid paraffin and wool fat)
|
01.02 |
Hyoscine Butylbromide Buscopan® |
- First choice for respiratory secretions
|
04.06 |
Hyoscine Hydrobromide |
- For the management of excessive secretions where tablets are unsuitable.
|
15.01.03 |
Hyoscine Hydrobromide 400microgram injection |
|
18.07.03 |
Hypafix® |
Permeable, Apertured Non-Woven Synthetic Adhesive Tape, BP 1988 |
03.07 |
Hypertonic sodium chloride 7% Nebusal® |
|
11.08.01 |
Hypromellose |
- 0.3% eye drops
- 0.3% preservative-free eye drops:
- 1st line Tear-Lac®;
- 2nd line PF Drops®
- treatment to be initiated on the advice of ophthalmologist only
|
06.06.02 |
Ibandronic Acid |
- Ibandronic acid 50mg tablets are approved for use in the reduction of bone damage in patients with metastatic breast cancer. Not approved for use in the treatment of patients with other forms of cancer (e.g. prostate).
- Ibandronic acid 150mg tablets are approved for the treatment of osteoporosis in line with NICE
![Green](images/TrafficLightsGreenV2.gif)
- Ibandronic acid 3mg in 3ml injection is approved for use where oral bisphosphonates are not appropriate (not tolerated, contra-indicated because of upper gastro-intestinal problems or insufficiently effective)
![Red](images/TrafficLightsRedV2.gif)
|
08.01.05 |
Ibrutinib Imbruvica® |
- Approved for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in line with NICE and NHS Commissioning Policy.
- Approved for treating relapsed or refractory mantle cell lymphoma in line with NICE and NHS England Commissioning Policy if:
- they have had only 1 previous line of therapy
- Approved for untreated chronic lymphocytic leukaemia in line with NICE
|
04.07.01 |
Ibuprofen |
|
04.07.04.01 |
Ibuprofen |
|
10.01.01 |
Ibuprofen |
Tablets: 200mg, 400mg, 600mg Suspension (sugar-free available): 100mg/5mL |
02.14 |
Ibuprofen 10mg injection Pedea® |
- Approved only for use when there is a supply problem with indometacin.
|
10.03.02 |
Ibuprofen gel |
|
07.01.01.01 |
Ibuprofen Injection Pedea® |
|
03.04.03 |
Icatibant Firazyr® |
- For use on the advice of immunologist in the treatment hereditary angioedema associated with C1-esterase inhibitor.
|
13.05.01 |
Ichthammol |
|
02.12 |
Icosapent ethyl Vazkepa® |
- 998mg capsules
- Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
- established cardiovascular disease (secondary prevention), defined as a history of any of the following:
- acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
- coronary or other arterial revascularisation procedures
- coronary heart disease
- ischaemic stroke
- peripheral arterial disease, and
- low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre
|
08.01.02 |
Idarubicin |
- Approved formulations include:
- 5mg and 10mg capsules;
- 10mg injection.
|
02.08 |
Idarucizumab |
- Approved for use as a rapid reversal agent for dabigatran.
|
08.01.05 |
Idelalisib |
- Approved in combination with rituximab for the treatment of:
- Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
- Chronic lympocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months NICE.
|
09.08.01 |
Idursulfase |
|
08.01.01 |
Ifosfamide |
|
02.05.01 |
Iloprost |
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
|
02.08.01 |
Iloprost |
- Mainly for use in treating pulmonary hypertension - see secton 2.5.1
|
08.01.05 |
Imatinib |
- Approved for the first-line management of people with KIT (CD117)- positive unresectable and/or KIT (CD117)-positive metastatic gastrointestinal stromal tumours (GISTs) in line with NICE.
- Approved for the adjuvant treatment of gastrointestinal stromal tumours (GISTs) after surgery when there is a high risk relapse of tumour NICE.
- Approved for Philadelphia-chromosome-positive CML in the accelerated phase or with blast crisis in line with NICE.
- A standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosomepositive CML in line with NICE.
|
09.08.01 |
Imiglucerase Cerezyme® |
|
05.01.02.02 |
Imipenem with Cilastatin & Relebactam Recarbrio® |
- Imipenem 500 mg, Cilastatin 500 mg & Relebactam 250 mg powder for solution for infusion
- Approved for the treatment of multi-resistant gram-negative infections ONLY on the advice of microbiologists
|
04.03.01 |
Imipramine |
|
04.07.04.02 |
Imipramine |
|
07.04.02 |
Imipramine |
- 10mg and 25mg tablets
- 25mg in 5ml syrup is also approved.
unlicensed.
|
13.08.01 |
Imiquimod Zyclara® |
|
13.07 |
Imiquimod 5% cream Aldara® |
- Second line specialist use for treatment of ano-genital warts (mainly in genitourinary medicine [GUM] clinics).
For the management of actinic keratosis.
|
13.07 |
Imiquimod |
|
08.01.05 |
Imlifidase Idefirix® |
- 11mg powder for concentrate for solution for infusion
- Approved for desensitisation treatment before kidney transplant in people with chronic kidney disease in line with NICE and NHSE Commissioning Policy
|
18.03.02 |
Inadine® |
Knitted viscose primary dressing impregnated with povidone-iodine ointment
|
02.12 |
Inclisiran Leqvio® |
- 284mg/1.5ml solution for injection pre-filled syringes
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults in line with NICE.
|
02.02.01 |
Indapamide 2.5mg tablets |
- First choice for new patients
- Modified release (MR) indapamide tablets are NON FORMULARY.
|
13.10.05 |
Indermil X-Fine® |
|
19 |
Indigo Carmine |
|
05.03.01 |
Indinavir |
|
11.08.02 |
Indocyanine green |
25mg injection. |
10.01.01 |
Indometacin |
- Capsules: 25 mg, 50 mg
- SR Capsules: 75 mg
- Suppositories: 100 mg
|
02.14 |
Indometacin 1mg injection |
unlicensed
|
13.11.01 |
Industrial Methylated Spirit BP |
70% liquid & 70% spray |
13.11.03 |
Infacare Baby Bath Additive |
|
01.05.03 |
Infliximab Remicade®, Inflectra®, Remsima® |
- Only approved for use in accordance with NICE guidance.
- Prescribe by brand only.
|
10.01.03 |
Infliximab Remsima®, Inflectra®, Remicade® |
- Approved for:
- Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs have failed in accordance with NICE.
- Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
- Psoriatic arthritis in accordance with NICE.
- JIA in patients who have not responded to etanercept.
- Juvenile dermatomyositis and paediatric onset Behcet’s disease where there has been intolerance or lack of response to 1st and 2nd line therapies.
- The treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
- Treating moderate rheumatoid arthritis after conventional DMARDs have failed in line with NICE
- Refractory sarcoidosis (excluding neurosarcoidosis) in adults in line with NHSE Specialised Commissioing Policy
- Prescribe by brand name; Remsima®, Inflectra®, Remicade®.
|
13.05.03 |
Infliximab Remsima®, Inflectra®, Remicade® |
- Approved for psoriasis in line with NICE.
|
19 |
Infloran® |
|
14.04 |
Influenza vaccine |
|
04.12 |
Inotersen Tegsedi® |
- Approved as an option for treating stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis in line with NICE
|
08.01.05 |
Inotuzumab ozogamicin Besponsa® |
- Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE
|
06.01.01.01 |
Insulin Actrapid® |
- Human Actrapid® 10ml vial approved.
|
06.01.01.01 |
Insulin Humulin® S |
- Approved formulations of Humulin® S include:
- 10ml vials;
- 5x3ml cartridges.
|
06.01.01.01 |
Insulin Aspart NovoRapid® Trurapi® |
- Approved formulations for Novorapid® include:
- 10ml vial;
- 5x3ml cartridge (for use with Novopen and Novopenmate devices);
- 5x3ml Flexpen®.
- Approved formulations for Trurapi® include:
- 100 units/ml 10ml vial
- 100 units/ml cartridge
- 100 units/ml pre-filled pen
Trurapi = BLACK TRIANGLE |
06.01.01.01 |
Insulin Aspart Fiasp® |
- Approved formulations for Fiasp® include:
- 10ml vial;
- 5x3ml cartridge;
- 5x3ml FlexpTouch pen®.
|
06.01.01.02 |
Insulin degludec Tresiba® |
- 100 units/mL only
- Pre-filled pen and cartridges
- Approved for use in patients with Type 1 diabetes with
- Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwsie progress to insuling pump treatment as per NICE TA151); or
- Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy
- Paediatric patients who cannot tolerate glargine sting
- Paediatric patients with poor control on the high HbA1c pathway
- Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.
|
06.01.01.02 |
Insulin Detemir Levemir® |
- Alternative choice long acting basal insulin.
- Approved Levemir® formualtions include:
- 5x3ml cartridges;
- 5x3ml pens.
|
06.01.01.02 |
Insulin Glargine Lantus® |
- Alternative choice long acting basal insulin.
- Approved Lantus® formulations include:
- 10ml vials;
- 5x3ml cartridges;
- 5x3ml pens (Solostar® - in line with NICE).
|
06.01.01.02 |
Insulin Glargine Toujeo® |
- Alternative choice long acting basal insulin.
- Approved Toujeo® formulations include:
|
06.01.01.02 |
Insulin Glargine biosimilar Abasaglar® |
- First choice long acting basal insulin in patients eligible for treatment in line with NICE and NTAG
- Approved Abasaglar® formulations include:
- 5x3ml cartridge
- 5x3ml Kwikpen®.
|
06.01.01.01 |
Insulin Glulisine Apidra® |
- Approved Apidra® formulations include:
- 10ml vials;
- 5x3ml cartridges
- 5x3ml Solostar® pens.
|
06.01.01.01 |
Insulin Human 500 units in 1mL Humulin R® |
- Humulin R 500units in 1ml (10ml vial) approved for a very small number of insulin resistant patients that require very high doses of insulin.
|
06.01.01.01 |
Insulin Lispro 100 units/ml Humalog® |
- Approved formulations for Humalog 100 ® include:
- 10ml vial;
- 5x3ml cartridge;
- 5x3ml Kwiikpen®.
- Prescriptions need to be written as Insulin Lispro Sanofi® or Humalog® to avoid prescribing/dispensing errors.
- Note that there are two strengths of Humalog® (insulin lispro). Caution should be exercised when prescribing and dispensing
|
06.01.01.01 |
Insulin Lispro 200 units/ml Humalog® |
- 200 units per ml
- Approved formulations for Humalog 200® include the 5x3ml Kwikpen®.
- Note that there are two strengths of Humalog® (insulin lispro). Caution should be exercised when prescribing and dispensing
|
06.01.01.01 |
Insulin Lispro Sanofi |
- 100units /ml
- 10ml vial 3ml cartridges (for AllStar Pro and JuniorSTAR pen), 3ml SoloStar prefilled pen
- Prescriptions need to be written as Insulin Lispro Sanofi® or Humalog® to avoid prescribing/dispensing errors. Insulin lispro biosimilar
|
19 |
Integuseal® IS 100 |
|
08.02.04 |
Interferon Alfa-2b |
|
08.02.04 |
Interferon Alfa-2b Roferon-A® |
|
08.02.04 |
Interferon Beta Avonex® |
|
08.02.04 |
Interferon Beta Rebif® |
|
08.02.04 |
Interferon Beta Betaferon® |
|
08.02.04 |
Interferon beta Extavia® |
|
16 |
Intralipid |
|
07.03.04 |
Intra-uterine Contraceptive Devices |
First choice
- TT380 Slimline® Intrauterine device – replacement every 10 years.
- Mini TT380 Slimline® Intrauterine device – replacement every 5 years.
- T-Safe Cu380A® Intrauterine device – replacement every 10 years.
Alternatives
- Nova T 380® Intrauterine device – replacement every 5 years.
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
- Levonorgestrel 52mg in a T-shaped intra-uterine system.
- For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection from endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.
|
07.03.02.03 |
Intra-uterine Progestogen Only System Levosert® |
- Levonorgestrel 52mg in a T-shaped intra-uterine system.
- For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection from endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 6 years - for use in accordance with agreed guidelines.
|
07.03.02.03 |
Intra-uterine Progestogen Only System Jaydess® |
- Levonorgestrel 13.5mg in a T-shaped intra-uterine system.
Low dose long acting reversible contraceptive. Lasts for up to 3 years - not recommended as first line for nulliparous women.
|
07.03.02.03 |
Intra-uterine Progestogen Only System Kyleena® |
- Levonorgestrel 19.5mg intra-uterine system.
Low dose long acting reversible contraceptive. Lasts for up to 5 years
|
06.02.02 |
Iodine Lugol's® Iodine |
- Oral solution containing 130mg total iodine/ml (5% iodine & 10% potassium iodide).
|
18.03.02 |
Iodoflex® |
Iodine 0.9% as cadexomer-iodine in a paste basis with gauze backing
|
18.03.02 |
Iodosorb® Ointment |
Iodine 0.9% as cadexomer-iodine in an ointment basis
|
17 |
Iohexol Omnipaque® |
|
17 |
Iopamidol (Niopam®) |
|
17 |
Iopamidol Gastromiro® |
|
06.02.02 |
Iopanoic acid |
- Approved for use in rapid blockade of thyrotoxicosis in otherwise medically resistant patients prior to surgery/thyroidectomy.
|
08.01.05 |
Ipilimumab Yervoy® |
- Approved for previously treated advanced melanoma in line with NICE.
- Approved for previously untreated advanced melanoma in line with NICE.
- Approved in combination with nivolumab for untreated renal cell carcinoma in line with NICE.
|
06.01.06 |
i-Port Advance® |
- Recommended for use only as per NTAG advice and NHS England Guidance.
|
12.02.02 |
Ipratropium Bromide 21 microgram/puff nasal spray Rinatec® |
|
03.01.02 |
Ipratropium Nebules |
- 250 microgram/1ml & 500 microgram/1ml nebuliser liquid
|
02.05.05.02 |
Irbesartan |
- Only to be used in the treatment of exisiting patients.
|
08.01.05 |
Irinotecan Hydrochloride |
|
09.01.01.02 |
Iron Dextran 100ml in 2ml and 500mg in 10ml injections |
|
09.01.01.02 |
Iron Isomaltoside 1000mg in 10ml injection Monofer® |
|
09.01.01.02 |
Iron Sucrose 100mg in 5ml injection Venofer® |
|
08.01.05 |
Isatuximab |
20mg/mL concentrate for solution for infusion.
Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:
• NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Not approved in accordance with the following NICE TAs:
• NICE TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm. |
05.02.01 |
Isavuconazole Cresemba® |
- Approved for use in line with licensed indications and specifically in solid organ transplant and bone marrow transplant recipients.
|
15.01.02 |
Isoflurane |
|
05.01.09 |
Isoniazid Injection |
|
05.01.09 |
Isoniazid Oral Preparations |
- 50mg & 100mg tablets
- 50mg in 5ml elixir
unlicensed
|
06.01.01.02 |
Isophane Insulin Insulatard® |
- Approved Insulatard® formulations include:
- 10ml vial;
- 5x3ml cartridges (for use with Novopen® and Novopenmate® devices);
- 5x3ml Innolet® pens.
|
06.01.01.02 |
Isophane Insulin Humulin® I |
- Approved Humulin® I formulations include:
- 10ml vials;
- 5x3ml cartridges;
- 5x3ml pens.
|
02.07.01 |
Isoprenaline |
|
13.11.01 |
Isopropyl alcohol 70% Skin Preparation Swabs Sterets® |
|
16 |
Isosorbide dinitrate |
|
02.06.01 |
Isosorbide Dinitrate 10mg in 10ml injection |
|
02.06.01 |
Isosorbide Mononitrate 10mg, 20mg and 40mg tablets, and 60mg MR tablets |
- 10mg, 20mg and 40mg tablets
- 60mg MR tablets - should only be used in patients when the non-modified release tablets are unsuitable
.
|
13.06.02 |
Isotretinoin capsules |
- 5mg, 10mg, 20mg & 40mg capsules
- Isotretinoin is a toxic drug only to be prescribed by or under the supervision of a consultant dermatologist – see BNF and product literature.
- Drug Safety Updates can be found via the following link:
|
01.06.01 |
Ispaghula Husk |
|
05.02.01 |
Itraconazole Infusion |
- 250mg in 25ml injection for IV infusion
|
05.02.01 |
Itraconazole Oral Preparations |
- 100mg capsules
- 50mg in 5ml oral solution
|
02.06.03 |
Ivabradine |
- Angina - for intiation on advice from a consultant cariologist in patients with contra-indications to or intolerance of beta-blockers.
- Heart failure - approved for use in accordance with NICE guidelines.
|
03.07 |
Ivacaftor |
- Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy.
- Only available from:
- South Tees Hopsitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
|
05.05 |
Ivermectin |
- Unlicensed Oral formulations - 3mg tablets
- Chronic strongyloides infection; cutaneous larva migrans;
|
13.10.04 |
Ivermectin |
- 3mg tablets
- Approved for the treatment of scabies in accordance with DHSC Medicine Supply Notification
- Note: The licensed preparation is currenly only avialable from Alliance.
|
13.06.01 |
Ivermectin 1% cream Soolantra® |
- For the treatment of papulopustular rosacea in patients as second line treatment in patient who have failed topical metronidazole.
|
08.01.05 |
Ivosidenib Tibsovo® |
- 250mg tablets
- Approved for for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy.
|
08.01.05 |
Ixazomib |
- Capsules: 2.3mg, 3mg, 4mg
|
10.01.03 |
Ixekizumab Taltz® |
- 80mg/ml pre-filled syringe or pen
- Approved for the treatment of axial spondyloarthritis in line with NICE
- Approved for the treatment of active psoriatic arthritis after inadequate response to DMARDS
|
13.05.03 |
Ixekizumab Taltz® |
- Approved for the treatment of moderate to severe plaque psoriasis in adults in line with NICE
|
14.04 |
Japanese Encephalitis Vaccine Ixiaro® |
|
19 |
Juvederm® Ultra 3 |
|
19 |
Juvederm® Ultra 4 |
|
18.08.08 |
Juxta CURES® |
|
18.08.02 |
K-Band® |
Knitted Polyamide and Cellulose Contour Bandage, BP 1988 |
18.04.02 |
Kelo-Cote® 15g Gel |
Silicone gel
- Burns Team and scar clinic initiation only
|
18.02.03 |
Kendall Telfa Clear® |
Clear non-adherent wound contact layer
|
18.03.04 |
Kendall® AMD Antimicrobial Foam |
- 5cm x 5cm and 8.8cm x 7.5cm only
|
18.03.04 |
Kendall® AMD Foam Discs |
|
18.01.02 |
KerraMax® Care |
Super absorbent cellulose primary dressing
|
18.10 |
Kerraped® |
|
18.10 |
Kerrapro® Pressure Reducing Pads |
|
04.07.02 |
Ketamine |
|
15.01.01 |
Ketamine |
|
15.01.01 |
Ketamine |
- 200mg in 20ml (10mg/ml), 500mg in 10ml (50mg/ml) & 1g in 10ml (100mg/ml) injections
- 50mg in 5ml oral solution
unlicensed
- Often used as an analgesic in the management of neuropathic pain by specialist pain teams
|
06.07 |
Ketoconazole Ketoconazole HRA |
Tablets: 200mg
Indication: Cushing's Syndrome |
13.10.02 |
Ketoconazole |
|
13.09 |
Ketoconazole 2% shampoo Nizoral® |
|
11.08.02 |
Ketorolac Acular® |
|
15.01.04.02 |
Ketorolac injection |
- 10mg/1ml & 30mg/1ml injection
- the use of this is no longer recommended, other parenteral analgesics are now preferred
|
11.04.02 |
Ketotifen Zaditen® |
Ophthalmology advice - atopic keratoconjunctivitis |
09.06.07 |
Ketovite® |
|
18.08.04 |
Knitted Elastomer and Viscose Bandage K- Lite® |
|
02.04 |
Labetalol |
- Tablets: 50mg, 100mg, 200mg, 400mg
|
02.04 |
Labetalol Injection |
|
04.08.01 |
Lacosamide |
- Only approved on advice from consultant neurologists, in patients that are refractory to treatment with other drugs.
|
01.06.04 |
Lactulose |
- Oral solution only
- Not for PRN use - not effective.
|
05.03.01 |
Lamivudine |
- 150 mg and 300 mg tablets
- 50 mg/5ml oral solution
|
05.03.03.01 |
Lamivudine |
|
04.02.03 |
Lamotrigine |
|
04.08.01 |
Lamotrigine |
|
03.04.03 |
Lanadelumab Takhzyro® |
- 300mg/2mL solution for injection
- Approved for preventing recurrent attacks of hereditary angioedema in line with NICE
|
13.10.05 |
Lanolin Cream |
|
08.03.04.03 |
Lanreotide |
- Approved formulation include lanreotide 30mg long-acting injection and lanreotide 60mg, 90mg, and 120mg autogel injections.
Existing patients
for acromegaly, neuroendocrine tumour and carcinoid. New patients (commenced treatment after July 2019)
for acromegaly, neuroendocrine tumour and carcinoid.
|
01.03.05 |
Lansoprazole |
- 15mg and 30mg capsules
- Orodispersible tablets should only be used in patients who cannot swallow capsules or tablets and for NG/PEG/PEJ use. Omeprazole capsules are currently cheaper than lansoprazole capsules in primary care.
|
09.05.02.02 |
Lanthanum Carbonate |
|
08.01.05 |
Lapatinib Tyverb® |
|
09.08.01 |
Laronidase Aldurazyme® |
|
08.01.05 |
Larotrectinib |
20 mg/mL oral solution |
19 |
LAT Gel |
|
11.06 |
Latanoprost 0.005% with Timolol 0.5% eye drops |
- For use as a second/third-line agent in patients insufficiently responsive
to monotherapy with a prostaglandin analogue or beta blocker.
|
11.06 |
Latanoprost eye drops |
- 50 microgram/ml drops
- 50 microgram/ml preservative free SDU (Monopost)
|
10.01.03 |
Leflunomide |
|
08.02.04 |
Lenalidomide |
- Approved for multiple myeloma in line with NICE - approved for myelodysplastic syndrome with 5q deletion in line with NICE.
- Approved in combination with dexamethasone for previously untreated multiple myeloma in line with NICE
- Approved in combination with dexamethasone for multiple myeloma after one treatment with bortezomib
- Approved for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults in line with NICE
- Approved with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults in line with NICE
|
09.01.06 |
Lenograstim (rHuG-CSF) Granocyte® |
- 263 microgram (33.6 million units) injection vials
|
08.01.05 |
Lenvatinib Kisplyx® |
- 4mg & 10mg capsules
- Approved with everolimus for previously treated advanced renal cell carcinoma in line with NICE
- Approved to the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE
- Approved for untreated advanced hepatocellular carcinoma in line with NICE
|
02.06.02 |
Lercanidipine |
- For use as a second line calcium channel blocker where amlodipine is not tolerated.
|
05.03.02.02 |
Letermovir Prevymis® |
- Approved for the prevention of cytomegalovirus disease after a stem cell transplant in line with NICE
|
08.03.04.01 |
Letrozole |
|
06.07.02 |
Leuprorelin |
- Approved formualtions include 3.75mg and 11.25mg pre filled syringes (also see section 8.3.4.2).
|
06.04.04 |
Leuprorelin 11.25mg injection |
|
08.03.04.02 |
Leuprorelin Acetate |
- Approved formulations include leuprorelin 3.75mg & 11.25mg prefilled syringes.
|
05.05 |
Levamisole |
- 50mg tablets
- For roundworm infections.
|
04.08.01 |
Levetiracetam |
- Injection is also approved for use in palliative care
![Green plus](images/TrafficLightsGreenPlus.gif)
|
04.09.01 |
Levidopa/carbidopa Intestinal Gel Duodopa® |
- levidopa 20mg/carbidopa 5mg intestinal gel
- Approved for the treatment of Parkinson's disease
|
11.06 |
Levobunolol |
Eye drops: 0.5% Unit dose eye drops: 0.5% |
15.02 |
Levobupivacaine Chirocaine® |
- 0.25%, 25mg in 10ml & 0.5%, 50mg in 10ml & 0.75%, 75mg in 10ml injections
- 0.625mg/ml & 1.25mg/ml infusion bags
![Red Traffic Light](images/TrafficLightsRedV2.gif) - for local infiltration in hip and knee replacement surgery.
|
15.01.04.03 |
Levobupivacaine with Fentanyl |
- 2 micrograms/ml with levobupivacaine 0.1% in sodium chloride 0.9% infusion, 100ml, 250ml & 500ml
unlicensed
- 4 micrograms/ml with levobupivacaine 0.125% in sodium chloride 0.9% infusion, 500ml (RVI)
unlicensed
|
11.03.01 |
Levofloxacin |
|
05.01.12 |
Levofloxacin Infusion |
|
05.01.12 |
Levofloxacin Nebuliser Solution Quinsair® |
- 240mg/2.4ml nebuliser solution in line with NHS England Commissioning Policy
|
05.01.12 |
Levofloxacin Oral Preparations |
|
04.02.01 |
Levomepromazine |
For use in palliative care.
- Levomepromazine 25mg in 1ml injection is approved for use in palliative care.
- Note: Methotrimeprazine / Levomepromazine 6mg tablets are
unlicense
|
06.04.01.02 |
Levonorgestrel Mirena® |
- Levonorgestrel 52mg in a T-shaped intra-uterine system.
- For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.
|
07.03.05 |
Levonorgestrel 1.5mg tablet Levonelle 1500 ® |
- Levonorgestrel is recommended for patients who present at up to 72 hours following unprotected intercourse, and the use of ulipristal should be second-line to the use of a copper containing IUCD.
|
02.07.01 |
Levosimendan |
- Approved for use in weaning paediatric and adult patients off extracorporeal membrane oxygenation (ECMO).
- Approved for use in paediatrics and adults where additional intravenous inotropic support is considered appropriate.
|
06.02.01 |
Levothyroxine |
- 25microgram, 50microgram, 75microgram & 100 microgram tablets
- 25microgram in 5ml, 50microgram in 5ml & 100microgram in 5ml sugar-free oral solution
|
02.03.02 |
Lidocaine |
- 100mg injection, pre-filled syringes
- 1mg/ml (0.1%) & 2mg/ml (0.2%) IV infusions 500ml
|
15.02 |
Lidocaine |
- Injections (plain)
- 0.5% 10ml
- 1% 2ml, 5ml, & 10ml (10mg/ml)
- approved for use in post-operative pain management subject to local protocols with a review of adverse events to be submitted by October 2018
- 2% 2ml, 5ml & 20ml injection (20mg/ml)
- 5% 2ml Heavy injection (50mg/ml)
- 5% 10ml injection (50mg/ml)
unlicensed
- Topical preparations
- 1% & 2% gel with chlorhexidine 0.25%
- 4% topical solution (some packs unlicensed)
- 5% ointment
- 2% spray
unlicensed
- 100mg lollipops
unlicensed
- Lidocaine 4%, adrenaline 0.1% & tetracaine 0.5% (LAT gel®)
unlicensed - approved for use in anaesthetising lacerations particularly in the paediatric population – not to be used in children weighing under 15kg.
|
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
15.02 |
Lidocaine 4% cream LMX4® |
|
11.07 |
Lidocaine 4% with Fluorescein 0.25% Minims® |
|
15.02 |
Lidocaine 5% and Phenylephrine 0.5% |
- 5% lidocaine & 0.5% phenylephrine solution with
applicator
|
04.07.03 |
Lidocaine 5% medicated plasters (700mg lidocaine/plaster) |
- For use in the treatment of post-herpetic neuralgia only, on the advice of pain specialists and subject to an appropriate trial of efficacy in each individual patient.
|
01.07.01 |
Lidocaine 5% ointment |
- Topical preparations containing local anaesthetics should only be used for a few days as they may cause sensitisation of the anal skin.
|
13.03 |
Lidocaine 5% ointment |
|
12.02.03 |
Lidocaine and Phenylephrine Nasal spray |
|
13.03 |
Lidocaine and prilocaine EMLA® |
|
15.02 |
Lidocaine Spray |
- Metered dose spray (10mg/spray)
|
15.02 |
Lidocaine with Adrenaline Injections |
|
06.01.04 |
LIFT Juice Shot |
- Carbohydrate drink
- Approved for the treatment of mild to moderate hypoglycaemia in children and young people
- First choice ahead of Glucogel®
![Green plus](images/TrafficLightsGreenPlus.gif)
|
18.10 |
Limbo® Waterproof Protector |
|
01.06.07 |
Linaclotide |
- Approved for specialist initiation for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C).
|
06.01.02.03 |
Linagliptin |
|
05.01.07 |
Linezolid Infusion |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
05.01.07 |
Linezolid Oral Preparations |
- 600mg tablets
- 100mg in 5ml suspension
To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.
Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).
Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing. |
05.01.07 |
Linezolid Oral Preparations |
- 600mg tablets
- 100mg in 5ml suspension
To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.
RED drug for courses greater than 14 days ![Red Traffic Light](../images/TrafficLightsRedV2.gif)
Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).
Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing. |
06.02.01 |
Liothyronine |
- The most cost effective strength/formulation should be used
- Note: Liothyronine tablets should only be prescribed as per the following guidance:
- In line with British Thyroid Association (BTA) guidance, where levothyoroxine has failed, liothyronine may be recommended for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.
- Existing patients should be reveiwed, as appropriate, by an endocrinologist to ensure the continuing need for liothyronine. Patients shouldn't have treatment stopped without review by an endocrinologist.
|
06.02.01 |
Liothyronine Injection |
20mcg injection
|
09.01.06 |
Lipegfilgrastim (G-CSF) |
|
15.02 |
Liposomal Bupivacaine Exparel® |
- 133mg/10ml & 266mg/20ml prolonged-release dispersion for injection.
- Alternative to local anaesthetic infusion via an indwelling brachial plexus nerve catheter for major shoulder/upper limb surgery.
- Audit of outcomes to be presented to trust Drug and therapeutic Committee's and Formulary Working Group within 12 months (from April 2024).
|
13.10.05 |
LiquiBand Optima® |
|
13.10.05 |
LiquiBand® |
|
04.05.01 |
Liraglutide Saxenda® |
Saxenda®![](../images/blacktriangle.gif) ![Red](../images/TrafficLightsRedV2.gif)
- Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing:
- it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and
- the company provides it according to the commercial arrangement
|
06.01.02.03 |
Liraglutide |
- Victoza®
![Green](images/TrafficLightsGreenV2.gif)
- Approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance
- Saxenda®
![](images/blacktriangle.gif) ![Red](images/TrafficLightsRedV2.gif)
- Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing:
- it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and
- the company provides it according to the commercial arrangement
|
04.04 |
Lisdexamfetamine |
- 20mg, 30mg, 40mg, 50mg, 60mg & 70mg capsules
- For third line use and specialist initiation. Should only transferred to GPs after at least three month stable symptom control
- Approved for the treatment of ADHD in adults
|
02.05.05.01 |
Lisinopril |
|
11.08.02 |
Lissamine Green |
1.5mg ophthalmic strips |
04.02.03 |
Lithium Carbonate |
|
04.07.04.03 |
Lithium carbonate |
- Lithium should be prescribed by brand name.
|
04.02.03 |
Lithium Citrate |
|
04.07.04.03 |
Lithium citrate |
- Lithium should be prescribed by brand name.
|
06.01.02.03 |
Lixisenatide |
|
19 |
l-lysine 2.5%, l-arginine 2.5% |
|
18.03.01 |
L-Mesitran® Ointment |
Medical grade honey
- Specialist tissue viability nurse use or recommendation only
|
18.03.01 |
L-Mesitran® Ointment S |
Medical grade honey
- Specialist tissue viability nurse use or recommendation only
|
04.03.01 |
Lofepramine |
- Safer than amitriptyline in overdosage, but not as effective.
|
04.10.03 |
Lofexidine BritLofex® |
South Tyneside and Sunderland only
|
08.01.01 |
Lomustine |
- Note: 10mg capsules are
unlicensed.
|
08.01.05 |
Loncastuximab tesirine Zynlonta® |
- 10mg powder for concentrate for solution for infusion
- Approved or treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy
|
01.04.02 |
Loperamide |
- 2mg tablets and capsules
- 2mg orodispersible tablets: approved for use in patients with high output stoma only when crushing tablets or opening capsules has failed. Also apporved for oral cancer patients struggling to take capsules
![Green plus](images/TrafficLightsGreenPlus.gif)
|
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
|
03.04.01 |
Loratadine |
|
04.01.02 |
Lorazepam |
|
04.08.02 |
Lorazepam |
- For initiation by neurologists only.
- Lorazepam 2mg/ml suspension & 4mg/ml suspension are also approved but are
unlicensed.
- Buccal administration of lorazepam suspensions are only approved for use in paediatrics in children with status epilepticus in whom buccal midazolam, rectal paraldehyde or rectal diazepam are ineffective.
![Red Traffic Light](images/TrafficLightsRedV2.gif)
|
15.01.04.01 |
Lorazepam |
|
16 |
Lorazepam |
|
08.01.05 |
Lorlatinib Lorviqua® |
- Approved for previously treated ALK-positive advanced non-small-cell lung cancer in adults in line with NICE
|
02.05.05.02 |
Losartan |
- To be used as first line treatment in all new patients.
|
11.04.01 |
Loteprednol Eye drops |
- Approved as a second line agent to conventional corticosteroid eye drops, treatment to be imitated with the advice of an ophthalmologist only.
|
19 |
Low dose Naltrexone |
|
13.11 |
Lubricating jelly |
|
03.07 |
Lumacaftor and Ivacaftor Orkambi® |
- Ivacaftor 125mg/lumacaftor 100mg & ivacaftor 200mg/lumacaftor tablets
- Ivacaftor 95mg/lumacaftor 75mg, ivacaftor 125mg/lumacaftor 100mg &
ivacaftor 188mg/lumacaftor 188mg granules in sachet
- Approved for the treatment of cystic fibrosis in patients 1 year and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in line with NHS England Specialised Commissioning Policy (SSC2538)
- Only available from:
- South Tees Hopsitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
|
04.02.01 |
Lurasidone Latuda® |
- 18.5mg, 37mg and 74mg tablets
- Approved for the treatment of schizophrenia in adults and adolescents aged 13 years and over
|
09.01.04 |
Lusutrombopag |
- 3mg film-coated tablets
- Approved as an option for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures in line with NICE
|
08.01.05 |
Lutetium (177Lu) |
- Lutetium (177Lu) oxodotreotide (Lutathera)
- Approved for treating unresectable or metastatic neuroendocrine tumours in adults in line with NICE
- Lutetium-177 vipivotide tetraxetan (Pluvicto)
- Approved for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults in line with NICE
|
06.05.01 |
Lutropin Alfa |
|
05.01.03 |
Lymecycline |
|
13.06.02 |
Lymecycline |
|
02.05.01 |
Macitentan |
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
|
01.06.04 |
Macrogol Movicol liquid® |
Approved as a second line macrogol laxative for care home residents only. |
16 |
Macrogol '3350' Klean-Prep® |
|
01.06.04 |
Macrogol oral powder |
|
01.06.04 |
Macrogol oral powder, Compound |
- Macrogol Compound oral powder
- Macrogol Compound oral powder, Half-Strength
- Macrogol Compound oral powder, Paediatric
Use the product with the lowest acquisition cost. |
01.06.05 |
Macrogols Klean-Prep® |
|
01.06.05 |
Macrogols Moviprep® |
|
13.11.06 |
Magenta Paint BPC Castellani's paint |
Paint containing magenta 0.4%, boric acid 0.8%, phenol 0.004%, resorcinol 8%, acetone and alcohol (or industrial methylated spirit). |
09.05.01.03 |
Magnesium Aspartate |
- 6.5g (10 mmol) sachets - first line for the treatment and prevention of magnesium deficiency.
- 614.8mg (2.5mmol) tablets
unlicensed - for second line treatment in patients with short bowel syndrome.
|
09.05.01.03 |
Magnesium chloride |
- 10 mmol magnesium in 1 litre sodium chloride 0.9% with potassium chloride 0.15% (20 mmol)
unlicensed
- 64mg sustained release tablets (2.6mmol magnesium)
unlicensed
|
09.05.01.03 |
Magnesium Glycerophosphate |
- 1g (4mmol) chewable tablets
- Use preparation with cheapest acquisition cost.
- Yourmag®
- Magnaphate®
unlicensed
- 1mmol/ml suspension -available if supply problems with tablets
unlicensed.
|
03.01 |
Magnesium Sulphate |
|
07.01.04 |
Magnesium Sulphate |
|
09.05.01.03 |
Magnesium Sulphate |
- 50% 2ml (4 mmol), 50% 10ml (20 mmol) & 10% 10ml (4mmol) injections
- 60 mmol in 500ml sodium chloride 0.9% infusion
unlicensed
|
19 |
Magnesium sulphate 10% solution for injection pre-filled syringe |
|
02.03 |
Magnesium Sulphate Injection |
|
13.10.05 |
Magnesium Sulphate Paste BP |
|
13.10.04 |
Malathion 0.5% solution (aqueous) |
|
02.02.05 |
Mannitol |
|
03.07 |
Mannitol inhalation |
- Approved for bronchial provocation testing in patients unable to tolerate the taste of methacholine.
|
03.07 |
Mannitol inhalation Bronchitol ® |
- Only approved for use in accordance with NICE guidance.
|
05.03.01 |
Maraviroc |
- Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
|
05.03.02.02 |
Maribavir Livtencity® |
- 200mg film coated tablets
|
02.16 |
Mavacamten Camzyos® |
- Approved as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3 in line with NICE and NHSE Specialised Commissioning guidance.
- It is recommended only if:
- it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.
The following providers are commissioned to provide this service:
- North Cumbria Integrated Care NHS Foundation Trust
- South Tees Hospitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
|
14.04 |
Measles, Mumps and Rubella Vaccine, Live (MMR) |
|
05.05.01 |
Mebendazole |
|
01.02 |
Mebeverine |
|
06.07.04 |
Mecasermin Increlex® |
|
18.10 |
Medi Derma® S |
- 1ml applicator
- 3ml applicator
- 50ml aerosol
- 30ml pump spray
|
18.10 |
Medi Derma® S |
|
13.02.02 |
Medi Derma-Pro Foam & Spray Skin Cleanser And Skin Protectant Ointment Medi Derma-Pro Foam & Spray Skin Cleanser® |
|
13.02.02 |
Medi Derma-S barrier film Medi Derma-S ®barrier film |
|
18.09.01 |
Medi® hosiery |
|
13.11.03 |
Mediscrub® |
|
06.04.01.02 |
Medroxyprogesterone Acetate |
Approved Medroxyprogesterone formulations include:
- 2.5mg, 5mg, and 10mg tablets (sometimes used as a progestogen component of HRT).
- 100mg & 200mg tablets (for use in malignant disease see section 8.3.2).
- 50mg in ml injection - see sections 7.3.2.2 for use of medroxyprogesterone acetate injection in contraception.
|
08.03.02 |
Medroxyprogesterone Acetate |
- Approved formualtion include 100mg, 200mg, and 400mg tablets.
- Medroxyprogesterone acetate 500mg in 2.5ml injection is also approved.
|
07.03.02.02 |
Medroxyprogesterone Acetate injection |
- Approved formulations include:
- Depo-Provera® - 150mg in 1ml depot injection;
- Sayana Press® - 104mg/0.65ml S/C injection.
|
10.01.01 |
Mefenamic Acid |
- Capsules: 250 mg
- Tablets: 500 mg
- Suspension: 50 mg/5 mL
|
18.07.03 |
Mefix® |
Permeable, Apertured Non-Woven Synthetic Adhesive Tape, BP 1988
|
05.04.01 |
Mefloquine |
Note: not approved on the NHS for prophylaxis. |
08.03.02 |
Megestrol Acetate |
|
18.02.06 |
Meglisorb® |
Calcium sodium alginate fibre, highly absorbent, gelling dressing, non-woven |
19 |
Meglumine gadoterate Dotarem® |
- Gadolinium MRI contrast medium that is licensed for use in children. Gadoterate is considered to be much less likely to cause nephrogenic systemic fibrosis than dimeglumine gadopentetate (Magnevist®), which has previously been used in children.
|
04.01.01 |
Melatonin |
- First line: melatonin 1mg and 5mg modified release tablets in line with licensed indications only.
- Second line: melatonin 1mg, 2mg, 3mg, 4mg and 5mg tablets (crushed if necessary).
- Third line: melatonin 1mg/1ml oral solution - 1st choice for patients unable to tolerate solid dose formulations. Consilient Health formulation to be used as it is alcohol and propylene glycol free
Approved Indications
Melatonin can be used to facilitate the induction of sleep, and increase the duration of sleep on the advice of an appropriate secondary care specialist, in the following situations:
1) Visually impaired or blind people with disturbed sleep wake cycles. ![Green plus](../images/TrafficLightsGreenPlus.gif) 2) Delayed sleep phase syndrome and other circadian rhythm disorders.![Green plus](../images/TrafficLightsGreenPlus.gif) 3) Children with neurological or behavioural disorders including: ![Amber](../images/TrafficLightsAmberV2.gif)
- Attention deficit hyperactivity disorder (ADHD).*
- Chronic sleep onset insomnia.*
- Neurodevelopmental disabilities (e.g. involving delayed brain maturation, sensory dysfunction - especially visual and dysfunction of sleep centres).*
4) Treatment of children and young adults with chronic fatigue syndrome / myalgic encephalomyelitis who have sleep difficulties (as recommended in NICE clinical guideline no. 53).* ![Amber](../images/TrafficLightsAmberV2.gif) 5) Prior to examinations such as a sleep encephalogram (EEG) in children and sedation prior to scans in paediatric oncology. ![Green plus](../images/TrafficLightsGreenPlus.gif) 6) Patients with REM sleep behaviour disorder (RBD) - e.g. associated with degenerative conditions such as Parkinson’s disease or dementia, as a second line treatment to clonazepam. ![Green plus](../images/TrafficLightsGreenPlus.gif) 7) To improve nocturnal sleep in critically ill patients (to aid weaning from mechanical ventilation) ![Green plus](../images/TrafficLightsGreenPlus.gif)
*Note that for indications 3 and 4 in children and young people melatonin is classified as an ‘amber’ drug and therefore subject to formal shared care guidance. Please follow relevant link below for the most recent guideline. |
18.01.02 |
Melolin® |
Absorbent, Perforated Plastic Film Faced, Dressing
|
08.01.01 |
Melphalan |
|
04.09.03 |
Memantine |
- Approved for use as last line drug after other alternatives have been considered, in the treatment of congenital and acquired nystagmus.
|
04.11 |
Memantine |
- Only approved for use in accordance with NICE guidance.
|
09.06.06 |
Menadiol Sodium Phosphate |
- 10mg tablets - water soluble derivative of vitamin K for use in patients with fat malabsorption, especially in hepatic disease or biliary obstruction including cystic fibrosis patients.
|
06.05.01 |
Menotrophin (75 units FSH & 75 units LH activity) injection |
|
13.03 |
Menthol and aqueous cream |
- available as Dermacool |
05.04.04 |
Mepacrine Hydrochloride |
|
18.04.02 |
Mepiform® |
Silicone gel sheet
- Burns Team and scar clinic initiation only
|
18.02.03 |
Mepilex® Border |
Absorbent soft silicone dressing with polyurethane foam and adhesive border
|
18.02.03 |
Mepilex® Border lite |
Thin absorbent soft silicone dressing with polyurethane foam and adhesive border
|
18.02.03 |
Mepilex® Border Post-op |
|
18.02.03 |
Mepilex® ST |
Absorbent soft silicone dressing with polyurethane foam film backing
|
15.02 |
Mepivacaine |
|
15.02 |
Mepivacaine IV |
|
03.04.02 |
Mepolizumab Nucala® |
- 100mg/1ml solution for injection (pre-filled devices)
- Approved for the treatment of severe refractory eosinophilic asthma in line with NICE and NHS England Commissioning Policy.
|
09.08.01 |
Mercaptamine |
|
11.08 |
Mercaptamine hydrocholride |
- Viscous eyedrops
- Approved for the treatment of corneal cystine deposits in people aged 2 years and over in line with NHS England Clinical Commissioning Policy
|
01.05.03 |
Mercaptopurine |
|
08.01.03 |
Mercaptopurine |
- A mercaptopurine 20mg in 1ml suspension (
unlicensed) is also approved for use.
- Note: when prescribed for inflammatory bowel disease.
![Amber Traffic Light](images/TrafficLightsAmberV2.gif)
|
05.01.02.02 |
Meropenem |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
05.01.02.02 |
Meropenem & vaborbactam Vaborem® |
- Meropenem 1 gram / vaborbactam 1 gram. To be used only on advice of microbiology/infectious disease physician
|
01.05.01 |
Mesalazine Rectal Preparations |
- 1g in 100ml retention enema, 2g in 59ml enema
|
01.05.01 |
Mesalazine |
First Choice
- Octasa MR® (400mg e/c m/r tablets): approved as first choice 400mg e/c m/r preparation for all new patients. Patients receiving Asacol® and Mesren® should be switched to Octasa® when appropriate. 800mg & 1600mg e/c m/r tablets also approved for suitable patients - to reduce tablet burden.
- Pentasa® (500mg & 1000mg m/r tablets).
- Mezavant® XL (1.2g e/c m/r tablets).
- Salofalk® (500mg, 1000mg, 1500mg & 3000mg m/r granules/sachet) - only to be used in patients with difficulty in swallowing.
|
08.01 |
Mesna |
- Approved formulations include 1gram in 10ml injection and 400mg tablets.
|
16 |
MESNA (sodium 2-mercapto-ethanesulphonate) |
|
02.07.02 |
Metaraminol |
|
06.01.02.02 |
Metformin |
- Metformin 500mg tablets
- Metformin 500mg oral powder sachets
- Metformin MR (once daily - Glucophage® SR) are only approved for use in patients who have failed to tolerate the conventional tablets despite careful dose titration.
- Note: metformin is also approved for use in Polycystic Ovary Syndrome.
|
07.05.01.01 |
Metformin |
- 500mg tablets
- For fertility indications
- Also approved for polycystic ovarian syndrome (PCOS)
|
04.07.02 |
Methadone |
The following preparations are approved:
- 5mg tablets;
- 5mg in 5ml mixture DTF & 5mg in 5ml sugar free solution
- 20mg in 1ml concentrated oral solution (
unlicensed)
- 10mg in 1ml injection
|
04.10.03 |
Methadone |
- Methadone 5mg in 5ml oral solution and 5mg in 5ml sugar free solution are both approved for the management of opioid dependence in line with NICE.
CD&TV and ST&S
|
05.01.13 |
Methenamine Hippurate |
|
16 |
Methionine 250mg and 500mg tablets |
Paracetamol overdose
|
01.05.03 |
Methotrexate |
- See section 8.1.3
- NOTE: Subcutaneous injection for chronic inflammatory conditions in Tees SICBL
![Red](images/TrafficLightsRedV2.gif)
|
08.01.03 |
Methotrexate |
- Approved formulations:
- Methotrexate 2.5mg tablets
- Methotrexate 10mg in 5ml oral solution.
unlicensed
- Methotrexate injections (various strengths) – including prefilled syringes.
- Methotrexate 5mg in 2ml intrathecal injection.
- NOTE: when used in chronic inflammatory conditions, e.g. Crohn’s disease, rheumatoid arthritis.
![Amber Traffic Light](images/TrafficLightsAmberV2.gif)
- NOTE: Subcutaneous injection for chronic inflammatory conditions in Tees SICBL
![Red](images/TrafficLightsRedV2.gif)
|
10.01.03 |
Methotrexate |
|
13.05.03 |
Methotrexate |
|
09.01.03 |
Methoxy Polyethylene Glycol-Epoetin Beta Mircera®, Pegzerepoetin® alfa |
- 30, 50, 100, 120, 150, 200 & 250 microgram in 0.3ml and 360 microgram in 0.6ml injections in prefilled syringes.
- Approved for use as a longer-acting alternative to darbepoetin in a
small number of patients receiving peritoneal dialysis.
|
15.01.02 |
Methoxyflurane Penthrox® |
- 99.9% inhalation vapour
- Approved for use in trauma related pain in Emergency Departments, in adults only
- Approved for procedural analgesia in procedures such as VAC dressing change/stent change/brachytherapy rod change, in adults only
|
13.05.02 |
Methoxypsoralen 1.2% bath additive |
|
02.05.02 |
Methyldopa |
|
04.04 |
Methylphenidate |
- Please prescribe by brand name
- Approved for ADHD and the treatment of narcolepsy in adult and paediatrics.
- Approved for improving working memory and processing speed following neurocognitive damage secondary to brain injury from; a brain tumour and its associated treatment (e.g. hydrocephalus and radiotherapy) or neurotoxic chemotherapy.
- 5mg & 10mg tablets
- 5mg, 10mg, 20mg, 30mg and 40mg m/r capsules (Medikinet® XL)
- 10mg, 20mg & 30mg m/r capsules (Equasym® XL)18mg, 27mg & 36mg m/r tablets (Xaggitin® XL)
- Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
- Xaggitin® XL is bioequivalent to Concerta® XL
|
07.04.02 |
Methylphenidate |
- Methylphenidate is approved for use as a third line option (after e.g. antimuscarinics, imipramine, and pelvic floor exercises) in the treatment of giggle incontinence in children. Its use should be subject to a therapeutic trial to be reviewed after two months and considered for Shared Care if patients have been shown to respond after the trial period.
- The following methylphenidate formulations are approved for giggle incontinence:
- 5mg & 10mg tablets.
- 10mg, 20mg & 30mg m/r capsules (Equasym XL®).
- 18mg, 27mg & 36mg m/r tablets (Xaggitin® XL)
- Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
- Xaggitin® XL is bioequivalent to Concerta® XL
- The effects of Equasym® XL last for about 8 hours compared with about 12 hours for Xaggitin® XL.
|
10.01.02.02 |
Methylprednisolone Acetate 40mg in 1ml injection |
|
10.01.02.02 |
Methylprednisolone Acetate 40mg with lidocaine 1% injection |
|
06.03.02 |
Methylprednisolone Acetate 40mgin 1ml and 120mg in 3ml (depot) |
|
06.03.02 |
Methylprednisolone sodium succinate 2mg, 4mg, and 16mg tablets |
|
06.03.02 |
Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg injection |
|
19 |
Methylthioninium Chloride |
|
01.02 |
Metoclopramide |
Tablets - 10mg Oral Solution - 5mg/5ml Caution in elderly, young adults and children Do not use in people under 20 years
MHRA Drug Safety Update Alert (Aug 2013): Metoclopramide: risk of neurological adverse effects |
04.06 |
Metoclopramide |
- Please refer to MHRA advice
|
04.07.04.01 |
Metoclopramide |
- Used to help promote absorption of analgesics.
|
04.06 |
Metoclopramide INJECTION |
|
02.02.01 |
Metolazone Xaqua® |
|
02.04 |
Metoprolol |
- Tablets: 50mg, 100mg
- SR Tablets: 200mg
|
04.07.04.02 |
Metoprolol |
|
02.04 |
Metoprolol Injection |
|
06.08 |
Metreleptin |
- 3mg, 5.5mg and 11.3mg powder for solution for injection
- Approved for treating lipodystrophy in children and adults in line with NICE
|
05.01.11 |
Metronidazole |
- 200mg & 400mg tablets
- 200mg in 5ml suspension
- 500mg & 1g suppositories
|
05.04.02 |
Metronidazole |
|
05.04.04 |
Metronidazole |
|
13.10.01.02 |
Metronidazole 0.75% |
Cream & gel |
07.02.02 |
Metronidazole 0.75% vaginal gel |
|
05.01.11 |
Metronidazole Infusion |
- 50mg in 10ml injection & 500mg in 100ml IV infusion
|
06.07.03 |
Metyrapone Metopirone® |
|
02.03.02 |
Mexiletine |
unlicensed
- ECG monitoring is required to be carried out by as part of the initiation process of mexiletine.
|
10.02 |
Mexiletine Namuscla® |
- Approved for the treatment of myotonia in patients with non-dystrophic myotonic disorders in line with NICE and NHSE commissioning policy (SSC2001).
|
05.02.04 |
Micafungin |
|
13.10.02 |
Miconazole 2% cream |
|
12.03.02 |
Miconazole 24mg/ml sugar-free oral gel Daktarin® |
|
12.03.02 |
Miconazole 50mg muco-adhesive buccal tablets Loramyc® |
- Restricted to use in immunocompromised patients with severe oropharyngeal candidiasis, where the use of other antifungal agents e. g. nystatin, fluconazole is not appropriate and for use on the advice of microbiologists.
|
06.04.01.02 |
Micronised progesterone Utrogestan® |
- 100mg oral capsules
![Green](https://formulary.sunderlandccg.nhs.uk/images/TrafficLightsGreenV2.gif)
- Approved for:
- adjunctive use with estrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT)
- Perimenopause (off-label)
- Premature ovarian insufficiency (off-label)
- Adolescents undergoing pubertal induction following chemotherapy (off-label)
|
04.08.02 |
Midazolam |
- Buccolam® 5mg in 1ml alcohol-free buccal solution, and Buccolam® 2.5mg, 5mg, 7.5mg and 10mg prefilled oral syringes are approved as first choice for status epilepticus in children aged 3 months to 18 years.
- Epistatus® 10mg in 1ml oromucosal solution pre-filled oral syringes is approved for use in the treatment of epileptic seizures in infants under 3 months and adults over 18 years of age. This use is off-label Injection solutions (section 15.1.4) can also be given buccally
|
15.01.04.01 |
Midazolam |
- 5mg in 5ml, 10mg in 2ml injections
- 50mg in 50ml prefilled syringes - ITU use only
- Intranasal midazolam 40mg/ml + lidocaine 20mg/ml
- approved for use prior to cannulation for adult patients with
special needs receiving dental treatment under IV sedation.
- Miprosed® 5mg in 1ml (7.5ml) oral solution is approved for use as a sedative and pre-medication in children
Palliative care
- 10mg/2ml injection
![Green](images/TrafficLightsGreenV2.gif)
|
02.07.02 |
Midodrine |
- For specialist initiation in treating symptomatic hypotension that has not responsed to conventional therapies.
|
08.01.05 |
Midostaurin Rydapt® |
- Approved for the treatment of advanced systemic mastocytosis in line with NICE
|
08.02.04 |
Mifamurtide |
- Approved for high-grade resectable non-metastatic osteosarcoma in line with NICE.
|
07.01.02 |
Mifepristone 200mg tablets |
|
09.08.01 |
Migalastat Galafold ® |
- Approved for the treatment of Fabry's disease in line with NICE
|
02.01.02 |
Milrinone |
|
05.01.03 |
Minocycline |
- Note: not be prescribed for the treatment of acne in new patients (July 2019).
|
10.01.03 |
Minocycline |
- Only approved for use in patients with rheumatoid arthritis who are unable to tolerate biologics and other DMARDs.
|
02.05.01 |
Minoxidil |
- Treatment should only be on the advice of a cardiologist/nephrologist.
|
07.04.02 |
Mirabegron |
- Approved for use when antimuscarinics don’t work, are not suitable or side effects are unacceptable, in line with NICE guidance.
|
11.09 |
Miraflow® daily cleaner |
|
01.05.03 |
Mirikizumab Omvoh® |
- 100mg/1ml solution for injection pre-filled pens & 300mg/15ml concentrate for solution for infusion
- Approved for treating moderately to severely active ulcerative colitis in adults in line with NICE
|
04.03.04 |
Mirtazapine |
- Orodispersible mirtazapine tablets should only be prescribed for use when other formulations are unsuitable (more expensive).
|
01.03.04 |
Misoprostol |
- Note: 100 microgram tablets (
unlicensed) are also on formulary - mainly for use in paediatric nephrology at the RVI.
|
07.01.01 |
Misoprostol |
|
08.01.02 |
Mitomycin |
- Also approved for treatment in combination with 5-Fluorouracil for bladder cancer concurrent with radiotherapy.
- Mitomycin 0.04% preservative free eye drops are also approved for use -
unlicensed.
|
08.01.05 |
Mitotane |
|
08.01.02 |
Mitoxantrone |
|
15.01.05 |
Mivacurium Mivacron® |
- 10mg in 5ml injection
- 20mg in 10ml injection
|
08.01.05 |
Mobocertinib |
|
04.03.02 |
Moclobemide |
- For use on advice from psychiatrists only.
|
04.04 |
Modafinil |
- Approved for:
- treatment of patients with narcolepsy
- treatment of idiopathic hypersomnia
|
08.01.05 |
Mogamulizumab Poteligeo® |
- Approved for previously treated mycosis fungoides and Sézary syndrome in line with NICE
|
05.03.06 |
Molnupiravir Lagevrio® |
|
08.01.05 |
Momelotinib Omjjara® |
- 100mg, 150mg and 200mg tablets
- Approved for treating myelofibrosis-related splenomegaly or symptoms in adults in line with NICE
|
03.02.03 |
Mometasone and indacaterol Atectura® |
- Mometasone furoate 127.5 microgram/dose & indacaterol 125 microcram/dose inhalation powder capsules (DPI)
- Mometasone furoate 260 microgram/dose & indacaterol 125 microcram/dose inhalation powder capsules (DPI)
- Both strengths approved for asthma only
|
13.04 |
Mometasone Furoate 0.1% Elocon® |
|
12.02.01 |
Mometasone Furoate 50microgram/metered dose nasal spray |
|
03.02.02 |
Mometasone, Indacaterol & glycopyrronium Enerzair Breezhaler® |
- Mometasone 136 microgram/dose, indacaterol 114 microcram/dose & glycopyrronium 46 microgram/dose inhalation powder capsules (DPI)
|
03.03.02 |
Montelukast |
- Review treatment after 6 weeks of initiation and discontinue if no evidence of improvement. Should typically only be initiated by hospital specialist.
- Montelukast is 2nd line after an inhaled corticosteroid for asthmatic children < 5 years old.
|
04.07.02 |
Morphine |
- Tablets - 10mg, 20mg, 50mg (Sevredol®)
- MR capsules - 10mg, 30mg, 60mg, 100mg, 200mg (Zomorph®)
- MR tablets - 5mg, 10mg, 15mg, 30mg, 60mg, 100mg, 200mg (MST®)
- Oral solution - 10mg in 5ml
- Injection - 10mg/ml, 15mg/ml, 20mg/ml, 30mg/ml
- Zomorph® is the preferred M/R formulation.
Note: the following preparations are also approved for use:
- morphine 5mg in 1ml injection
unlicensed
- 10mg in 1ml preservative free injection
unlicensed
- 2mg in 5ml epidural
unlicensed
- 100 micrograms/1 ml oral solution. For use in neonates.
unlicensed
- 50mg in 50ml PCA injection
|
05.01.12 |
Moxifloxacin |
|
11.03.01 |
Moxifloxacin |
|
02.05.02 |
Moxonidine |
|
12.02.03 |
Mupirocin 2% Bactroban Nasal® |
- First choice the treatment of MRSA
|
13.10.01.01 |
Mupirocin 2% Ointment Bactroban® |
|
09.06.07 |
Mutivitamins BPC |
- Capsules containing ascorbic acid 15mg, nicotinamide 7.5mg, riboflavin 500 micrograms, thiamine HCl 1mg, vitamin A 2,500 units, & vitamin D 300 units
|
10.01.03 |
Mycophenolate |
|
08.02.01 |
Mycophenolate Mofetil |
- For Transplant indications
unless from a Trust/speciality that hasn't formaly repatriated it's patients or for patients who require weekly scripts for MDS boxes .
|
08.02.01 |
Mycophenolate Sodium Myfortic® |
- Approved as second-line therapy in patients who do not tolerate mycophenolate mofetil.
- For Transplant indications
unless from a Trust/speciality that hasn't formaly repatriated it's patients or for patients who require weekly scripts for MDS boxes .
|
11.08.02.04 |
Mydrane |
Intracameral injection: tropicamide 0.2 mg/mL, phenylephrine 3.1 mg/mL, lidocaine 10 mg/mL; 0.6 mL ampoules |
18.01.01 |
N/A Ultra® (Silicone-coated) |
|
04.06 |
Nabilone |
|
10.01.01 |
Nabumetone |
|
02.04 |
Nadolol |
- Limited to use by cardiologists in patients with long QT syndrome/idiopathic ventricular fibrillation.
- Liquid formulations (
unlicensed) can be obtained for use in children if necessary. Treatment should only be on the advice of a cardiologist.
|
06.07.02 |
Nafarelin |
|
02.06.04 |
Naftidrofuryl |
- Approved for the treatment of intermittent claudication in people with peripheral arterial disease.
|
01.06.06 |
Naldemedine Rizmoic® |
- 200microgram tablet
- Approved for the treatment of opioid-induced constipation in line with NICE
|
04.10.01 |
Nalmefene |
- Only approved for use in accordance with NICE guidance.
- COUNTY DURHAM
acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
|
01.06.06 |
Naloxegol |
- 12.5mg and 25mg tablets
- Approved for the treatment of opioid-induced constipation in line with NICE
|
15.01.07 |
Naloxone |
- 400 microgram in 1ml injection (ampoules).
- 2mg/2ml pre-filled syringes (as per ACMD guidance).
|
16 |
Naloxone |
- 400 microgram injection – ampoules and prefilled syringes
![Green](images/TrafficLightsGreenV2.gif)
- 1.8mg/0.1ml nasal spray (single use)
- approved to offer a more convenient method of administration by non-healthcare professionals from Drug and Alcohol Services in accordance with local written protocols.
|
04.10.01 |
Naltrexone |
|
04.10.03 |
Naltrexone 50 mg tablets Nalorex® |
- Approved for the management of opioid dependence in detoxified formerly opioid-dependent people in line with NICE.
- Also approved NoTGhdNC for use in reducing agitation and/ or selfinjurious behaviour in patients with learning disabilities or autism (
unlicensed indication). Treatment must be initiated by an appropriate hospital specialist.
|
04.07.01 |
Naproxen tablets |
|
04.07.04.01 |
Naproxen tablets |
|
10.01.01 |
Naproxen tablets |
Tablets: 250mg, 500mg
Note: a naproxen 125mg in 5ml suspension ( unlicensed) is also approved. |
08.02.04 |
Natalizumab |
- Approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE and NHS England commissioning policy.
|
02.04 |
Nebivolol |
- For specialist use in the treatment of patients who cannot tolerate other beta-blockers. Treatment should only be on the advice of a cardiologist.
|
08.01.03 |
Nelarabine Atriance® |
|
05.03.01 |
Nelfinavir |
|
A2.03.01 |
Neocate LCP |
|
05.01.04 |
Neomycin |
- 500mg tablets
- 1g in 10ml syrup
unlicensed.
|
10.02.01 |
Neostigmine |
|
15.01.06 |
Neostigmine |
|
15.01.06 |
Neostigmine with Glycopyrronium |
- Glycopyrronium 500 microgram & neostigmine 2.5mg in 1ml injection (Robinul – neostigmine)
|
11.08.02 |
Nepafenac |
|
08.01.05 |
Neratinib Nerlynx® |
- Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE
|
04.06 |
Netupitant & Palonosetron Akynzeo® |
- To be used in accordance with Northern England Strategic Clincial Cancer Network (NCCN) Guidelines
|
05.03.01 |
Nevirapine |
|
19 |
Nexobrid |
- Enzyme-based debriding agent for the removal of eschar in adults with deep partial and full thickness thermal burns
|
02.06.02 |
Nicardipine 1mg in 1ml injection |
- Approved as a second line agent for the treatment of aortic dissection and pre-eclampsia.
|
02.06.03 |
Nicorandil |
|
04.10.02 |
Nicotine |
- The following nicotine replacement treatments are approved:
- Nicotine gum - 2mg & 4mg sugar-free chewing gum (Nicorette® is the gum of choice).
- Nicotine 16 hour patch - 10mg, 15mg, and 25mg/16 hour patches (Nicorette® Invisi).
- Nicotine 24 hour patch - 7mg & 14mg, and 21mg /24 hour patches (Nicotinell® is the patch of choice as potential savings to be made).
- Nicotine lozenges - 2mg and 4mg lozenges (Niquitin® is the lozenge of choice), 1.5mg and 4mg mini lozenges (NiQuitin® Minis Lozenges).
- Nicotine 2mg sublingual tablets.
- Nicotine inhalator - 15mg cartridges for use in inhalator.
- Nicotine oromucosal spray - Nicorette® Quickmist 1mg per dose.
- North Cumbria - Smoking Cessation is commissioned separately through community pharmacies and should not be prescribed on FP10's
- Newcastle/Gateshead - Local Authority smoking cessation programme should be used. NRT should not routinely be prescribed on FP10
|
02.06.02 |
Nifedipine |
- Once daily formualtions are preferred
- 20mg controlled release tablets (Adalat LA), 30mg & 60mg m/r capsules (Coracten XL)
- 5mg & 10mg capsules
- 10mg & 20mg retard tablets
- 20mg in 1ml (1mg/drop) nifedipine oral solution is also approved for use
unlicensed.
|
07.01.04 |
Nifedipine |
|
08.01.05 |
Nilotinib Tasigna® |
- Approved for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML in line with NICE and NHS Commissioning Policy
|
02.06.02 |
Nimodipine |
- 30mg tablets - treatment should be on the advice of the stroke team or a cardiologist.
|
02.06.02 |
Nimodipine Injection |
- 10mg in 50ml for IV infusion
|
03.11 |
Nintedanib Ofev® |
- Approved for treating idiopathic pulmonary fibrosis
- Approved for treating progressive fibrosing interstitial lung diseases in line with NICE
|
08.01.05 |
Nintedanib |
- Approved for the treatment of locally advanced, metastatic or locally recurrent non-small-cell lung cancer who have previously been treated been with first-line chemotherapy in accordance with NICE.
- Approved for treating idiopathic pumonary fibrosis in line with NICE
|
08.01.05 |
Niraparib Zejula® |
- Approved for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE
|
05.03.06 |
Nirmatrelvir and Ritonavir Paxlovid® |
- Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid®)
- As per NICE TA 878
|
09.08.01 |
Nitisinone |
|
15.01.02 |
Nitric Oxide |
|
05.01.13 |
Nitrofurantoin |
- Note: Liquid presentations of nitrofurantoin are very expensive compared to
other solid dosage formulation. Please consider whether capsules can be used.
|
13.10.01.01 |
Nitrofurazone 0.2% Ointment |
- For limited use in burns/plastic surgery patients only.
|
15.01.02 |
Nitrous oxide |
|
08.01.05 |
Nivolumab Opdivo® |
- For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults.
- Approved for the treatment of advanced (unresectable or metastatic) melanoma in adults in line with NICE.
- Approved in combination with ipilimumab for treating advanced melanoma in line with NICE and NHS England Commissioning Policy (SSC1664)
- Approved for the treatment of advanced renal cell carcinoma in adults in line with NICE and NHS England Commissioning Policy
- Approved for the treatment of relapsed of refractory classical Hodgkin lymphoma in line with NICE and NHS England Commissioning Policy
- Approved for the treatment of locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
- Approved for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults
- Approved for use in patients with previously untreated unresectable advanced or recurrent oesophageal cancer in line with NICE
- Approved in combination ipilimumab for use in patients with previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
- Approved for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults in line with NICE
- Approved adjuvant treatment of completely resected oesophageal or gastro‑oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy in line with NICE
- Approved in combination with ipilimumab for untreated advanced renal cell carcinoma in line with NICE
- Approved for adjuvant treatment of invasive urothelial cancer at high risk of recurrence in line with NICE
- Approved with ipilimumab or untreated unresectable malignant pleural mesothelioma in adults in line with NICE
- Approved for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
- Approved (with fluoropyrimidine-based and platinum-based combination chemotherapy) for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more.
- Approved as an option for the neoadjuvant treatment of resectable (tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults - in line with NICE TA876.
|
08.01.05 |
Nivolumab-relatlimab Opdualag® |
- 240mg/20ml (12mg/1ml) & 80mg/20ml (4mg/1ml) concentrate for solution for infusion
- Approved for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over in line with NICE
|
01.03.01 |
Nizatidine |
|
18.07.02 |
Non-woven Fabric Swab |
Non-woven fabric folded 4-ply |
07.03.03 |
Nonxynol ’9’ - 2% gel Gygel® |
|
02.07.02 |
Noradrenaline / Norepinephrine |
|
08.03.02 |
Norethisterone |
|
06.04.01.02 |
Norethisterone 5mg tablets |
|
14.05.01 |
Normal Immunoglobulin Kiovig® |
- 10% - 1g, 2.5g, 5g, 10g, 20g & 30g
|
14.05.01 |
Normal Immunoglobulin Subcuvia® |
|
14.05.01 |
Normal Immunoglobulin Privigen® |
- 10% - 2.5g, 5g, 10g & 20g
|
14.05.01 |
Normal Immunoglobulin Octagam® |
- 5% - 5g & 10g
- 10% - 2g, 5g, 10g & 20g
|
14.05.01 |
Normal Immunoglobulin Flebogamma®DIF |
|
14.05.01 |
Normal Immunoglobulin Gammunex® |
|
14.05.01 |
Normal Immunoglobulin Iqymune® |
|
14.05.01 |
Normal Immunoglobulin Intratect® |
- 5% - 1g, 2.5g, 5g & 10g
- 10% - 1g, 5g, 10g & 20g
|
14.05.01 |
Normal Immunoglobulin Cuvitru® |
|
14.05.01 |
Normal Immunoglobulin Gammanorm® |
- 16.5% - 1g, 1.65g, 2g, 3.3g, 4g & 8g
|
14.05.01 |
Normal immunoglobulin for Intramuscular use |
|
04.07.03 |
Nortriptyline |
|
18.07.01 |
Nurse It® Dressing Pack |
Contains latex-free, powder-free nitrile gloves, sterile laminated paper sheet, large apron, non-woven swabs, paper towel, disposable bag, compartmented tray, disposable forceps, paper measuring tape |
10.02 |
Nusinersen Spinraza® |
- 12mg solution for injection
- Approved as an option for treating 5q spinal muscular atrophy (SMA) types 1, 2 or 3 in line with NICE.
|
A2.05.02 |
Nutilis Clear Nutilis® |
|
A2.03.01 |
Nutramigen Puramino |
|
A2.01.03.02 |
Nutrini® |
|
A2.01.01.01 |
Nutrison® |
|
13.04 |
Nystaform-HC® |
|
05.02.03 |
Nystatin |
- 100,000 units/ml suspension
.
- 100,000 unit pessaries
unlicensed ![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Second line treatment for vaginal non albicans infection, for patients who have not responded to standard treatments such as azoles. Prescribing is restricted to the GUM clinics.
|
12.03.02 |
Nystatin 1000,000units/ml suspension Nystan® |
|
07.02.02 |
Nystatin Pessaries |
- Nystatin 100,000 Pessaries (unlicensed)
- As per BASHH guidelines for non-albicans vulvovaginal candida or in azole resistance.
|
01.09.01 |
Obeticholic acid |
- 5mg & 10mg tablets
- Approved for the treatment of primary biliary cholangitis in line with NICE and NHS England Commissioning Policy.
|
08.02.03 |
Obinutuzumab |
- Approved for use in chronic lymphocytic leukaemia in combination with chlorambucil in patients who have co-morbitities that make full‑dose fludarabine‑based therapy unsuitable for them, only if bendamustine‑based therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding).
- Approved for the treatment of rituximab-refractory follicular lymphoma in combination bendamustine in line with NICE and NHS England Commissioning Policy
- Approved with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults in line with NICE
- Approved to prevent immune immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant
to rituximab (adults) in line with NHSE Commissioning Policy
- Only available at The Newcastle upon Tyne Hospitals NHS Trust
|
08.02.03 |
Ocrelizumab Ocrevus® |
- Approved for the treatment of relapsing-remitting multiple sclerosis in line with NICE
|
11.08.02 |
Ocriplasmin Jetrea® |
- Approved for use in patients with vitreomacular traction who also have no epiretinal membrane and a hole (up to 400 micrometres) in the centre of their retina or severe sight problems in line with NICE.
|
02.11 |
Octanate |
- Approved for patients with severe Haemophilia A and an inhibitor and in whom there is agreement to undertake immune tolerance induction with a plasma derived product.
|
02.11 |
Octaplas and Octaplas LG |
- Solution for infusion containing 45-75mg/ml human plasma proteins.
|
13.11.03 |
Octenisan® wash |
- Used in some trusts as an alternative to chlorhexidine scrub and Triclosan skin cleanser in MRSA prophylaxis/eradication on secondary care advice.
|
08.03.04.03 |
Octreotide |
- Approved formulations include octreotide 50microgram, 100microgram, and 500 microgram in 1ml, and 1mg in 5ml injections, and octreotide 10mg, 20mg and 30mg long-acting injections.
Existing patients
for acromegaly, neuroendocrine tumour and carcinoid. New patients (commenced treatment after July 2019)
for acromegaly, neuroendocrine tumour and carcinoid.
Approved for the management of GI secretions in end of life care
|
16 |
Octreotide |
|
01.09.01 |
Odevixibat Bylvay® |
- Approved for the treatment of progressive familial intrahepatic cholestasis in line with NICE
|
06.04.01.01 |
Oestrogen conjugated tablets 625microgram and 1.2mg Premarin® |
|
08.02.03 |
Ofatumumab Kesimpta® |
- 20mg/0.4ml solution for injection (pre-filled pens)
- Approved for the treatment of relapsing-remitting multiple sclerosis in adults with active diseases defined by clinical or imaging features in line with NICE
|
11.03.01 |
Ofloxacin 0.3% Eye drops |
|
05.01.12 |
Ofloxacin Infusion |
|
05.01.12 |
Ofloxacin Oral Preparations |
- Tablets: 200mg, 400mg
- For use in the treatment of pelvic inflammatory disease and chlamydia genital tract infections in accordance with local primary care guidelines.
|
13.09 |
Oilatum shampoo |
|
13.02.01 |
Oilatum® cream |
|
13.02.01 |
Oilatum® Junior cream |
|
01.07.03 |
Oily phenol injection BP |
|
04.02.01 |
Olanzapine |
- Olanzapine orodispersible tablets should only be used in situations where the plain tablets are unsuitable.
- Olanzapine orodispersible tablets and injection are also approved for 2nd/3rd- line use in the management of delirium in critical care patients
unlicensed indication. ![Green plus](images/TrafficLightsGreenPlus.gif)
- 10 mg injection
- for rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
- for delirium at end of life
- 210mg, 300mg & 405mg powder and solvent for suspension for long-acting injection (as olanzapine embonate monohydrate)
![Red](images/TrafficLightsRedV2.gif)
- approved for the treatment of schizophrenia in adults within secure psychiatric services
|
04.02.03 |
Olanzapine (oral) |
|
04.02.02 |
Olanzapine Embonate ZypAdhera® |
|
08.01.05 |
Olaparib Lynparza® |
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
- Approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation in line with NICE
- Approved for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults in line with NICE
- Approved for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults in line with NICE
- Approved as maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults in line with NICE and NHSE Specialised Commissioning policy
- Approved with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE and NHSE Specialised Commissioning policy
- Approved with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults in line with NICE
- Approved for maintenance treatment of BRCA muatation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
|
12.01.03 |
Olive Oil Ear Drops |
|
11.04.02 |
Olopatadine Opatanol® |
|
03.04.02 |
Omalizumab Xolair® |
- 75mg/0.5ml & 150mg/1ml solution for injection (pre-filled devices)
- Only approved for use in accordance with NICE guidance.
|
01.03.05 |
Omeprazole |
- 10mg, 20mg & 40m capsules
- Dispersible tablets (Losec® MUPS) should only be used in patients who cannot swallow capsules or tablets and where lansoprazole orodispersible tablets are unsuitable.
- 10mg in 5ml oral suspension can be obtained for use in very small children and where a suspension has to be given down a very fine NG tube (below French Size 8) .
Green plus
- For acute Gastrointestinal bleeding see local guidelines
|
01.03.05 |
Omeprazole IV |
- 40mg IV Infusion
- 40mg Injection (powder for reconstitution)
|
19 |
Onasemnogene abeparvovec Zolgenmsa® |
- Approved for the treatment of spinal muscular atrophy in line with NICE
|
04.06 |
Ondansetron |
- The cheapest available formulation should be used.
- Ondansetron 4mg and 8mg oro-dispersible tablets/films are approved for the treatment of post-operative nausea and vomiting in patients who do not require IV access or are nil by mouth
|
04.06 |
Ondansetron INJECTION |
|
04.09.01 |
Opicapone |
|
18.02.02 |
Opsite® Post-Op |
|
09.04 |
Oral Nutritional Supplements |
|
07.03.02.01 |
Oral progestrogen-only contraceptive |
First choice
- Cerelle® (desogestrel 75 microgram tablets).
- Cerazette® (desogestrel 75 microgram tablets).
- Zelleta® (desogestrel 75 microgram tablets).
Alternatives
- Norgeston® (levonorgestrel 30 microgram tablets).
|
09.01 |
Oral Rehydration Salts Dioralyte® |
|
04.05.01 |
Orlistat |
- Only approved for use in accordance with NICE guidance.
|
04.09.02 |
Orphenadrine |
|
05.03.04 |
Oseltamivir Tamiflu® |
- 30mg, 45mg and 75mg capsules
- 6mg/mL oral suspension
- Only approved for use in accordance with NICE guidance.
|
08.02.04 |
Osimertinib Tagrisso |
- 40mg and 80mg tablet
- Approved for the treatment of EGFR mutation-positive non-small-cell lung cancer in line with NICE
- Approved for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in line with NICE
|
09.05.02.02 |
Osvaren® |
- Tablets containing calcium acetate 435mg & Magnesium carbonate heavy 235mg.
- For use, after calcium carbonate and calcium acetate, but before the
much more expensive sevelamer and lanthanum.
|
08.01.05 |
Oxaliplatin |
- Approved for Dukes C colon cancer in combination with 5-fluorouracil
and folinic acid in line with NICE.
- Approved for advanced and metastatic colorectal cancer in line with NICE.
|
03.04.03 |
Oxandrolone 2.5mg and 10mg capsules |
- For use on the advice of an immunologist in the prophylaxis treatment hereditary angioedema associated with C1-esterase inhibitor deficiency when danzol and stanozolol are not available.
|
04.08.01 |
Oxcarbazepine |
|
11.07 |
Oxybuprocaine 0.4% Minims® |
|
07.04.02 |
Oxybutynin |
- 2.5mg in 5ml & 1mg/1ml oral solution
- Immediate release oxybutinin is not appropriate for frail elderly people or those with cognitive impairment.
|
07.04.02 |
Oxybutynin Hydrochloride - patch |
- Oxybutinin patch 36mg (releases approximately 3.6mg in 24 hours).
- Approved for patients in whom two antimuscarinics have proved to be efficacious but the side effects are intolerable, or for patients who cannot swallow tablets.
|
04.07.02 |
Oxycodone |
- Approved only for use in patients who are intolerant of morphine.
![Green](images/TrafficLightsGreenV2.gif)
- Note: Oxycodone 50mg in 1ml injection is also approved for use, but is restricted to controlled circumstances in palliative patients following risk assessment by individual organisations.
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
- Approved for use as part of Enhanced Recovery After Surgery (ERAS) as part of multi-modal enhanced recovery pathway following hip and knee surgery
![Red](images/TrafficLightsRedV2.gif)
- The OxyPro® branded generic is preferred (most cost effective option).
- The oral solution should be used instead of immediate release tablets.
|
15.01.02 |
Oxygen |
|
11.09 |
Oxysept® 1 Step |
|
05.01.03 |
Oxytetracycline |
|
07.01.01 |
Oxytocin |
- The following formulations are approved for use:
- 10 units in 1ml injection
- 5 units in 50ml syringes
unlicensed.
|
01.05.03 |
Ozanimod Zeposia® |
- Approved for moderately to severely active ulcerative colitis in adults in line with NICE.
|
08.01.05 |
Pablociclib Ibrance® |
|
08.01.05 |
Paclitaxel |
- The following formulations are approved:
- 30mg in 5ml, 100mg in 16.7ml, and 150mg in 25ml concentrate for preparing IV infusion.
- Approved for the treatment of recurrent ovarian cancer in line with NICE.
|
08.01.05 |
Paclitaxel - Albumin Bound Formulation Abraxane® |
- Note: Abraxane® 5mg in 1ml powder for suspension for infusion is restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.
- Approved in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) for first line therapy in ovarian cancer in line with NICE.
- Approved in combination with a platinum-based drug (carboplatin or cisplatin) for second-line (or subsequent) therapy in ovarian cancer in line with NICE
- Approved metastatic breast cancer in line with NICE.
- Abraxane is not recommended for the adjuvant treatment of women with early node-positive breast cancer NICE.
- Approved in combination with gemcitabine for untreated metastatic pancreatic cancer in line with NICE and NHS England Commissioning Policy as of 5th December 2017
|
08.03.04.01 |
Palbociclib Ibrance® |
- 75mg, 100mg & 125mg capsules
- Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE
- Approved with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in line with NICE
|
04.02.02 |
Paliperidone |
CNTW
TEWV
- Approved for the treatment of psychosis and schizophrenia in line with NICE guidance
|
05.03.05 |
Palivizumab |
- To be used in accordance with NHS England Commissioning Policy.
|
04.06 |
Palonosetron |
- Only approved for the second line treatment of chemotherapy induced nausea vomiting only.
|
01.09.04 |
Pancreatin Creon® |
|
01.09.04 |
Pancreatin Pancrex® V |
|
01.09.04 |
Pancreatin Creon® Micro |
|
15.01.05 |
Pancuronium |
|
08.01.05 |
Panitumumab Vectibix® |
- Approved for previously untreated metastatic colorectal cancer in line with NICE.
|
08.01.05 |
Panobinostat |
- Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.
|
01.03.05 |
Pantoprazole IV |
|
15.01.05 |
Papaverine |
- 30mg/2ml injection
unlicensed
|
04.07.01 |
Paracetamol |
- Paracetamol 500mg tablets / soluble tablets
- Paracetamol 1gram injection for IV infusion
- NoTGhdNC: approved for limited short-term use where oral and rectal routes cannot be used and NSAIDs are not appropriate in paediatric areas only, the 50ml formulation should be stocked.
- Paracetamol suppositories
- Licensed preparations include 60mg,125mg, 250mg, and 500mg suppositories are available in primary care.
unlicensed preparations include 15mg, 30mg, 60mg, 120mg, 240mg, and 500mg. These are used in NUTH.
|
04.07.04.01 |
Paracetamol |
|
04.08.03 |
Paracetamol |
Paracetamol suppositories
unlicensed preparations include 15mg, 30mg, 60mg, 120mg, 240mg, and 500mg. These are used in NUTH.
- Licensed preparations include 60mg, 125mg, 250mg, and 500mg suppositories are available in primary care.
|
18.01.01 |
Paraffin Gauze Dressing BP Sterile Paranet® |
|
13.02.01 |
Paraffin sterile liquid |
|
04.08.02 |
Paraldehyde rectal liquid |
- For initiation by neurologists only.
|
15.01.04.02 |
Parecoxib 40mg injection Dynastat® |
- For peri-operative use only.
|
09.05.01.02 |
Paricalcitol |
- Approved for use in patients with PTH levels < 800mcg/l but whose treatment with alfacalcidol is restricted due to a high calcium level.
|
05.04 |
Paromomycin |
- 250mg tablets and Injection
- For Leishmaniasis
- Infectious diseases of microbiology advice only
|
04.03.03 |
Paroxetine |
|
08.03.04.03 |
Pasireotide Signifor® |
- Approved for the treatment of Cushing’s disease in line with NHS England Policy.
|
19 |
Patent Blue V Sodium |
|
09.02.01.01 |
Patiromer calcium (as Patiromer sorbitex calcium) |
- Approved for the treatment of hyperkalaemia in adults in line with NICE
![Green plus](images/TrafficLightsGreenPlus.gif)
- Approved for emergency acute treatment
![Red](images/TrafficLightsRedV2.gif)
|
04.12 |
Patisiran Onpattro® |
- 10mg vial
- Approved for the treatment of hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuopathy in line with NICE
|
08.01.05 |
Pazopanib Votrient® |
- Approved for advanced renal cell carcinoma in line with NICE
|
03.04.02 |
Peanut Allergy Palforzia® |
- 0.5mg, 1mg, 10mg, 20mg and 100mg oral powder in capsules for opening
- 300mg oral powder (sachets)
- Approved for the treatment of peanut allergy in children and young people in line with NICE
|
08.01 |
Pegaspargase 3750iu vial |
|
09.01.03 |
Pegcetacoplan Aspaveli® |
- 1080mg/20 solution for infusion
- Approved for the treatment paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor in line with NICE and NHSE Commissioning Policy.
- Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:
- King’s College Hospital NHS Foundation Trust, London - London and South East
- Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom
|
09.01.06 |
Pegfilgrastim (G-CSF) |
|
05.03.03.02 |
Peginterferon Alfa Pegasys®, ViraferonPeg® |
- Approved for hepatitis B and C in accordance with NICE guidelines and NHS England Commissioning Policies.
|
08.02.04 |
Peginterferon Alfa Pegasys®, ViraferonPeg® |
- Approved for hepatitis B and C in accordance with NICE guidelines and NHS England Commissioning Policies.
|
08.02.04 |
Peginterferon Beta-1a Plegridy® |
- Approved treating relapsing–remitting multiple sclerosis in adults in line with NICE.
|
09.08.01 |
Pegunigalsidase alfa Elfabrio® |
- 20mg/10ml concentrate for solution for infusion
- Approved for treating Fabry disease in line with NICE and NHSE Specialised Commissioning guidance
|
06.05.01 |
Pegvisomant Somavert® |
|
08.01.05 |
Pembrolizumab Keytruda® |
- Approved for the treatment of advanced melanoma after disease progression with ipilimumab in accordance with NICE.
- Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE.
- Approved for treating PD-L1-positive non-small-cell lung cancer
- Approved for treating PD-L1-positive metastatic non-small-cell lung cancer
- Approved for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more in line with NICE
- Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
- Approved for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults in line with NICE
- Approved for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
- Approved with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults in line with NICE
- Approved for adjuvant treatment of completely resected stage 3 melanoma in line with NICE
- Approved in combination with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer in line with NICE
- Approved for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies in line with NICE
- Approved with paclitaxel or nab‑paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
- Approved for adjuvant treatment of renal cell carcinoma in adults in line with NICE
- Approved for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over in line with NICE
- Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations in line with NICE
- Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults in line with NICE
- Approved with lenvatinib for previously treated advanced or recurrent endometrial cancer in line with NICE and NHSE Specialised Commissioning guidance
- Approved for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE and NHSE Specialised Commissioning guidance
- Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in line with NICE
|
08.01.03 |
Pemetrexed |
- Approved for:
- Mesothelioma in line with NICE (funding has to be agreed on an individual patient basis if treatment is not in line with NICE).
- Combination with cisplatin for the first line treatment of locally advanced or metastatic NSCLC (non-squamous cell histology) in line with NICE.
- Maintenance treatment of locally advanced or metastatic NSCLC (non-squamous cell histology) in line with NICE.
- Maintenance treatment of non-squamous non-small lung cancer after pemetrexed and cisplatin in line with NICE and NHS England Commissioning Policy.
- Note: pemetrexed is not approved for locally advanced or metastatic NSCLC as per NICE.
|
08.01.05 |
Pemigatinib Pemaryze® |
- 4.5mg, 9mg and 13.5mg tablets
- Approved for the treatment of relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in line with NICE
|
09.08.01 |
Penicillamine |
- 125mg & 250mg tablets - also used for the treatment ofcystinuria and rheumatoid arthritis – section 10.1.3
|
10.01.03 |
Penicillamine |
|
16 |
Penicillamine |
|
05.04.08 |
Pentamidine Isetionate |
|
07.04.03 |
Pentosan Polysulphate Sodium Elmiron® |
- Approved for treating bladder pain in line with NICE
|
08.01.05 |
Pentostatin Nipent® |
|
01.02 |
Peppermint Oil Colpermin® |
|
01.02 |
Peppermint water |
|
01.01.02 |
Peptac |
- Preferred antacid for treating reflux. Use instead of Gaviscon®.
|
04.08.01 |
Perampanel |
- NETAG approved for partial (focal) seizure epilepsy only when other treatment options recommended by NICE have been tried or fully considered.
|
02.05.05.01 |
Perindopril erbumine |
- Perindopril is third line for all indications including prevention of stroke.
- Note: Perindopril arginine is Non-Formulary.
|
13.10.04 |
Permethrin 1% Lyclear® Creme Rinse |
|
13.10.04 |
Permethrin 5% Lyclear® Dermal Cream |
|
13.10.04 |
Permethrin 5% Lyclear® Dermal Cream |
|
04.02.01 |
Perphenazine |
|
08.01.05 |
Pertuzumab Perjeta® |
- Approved for the neoadjuvant treatment of HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
- Approved with trastuzumab and docetaxel for treating HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
- Approved for adjuvant treatment of HER2-positive early stage breast cancer in line with NICE
|
04.07.02 |
Pethidine |
|
12.01.02 |
Phenazone with lidocaine Otigo® |
- Phenazone 40mg/1g & lidocaine hydrochloride 10mg/1g ear drops
- Approved for the treatment of Acute otitis media & Barotraumatic otitis in line NICE
|
19 |
Phenazopyridine tablets |
|
04.03.02 |
Phenelzine |
- For use on advice from psychiatrists only.
|
02.08.02 |
Phenindione |
|
04.08.01 |
Phenobarbital |
- 15mg/5ml oral solution
- not suitable for use in children
- 50mg/5ml alcohol free oral solution e.g. Rosement (unlicensed)
- to be used for all children (<18yrs) who require a liquid preparation.
|
04.08.02 |
Phenobarbital Sodium |
|
04.08.01 |
Phenobarbital INJECTION |
|
19 |
Phenol (aqueous) Injection 6% |
|
04.12 |
Phenol 5% in Glycerol Injection |
- Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients
|
02.05.04 |
Phenoxybenzamine |
|
05.01.01.01 |
Phenoxymethylpenicillin |
|
02.05.04 |
Phentolamine |
|
16 |
Phentolamine |
|
10.01.01 |
Phenylbutazone |
Tablets: 100mg
Indication: Ankylosing Spondylitis.
Used only by a specialist in severe cases where other treatments have been found unsuitable. |
02.07.02 |
Phenylephrine |
|
11.05 |
Phenylephrine |
- 2.5% eye drops
unlicensed
- 2.5% single use Minims®
|
11.05 |
Phenylephrine Hydrochloride |
- 2.5% eye drops
unlicensed.
- 2.5% single use Minims®.
|
04.07.03 |
Phenytoin |
|
04.08.01 |
Phenytoin |
- Note: phenytoin 30mg in 5ml suspension (base) – 90mg (15ml) is equivalent to one 100mg phenytoin sodium capsule 250mg in 5ml injection (sodium salt).
|
04.08.02 |
Phenytoin sodium 250mg in 5ml injection |
- For initiation by neurologists only.
|
09.05.02.01 |
Phosphate |
- 4.15 mmol phosphate in 10ml oral solution
unlicensed
|
09.05.02.01 |
Phosphate Polyfusor |
- 500ml intravenous infusion containing 50mmol phosphate
per 500ml (PO4 3- 100 mmol, K+ 19 mmol, and Na+ 162 mmol/litre).
|
01.06.04 |
Phosphates |
|
09.05.02.01 |
Phosphate-Sandoz® |
- Effervescent tablets (phosphate 16.1 mmol, sodium 20.4mmol & potassium 3.1 mmol / tablet)
|
09.02.02.02 |
Phoxilium 1.2mmol/l phosphate |
- A haemofiltration and haemodialysis fluid containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 0.6 mmol, Ca2+ 1.25mmol/l, Cl- 115.9 mmol/l, HCO3 - 30.0mmol/l, HPO4 2- 1.20mmol/l.
- Approved for use in CRRT in patients not requiring reduced potassium or low bicarbonate.
|
15.01.06 |
Physostigmine |
- 1mg in 1ml injection
unlicensed
|
09.06.06 |
Phytomenadione |
- 50 microgram in 0.25ml drops (NeoKay®)
unlicensed
- 1mg capsule- preferred product for use in neonates
- 10mg in 1ml injection
unlicensed
- 2mg in 0.2ml mixed micelles injection (Konakion® MM
Paediatric) – may be taken by mouth as well as being given by IM or IV injection
|
16 |
Phytomenadione (vitamin K) |
|
08.01.05 |
Picibanil |
|
18.06.01 |
PICO® Single Use NPWT System |
|
11.06 |
Pilocarpine |
- 2% and 4% eye drops.
- 1% and 2% unit dose eye drops.
|
12.03.05 |
Pilocarpine 5mg tablets |
- Treatment to be initiated with specialist advice.
|
13.05.03 |
Pimecrolimus cream Elidel® |
- Approved for moderate disease on face and neck for those between 2 and 16 years in line NICE.
|
06.01.02.03 |
Pioglitazone |
|
05.01.01.04 |
Piperacillin and Tazobactam |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
04.08.01 |
Piracetam |
|
03.11 |
Pirfenidone |
- Approved for the treatment of idiopathic pulmonary fibrosis in line with NICE and NHS England Commissioning Policy
|
04.04 |
Pitolisant Wakix® |
- Approved for use in patients with narcolepsy who experience psychomotor side effects with modafinil and dexamfetamine.
- To be used in line with NTAG
|
05.01.01.05 |
Pivmecillinam |
|
08.01.02 |
Pixantrone |
- Approved as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma if they have previously been treated with rituximab and they are having third- or fourth-line treatment in line with NICE.
|
04.07.04.02 |
Pizotifen |
|
09.02.02.02 |
Plasma-lyte 148 with Glucose 5% |
- Infusion in a balanced electrolyte solution containing Na+ 140 mmol, K+ 5 mmol, Mg2+ 1.5 mmol, acetate 27 mmol/litre. Gluconate 23 mmol/litre. Note calcium free.
- Approved for use in paediatric theatres only.
|
13.11 |
Plaster remover |
|
01.06.05 |
Plenvu ® |
- Approved as a second line option to Moviprep for bowel cleansing prior to colonoscopy where large fluid volumes are a problem.
|
09.01.07 |
Plerixafor Mozobil® |
- Approved by NHS England Specialist Services for stem cell mobilisation for patients with Hodgkin’s disease, Non-Hodgkins lymphoma or multiple myeloma and meet the policy for Haematopoietic Stem Cell Transplantation.
|
14.04 |
Pneumococcal polysaccharide conjugate vaccine |
|
13.07 |
Podophyllotoxin 0.15% cream Warticon® |
|
08.01.05 |
Polatuzumab vedotin Polivy® |
- Approved with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant in line with NICE
- Approved with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults - in line with NICE TA874.
|
11.03.01 |
Polihexanide |
Unlicensed |
14.04 |
Poliomyelitis Vaccine Inactivated (Salk) |
|
14.04 |
Poliomyelitis Vaccine Live (oral) |
|
18.07.01 |
Polyfield ® Nitrile Patient Pack |
Contains powder-free nitrile gloves, laminate sheet, non-woven swabs, towel, polythene disposable bag, apron
|
11.03.01 |
Polyhexamethylene biguinide (PHMB) 0.02% Eye drops |
|
08.01.05 |
Pomalidomide |
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm
|
08.02.04 |
Pomalidomide Imnovid® |
- For the treatment of multiple myeloma previously treated with lenalidomide and bortezomib in line with NICE and NHS Commissioning Policy
|
08.01.05 |
Ponatinib Iclusig® |
- 15mg, 30mg & 45mg film-coated tablets
- Approved for the treatment of chronic myeloid leukaemia and acute lymphoblastic leukaemia in line with NICE and NHS England Commissioning Policy
|
08.02.04 |
Ponesimod Ponvory® |
- 20mg tablets
- Approved for treating relapsing–remitting multiple sclerosis with active disease defined by clinical or imaging features in adults in line with NICE
|
03.05.02 |
Poractant Alfa |
|
08.01.05 |
Porfimer Sodium Photofrin ® |
|
05.02.01 |
Posaconazole Noxafil® |
- Approved for the prevention of invasive fungal infection in immunocompromised patients in whom there is a specific risk of aspergillus infection or where fluconazole and itraconazole are not tolerated or are unlikely to be sufficiently effective (largely for secondary prevention).
- Approved for patients with invasive fungal infections that are not responding to other treatments or where they are not tolerated (largely in place of liposomal amphotericin/ voriconazole).
|
09.02.01.01 |
Potassium Chloride Sando-K® |
- Effervescent tablets (12mmol potassium 8 mmol chloride)
|
09.02.01.01 |
Potassium Chloride |
5mmol in 5ml sugar-free syrup (Kay-Cee-L) |
07.04.03 |
Potassium Citrate Mixture |
- potassium citrate 3g & citric acid 500mg in 10ml
Note: for the treatment of mild cystitis potassium citrate mixture is suitable for self-care. |
06.02.02 |
Potassium Iodate 85mg tablets |
- Mainly used by medical physics.
|
13.10.01.01 |
Potassium Iodide capsules |
Unlicensed
- Potassium Iodide 60mg and 300mg capsules
- Approved for neutrophilic dermatoses (Sweet syndrome and pyoderma gangrenosum) and panniculitis (including erythema nodosum and nodular vasculitis)
- Dermatology only
|
13.11.06 |
Potassium Permanganate |
- 5% solution
unlicensed
- 400mg tablets
- Potassium permanganate not to be issued on repeat prescription
|
09.02.01.01 |
Potassium Removal Polystyrene Sulphonate Resin Powder (Calcium polystyrene sulphonate) Sorbisterit |
|
11.03.01 |
Povidone iodine 5% |
|
11.08.02 |
Povidone iodine 5% eye drops |
- For use in eye surgery only.
|
13.11.04 |
Povidone-Iodine |
- 2.5% dry powder spray
- 10% alcoholic solution
- 7.5% surgical scrub
- 10% antiseptic solution (aqueous)
- 0.35% sterile aqueous solution
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- approved for use in the prevention of surgical site infection in arthroplasty.
|
18.03.02 |
Povitulle® |
Knitted viscose primary dressing impregnated with povidone-iodine ointment
- First choice in primary care
|
15.02 |
PR Freeze Spray |
|
16 |
Pralidoxime Mesylate |
|
04.09.01 |
Pramipexole |
- Approved for second line use in Parkinson's disease.
|
04.09.01 |
Pramipexole (restless legs) |
|
02.09 |
Prasugrel |
- Only approved for use in accordance with NICE guidance.
|
02.12 |
Pravastatin |
- 10mg, 20mg & 40mg tablets
|
05.05.05 |
Praziquatel Biltricide |
|
07.04.01 |
Prazosin |
|
01.05.02 |
Prednisolone |
|
01.05.02 |
Prednisolone |
First Choice
See BNF 06:03:02 for formulations
|
06.03.02 |
Prednisolone |
- The lowest cost formulation should be used when clinically appropriate. Formulations approved include:
- 1mg in 1ml oral solution (Prednisolone Dompé®);
|
12.01.01 |
Prednisolone 0.5% ear/eye drops |
- Second choice corticosteroid ear drops.
|
11.04.01 |
Prednisolone 0.5% Single Use Minims® |
|
11.04.01 |
Prednisolone eye drops |
- The following formulations are approved
- 0.5% eye drops and 1% (Pred-Forte).
- 0.1% and 0.3% eye drops - both
unlicensed.
- Approved preservative free formulations include
- 0.5% minims.
- 0.1%, 0.3%, 0.5% and 1% - all
unlicensed.
|
04.01.02 |
Pregabalin |
|
04.07.03 |
Pregabalin |
- Pregabalin is restricted to use in the management neuropathic pain as a second choice where treatment with gabapentin has been unsuccessful or not tolerated.
|
04.08.01 |
Pregabalin |
- Approved for specialist advice in the management of treatment resistant epilepsy.
- Also approved as a second line agent for General Anxiety Disorder. Although treatment can be given 2-3 times daily, it is more cost effective to give as a twice daily dose.
|
06.01.05 |
Pregabalin |
|
09.02.02.01 |
Premixed potassium infusion bags |
Infusion: 0.15% (10 mmol) potassium chloride & 0.9% sodium chloride 500ml Infusion: 0.15% (20 mmol) potassium chloride & 0.9% sodium chloride 1000ml Infusion: 0.15% (10 mmol) potassium chloride & 5% glucose 500ml Infusion: 0.15% (20 mmol) potassium chloride & 5% glucose 1000ml Infusion: 0.15% (10 mmol) potassium chloride & 10% glucose 500ml Infusion: 0.15% (10 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml Infusion: 0.15% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml Infusion: 0.15% (10 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml Infusion: 0.2% (13.5 mmol) potassium chloride & 0.9% sodium chloride 500ml Infusion: 0.2% (27 mmol) potassium chloride & 0.9% sodium chloride 1000ml Infusion: 0.2% (13.5 mmol) potassium chloride & 5% glucose 500ml Infusion: 0.2% (27 mmol) potassium chloride & 5% glucose 1000ml Infusion: 0.2% (13.5 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml Infusion: 0.2% (27 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml Infusion: 0.3% (20 mmol) potassium chloride & 0.9% sodium chloride 500ml Infusion: 0.3% (40 mmol) potassium chloride & 0.9% sodium chloride 1000ml Infusion: 0.3% (20 mmol) potassium chloride & 5% glucose 500ml Infusion: 0.3% (40 mmol) potassium chloride & 5% glucose 1000ml Infusion: 0.3% (20 mmol) potassium chloride & 10% glucose 500ml Infusion: 0.3% (20 mmol) potassium chloride & 20% glucose 500ml Infusion: 0.3% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml Infusion: 0.3% (40 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml Infusion: 0.3% (20 mmol) potassium chloride, 0.45% sodium chloride & 5% glucose 500ml Infusion: 0.3% (20 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml Infusion: 0.6% (40 mmol) potassium chloride & 0.9% sodium chloride 500ml Infusion: 0.6% (40 mmol) potassium chloride & 5% glucose 500ml
|
09.04 |
Preterm Infants in Primary Care |
|
15.02 |
Prilocaine Hydrochloride |
- 0.5% 10ml injection
unlicensed, 1% 20ml injection.
- 4% 2ml injection (cartridges).
- 2% 5ml injection (cartridges)
- Only to be used in patients undergoing spinal anaesthesia for day surgery where the procedure is anticipated to last less than 90 minutes.
- 3% & felypressin injection (cartridges).
|
05.04.01 |
Primaquine |
|
04.08.01 |
Primidone |
|
19 |
PrimsOcal® B22 |
|
19 |
Primsocitrate® 18/0 |
|
05.01.07 |
Pristinamycin |
- Approved for
- Pregnant women infected with Mycoplasma Genitalium (MG) infection that is resistant to macrolides
- Mycoplasma Genitalium (MG) infection that is resistant to macrolides, quinolones and tetracyclines in both men and women
|
10.01.04 |
Probenecid |
Tablets: 500mg |
11.05 |
Procaine hydrochloride, atropine sulphate & adrenaline acid tartrate Mydricaine® |
- Mydricaine® No.2 [Contains procaine hydrochloride 6mg, atropine sulphate 1mg, adrenaline 1:1,000; (0.12mg)]
- Approved for the treatment of anterior uveitis
|
05.01.01.01 |
Procaine Penicillin |
|
08.01.05 |
Procarbazine |
|
04.06 |
Prochlorperazine |
- Note: Buccastem® 3mg tablets are only approved for the treatment of nausea associated with migraine when the oral route cannot be used due to vomiting.
|
01.07.02 |
Proctosedyl® |
- Cinchocaine 0.5% / Hydrocortisone 0.5% ointment
Self Care Medicine: Advise CCGs that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
- Topical corticosteroids are suitable for occasional short-term use (no more than 7 days) after exclusion of infections
|
04.09.02 |
Procyclidine |
|
16 |
Procyclidine |
|
06.04.01.02 |
Progesterone |
- Approved formulations include:
- 200mg & 400mg pessaries (Cyclogest®)
![Green](images/TrafficLightsGreenV2.gif)
- 25mg SC/IM injection (Lubion®)
![Red](images/TrafficLightsRedV2.gif)
- Approved for luteal support in patients who have had a previous failed biochemical pregnancy in a froxen embryo transfer (FET) cycle
- CD&TV
for Luteal Phase support following IVF.
- Full course to be supplied by hospital
- CD&TV
to support the pregnancies of women who have a history of miscarriage or premature labour as per NICE NG25: Preterm labour and birth.
|
03.04.01 |
Promethazine |
|
04.01.01 |
Promethazine Hydrochloride |
|
04.06 |
Promethazine Hydrochloride Phenergan |
|
13.11.02 |
Prontosan |
- Solution containing Betaine 0.1% (surfactant) and Polyhexanide 0.1% (a chlorhexidine polymer). Mainly for use from 40ml plastic ampoules.
Also available as a gel.
- To be prescribed/used only on the advice of tissue viability specialists.
|
18.03.04 |
Prontosan® Wound Gel 30ml |
Hydrogel containing betaine surfactant and polihexanide
|
18.03.04 |
Prontosan® Wound Irrigation Solution |
Aqueous solution containing betaine surfactant and polihexanide
|
02.03.02 |
Propafenone |
|
11.03.01 |
Propamidine Isetionate |
- For use in the treatment of acanthamoeba keratitis – used with PHMB.
|
01.02 |
Propantheline |
|
07.04.02 |
Propiverine |
|
15.01.01 |
Propofol |
- 1% (10mg/ml) injections (Propofol Lipuro®) available as 200mg in 20ml ampoules.
- 500mg in 50ml and 1g in 100ml bottles.
- 1% (10mg/ml) 50ml (500mg) prefilled syringes for use in Diprifusor pumps (Diprivan®).
- 2% (20mg/ml) injection - 1g in 50ml bottles for ITU use only.
|
02.04 |
Propranolol |
|
04.07.04.02 |
Propranolol |
|
06.02.02 |
Propranolol 80mg MR capsules |
- Propranolol 80mg MR capsules is the preferred formulation for relief of thyrotoxic symptoms.
|
02.04 |
Propranolol Injection |
|
19 |
Pro-Prems® |
- Approved for the prevention of necrotising enterocolitis (NEC) in pre-term infants.
|
06.02.02 |
Propylthiouracil |
|
02.08.03 |
Protamine Sulphate |
|
16 |
Protamine Sulphate |
|
02.11 |
Protein C Concentrate Ceprotin® |
|
05.01.09 |
Prothionamide |
- 250mg tablets - Unlicensed
- Infectious diseases, microbiology or respiratory advice only
|
02.11 |
Prothrombin Complex Concentrate Octaplex® |
|
06.05.01 |
Protirelin (TRH) |
|
11.07 |
Proxymetacaine 0.5% Minims® |
Minims® eye drops (preservative free): 0.5% |
01.06.07 |
Prucalopride |
- Approved for chronic constipation in women in line with NICE guidance.
- Also approved for use in men with chronic constipation according to the NICE criteria for women.
|
03.10 |
Pseudoephedrine Hydrochloride |
|
05.01.09 |
Pyrazinamide |
|
10.02.01 |
Pyridostigmine Bromide |
|
09.06.02 |
Pyridoxal Phosphate |
- 25mg tablets
unlicensed
- 50mg capsules
unlicensed
|
16 |
Pyridoxine (high dose) |
|
09.06.02 |
Pyridoxine Hydrochloride |
- 10mg
unlicensed
- 50mg tablets
|
09.06.02 |
Pyridoxine Hydrochloride Injection |
Injection: 50 mg/2 mL |
05.04.01 |
Pyrimethamine Darprim® |
|
04.02.01 |
Quetiapine |
- 25mg, 100mg, 150mg 200mg & 300mg tablets
![Green plus](images/TrafficLightsGreenPlus.gif)
- 50mg, 200mg, 300mg & 400mg prolonged release tablets
- Prolonged release tablets are approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital.
- Quetiapine 20mg/ml Oral Suspension (Rosemont) - CNTW only
|
04.02.03 |
Quetiapine |
|
06.07.01 |
Quinagolide |
|
05.04.01 |
Quinine Dyhydrochloride |
|
10.02.02 |
Quinine sulfate |
- 300mg tablets
- Approved for nocturnal leg cramps in accordance with MHRA advice
|
05.04.01 |
Quinine sulphate |
|
13.02.01 |
QV® |
- Approved for used in radiotherapy only.
|
14.04 |
Rabies vaccine |
|
19 |
Radiesse Voice® |
|
08.03.04.02 |
Radium-223 dichloride |
- Provided by radiotherapy department in accordance with NICE
|
08.03.04.01 |
Raloxifene |
60mg tablets |
06.04.01.01 |
Raloxifene Hydrochloride |
- For use on the advice of specialists in the prevention and treatment of osteoporosis where alternative treatments are inappropriate.
|
05.03.01 |
Raltegravir |
- Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
|
08.01.03 |
Raltitrexed Tomudex® |
|
02.05.05.01 |
Ramipril |
- Most cost effective formulation to be prescribed
|
08.01.05 |
Ramucirumab Cyramza® |
|
11.08.02 |
Ranibizumab 10mg/1ml injection Lucentis® |
- Approved for wet age related macular degeneration in line with NICE.
- Approved for diabetic macular oedema in line with NICE.
- Approved for visual impairment caused by macular oedema secondary
to retinal vein occlusion in line with NICE.
- Approved as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia in line with NICE.
|
02.06.03 |
Ranolazine |
- For use in the treatment of angina in those patients for whom other treatments have been unsuccesful.
- Initial prescribing should be by a consultant cardiologist only.
|
04.09.01 |
Rasagiline |
|
10.01.04 |
Rasburicase |
- Only approved for prophylactic use in high risk patients.
|
09.01.03 |
Ravulizumab Ultomiris® |
- 300mg/30ml & 1,100mg/11ml concentrate for solution for infusion
- Approved for the treatment of paroxysmal nocturnal haemoglobinuria in adults in line with NICE
- Approved for the treatment of atypical haemolytic uraemic syndrome in line with NICE
- Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from
- King’s College Hospital NHS Foundation Trust, London - London and South East
- Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom
|
04.03.04 |
Reboxetine |
- Not licensed in the elderly
|
02.03.02 |
Regadenoson |
- For radionuclide myocardial perfusion imaging in patients who are unable to undergo adequate exercise stress (e.g. COPD and asthma patients where dobutamine is indicated, and obese patients who require several vials of adenosine).
|
08.01.05 |
Regorafenib Stivarga® |
- 40mg tablets
- Approved for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib in line with NICE and NHS England Commissioning Policy.
- Approved for treating advanced hepatocellular carcinoma in adults who have had sorafenib in line with NICE
- Approved as an option for metastatic colorectal cancer in adults who have had previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are unsuitable - in line with NICE.
|
06.07.02 |
Relugolix–estradiol–norethisterone acetate Ryeqo® |
- Approved as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age - in line with NICE TA832.
|
05.03.06 |
Remdesivir Veklury® |
- 100mg powder for concentrate for solution for infusion
- Approved as an option for treating COVID-10 in hospitals in line with NICE:
|
15.01.04.03 |
Remifentanil |
- 1mg, 2mg & 5mg injections.
|
18.06.01 |
Renasys® Go |
|
09.06.07 |
Renavit® tablets |
- Water soluble vitamin supplementation therapy for maintenance haemodialysis patients only.
|
06.01.02.03 |
Repaglinide |
|
03.04.02 |
Reslizumab Cinquil® |
- 10 mg/mL concentrate for solution for infusion
- Approved for the treatment of severe eosinophilic asthma in line with NICE and NHS England Commissioning Policy
|
09.02.01.01 |
Resonium A® |
- Powder (Sodium polystyrene sulphonate)
|
A2.05.02 |
Resource® Thickened Drink |
|
A2.05.02 |
Resource® ThickenUp Clear |
|
05.03.03.02 |
Ribavirin |
|
05.03.05 |
Ribavirin Virazole® |
|
08.03.04.01 |
Ribociclib Kisqali® |
- 200mg tablets
- Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE and NHS England Commissioning Policy
- Approved for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy in line with NICE
|
05.01.09 |
Rifabutin |
|
05.01.09 |
Rifampicin |
- 150mg & 300mg capsules
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
- 100mg in 5ml syrup
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
- 600mg vials for IV infusion
|
05.01.09 |
Rifampicin and Isoniazid |
|
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide |
|
05.01.07 |
Rifaximin |
- 550mg Tablets: Only approved for use in accordance with NICE guidance.
|
05.03.01 |
Rilpivirine hydrochloride |
- For patients who, due to renal impairment, require reduced doses that are not able to be accommodated by the fixed combination product.
|
04.09.03 |
Riluzole |
- 50mg tablets; 50mg orodispersible tablets (Emylif); 5mg/1ml oral suspension
- Approved for motor neurone disease in line with NICE.
- Note: riluzole orodispersible film and oral suspension approved only when other preparations (including crushing tablets) are not suitable.
|
04.07.04.02 |
Rimegepant Vydura® |
- 75mg oral lyophilisates
- Approved for preventing migraine in line with NICE
- First three month's supply from secondary care followed by 12 week review and then transfer to primary care with a 4 week prescription to allow for handover
- Approved for treating migraine in line with NICE
![Green](../images/TrafficLightsGreenV2.gif)
|
11.04.01 |
Rimexolone |
ophthalmology advice only - second line if flurometholone unsuitable |
02.05.01 |
Riociguat |
- Approved for Chronic Thromboembolic Pulmonary Hypertension - in accordance with NHS England Commissioning policy.
|
01.05.03 |
Risankizumab Skyrizi® |
- 150mg/1ml solution for injection (pre-filled devices)
- Approved for previously treated moderately to severely active Crohn's disease in people 16 years and over in line with NICE
|
13.05.03 |
Risankizumab Skyrizi® |
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
10.02 |
Risdiplam Evrysdi® |
- 0.75mg/1ml oral solution
- Approved for treating spinal muscular atrophy in line with NICE
- To be provided by Newcastle Hospitals homecare service only
|
06.06.02 |
Risedronate |
- Approved risedronate formulations include:
- 5mg tablets (taken daily);
- 35mg tablets (taken once weekly for osteoporosis) -preferred.
- Risedronate is approved for the primary prevention of osteoporosis in line with NICE, and for for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis in line with NICE.
- Risedronate 30mg tablets are also approved for Paget’s disease.
- Approved for the treatment of osteoporosis in line with NICE
|
04.02.01 |
Risperidone |
- Note: risperidone orodispersible tablets should only be used in situations where the plain tablets are unsuitable.
|
04.02.02 |
Risperidone Risperdal Consta® |
CNTW
TEWV
- Only for use by psychiatrists in accordance with NTAG guidelines.
|
04.02.03 |
Risperidone (oral) |
|
07.01.03 |
Ritodrine |
|
05.03.01 |
Ritonavir |
|
08.02.03 |
Rituximab |
NICE have approved rituximab for the following indications:
- First line use in NHL in combination with CHOP.
- Maintenance therapy in follicular NHL that has responded to first line induction therapy with rituximab in combination with chemotherapy.
- Stage III and IV follicular lymphoma in previously untreated people.
- Replased or refractory follicular NHL.
- Post-transplant lymphoproliferative disease.
- First line use in CLL in combination with fludarabine and cyclophosphamide.
- Combination with fludarabine and cyclophosphamide for relapsed or refractory CLL.
- Autoimmune haematological conditions (where conventional treatments have failed)
- Autoimmune haemolytic anaemia (AIHA), Evans syndrome, pure red cell aplasia (PRCA), & thrombocytopenia purpura (TTP).
- Combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.Vasculitis (including Wegener’s granulomatosis in adults and children) that has not responded adequately to conventional treatment (e.g. corticosteroids, cyclophosphamide) in line with NICE and additional NHS England criteria.
NECDAG have approved rituximab for the following indications:
- Treatment of NLPHL
- Newly diagnosed mantle cell NHL in patients aged
- In combination with bendamustine for patients with CLL not fit for FCR chemotherapy or for patients who relapse within 2 years of FCR chemotherapy and not fit for alemtuzumab.
- Salvage chemotherapy for patients relapsing > 12 months post 1st line therapy with R-CHOP.
- Standard NHL induction regimen in patients who cannot be given an anthracycline. Rituximab with other chemotherapy regimens is an alternative treatment option e.g. DECC, CVP for this group of patients, as part of their first line therapy. Also in addition to the MACOP-B regimen for the small number of young patients with DLBCL, subtype Primary Mediastinal B cell Lymphoma.
- Treatment of Hairy Cell Leukaemia (HCL) or HCL varian (HCL-v) who:
- relapse early after purine analogue therapy (< 2 years post treatment)
- are refractory to purine analogues.
NTAG have approved rituximab for the following indications:
- Treatment of immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children.
NHS England have approved rituximab for the following indications:
- Treatment of immunobullous disease
- Steroid Sensitive Nephrotic Syndrome in Children
- Steroid Resistant Nephrotic Syndrome in Children
- Acquired Haemophilia
- Cytopenia Complicating Primary Immunodeficiency
- Maintenance single agent therapy in FL, mantle cell lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma in line with (SSC1434) - 1.4g solution for sc injection.
- Second line treatment for anti-NMDAR auto-immune encephalitis (all ages)
- Treatment of refractory myasthenia gravis in a specialised neuroscience centre
- Treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and post-pubescent children
- Treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults
- Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
- Treatment of Idiopathic Membranous Nephropathy (IMN)
North of Tyne, Gateshead and North Cumbria APC have approved rituxumab for the following indication:
- Autoimmune hepatitis in patients who have failed or who are intolerant of therapies such as azathioprine, mycophenolate mofetil, corticosteroids and tacrolimus.
For musculoskeletal indications see chapter 10 |
10.01.03 |
Rituximab |
- Approved for:
- Adults with severe systemic lupus erythematosus who have failed conventional therapies.
- Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
- Combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitors (NETAG approval).
- Combination with other (non-methotrexate) disease modifying antirheumatic drugs and as monotherapy in cases in which conventional treatment with tumour necrosis factor inhibitors or methotrexate is deemed unsafe (NETAG approval).
- For immunoglobulin G4-related disease (IgG4-RD) in accordance with NHS England Commissioning Criteria
- Myositis in accordance with NHS England Commissioning Criteria
- Juvenile Idiopathic Arthritis (JIA) in accordance with NHS England Commissioning Criteria
|
02.08.02 |
Rivaroxaban |
- Rivaroxaban co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
- Approved for use in accordance with NICE TA607
|
02.08.02 |
Rivaroxaban |
- 2.5mg, 10mg, 15mg & 20mg tablets
- 1mg/1ml granules for oral suspension
- approved for the treatment of VTE in children
- Only approved for use in accordance with NICE guidance.
|
04.11 |
Rivastigmine |
- Only approved for use in accordance with NICE guidance.
- Rivastigmine patches are approved for patients unable to tolerate treatment with oral rivastigmine due to nausea and vomiting, and for patients requiring treatment with an acetylcholinesterase inhibitor who are unable to take oral medication e.g. due to swallowing difficulties or ‘nil by mouth’ prior to surgery.
|
04.07.04.01 |
Rizatriptan |
|
15.01.05 |
Rocuronium Esmeron® |
|
03.03.03 |
Roflumilast Daxas® |
- 500microgram film-coated tablets
- Approved for the treatment of chronic obstructive pulmonary disease in line with NICE
|
09.01.04 |
Romiplostim |
- For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.
|
06.06.02 |
Romosozumab Evenity ® |
- Approved for severe osteoporosis in people after menopause who are at high risk of fracture in line with NICE.
|
04.09.01 |
Ropinirole |
- Ropinirole once daily formulation is only approved for use in Parkinson’s disease patients with proven compliance.
![Green plus](../images/TrafficLightsGreenPlus.gif)
- Approved for first line use in patients with restless legs syndrome.
![Green](images/TrafficLightsGreenV2.gif)
|
15.02 |
Ropivacaine Hydrochloride |
- 0.2% (200mL) infusion
- approved for peripheral nerve block infusions for post-operative pain
- 0.75% (10mL)
- approved for use in setting of conversion from labour epidural analgesia to surgical analgesia for emergency caesarean section
- 0.2% (10mL) solution for injection
- approved as an option for ambulatory day case hand surgery
|
02.12 |
Rosuvastatin |
- 5mg, 10mg, 20mg & 40mg tablets
- May be used as an alternative to atorvastatin for primary or secondary prevention in line with NEELI guidance
|
14.04 |
Rotavirus vaccine Rotarix® |
|
04.09.01 |
Rotigotine |
- For use on the advice of specialists in the treatment of Parkinson's disease. Mainly for use in patients who have difficulty with swallowing.
- Approved for second line use in patients with restless legs syndrome.
|
09.01.03 |
Roxadustat Evrenzo® |
- 20mg, 50mg, 70mg, 100mg and 150mg tablets
- Approved for treating symptomatic anaemia associated with chronic kidney disease in adults in line with NICE
|
08.01.05 |
Rucaparib |
|
04.08.01 |
Rufinamide |
- Approved for limited use as a second or third-line treatment in patients with Lennox-Gastaut syndrome and related encephalopathies.
- Should only be used on the advice of paediatric neurologists and other neurologists specialising in the treatment of epilepsy.
|
08.01.05 |
Ruxolitinib |
- Approved for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemiaa myelofibrosis, only in people with intermediate-2 or high-risk disease in line with NICE.
- Approved for treating polycythaemia vera in line with NICE and NHSE Specialised Commissioning guidance
|
08.01.05 |
Sacituzumab govitecan Trodelvy® |
- 180mg powder for solution for infusion
|
02.05.05.02 |
Sacubitril & valsartan Entresto® |
- Only approved for use in accordance with NICE guidance.
|
04.09.01 |
Safinamide |
- 50mg and 100mg tablets
- Approved for use in Parkinson's Disease patients on levodopa who are having motor fluctuations affecting their quality of life as an alternative to rasagiline.
|
03.01.01.01 |
Salbutamol |
- REFER TO LOCAL GUIDELINES FOR ADVICE ON PREFERRED CHOICE
- Easyhaler® breath actuated dry powder inhaler 100 mcg/puff (DPI)
- Accuhaler® breath actuated dry powder inhaler 200 mcg/puff (DPI)
- 100 mcg/puff CFC-free MDI - Salamol® (pMDI)
- 100 mcg/puff breath actuated CFC-free MDI (pMDI)
- Salamol® Easi-Breathe - alternative for patients hypersensitive to lactose or milk protein
- 2.5mg in 2.5ml & 5mg in 2.5ml nebules (Medicine Supply Notification 028 - Supply issue with salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials)
- 2mg in 5ml sugar-free oral solution
|
03.01.01.01 |
Salbutamol Injection |
- 500 mcg in 1ml & 5mg in 5ml injections
|
13.07 |
Salicylic Acid |
See section 13.5.2 |
13.07 |
Salicylic Acid 16.7% with Lactic Acid 16.7% Paint Salactol® |
In flexible collodion |
13.05.02 |
Salicylic Acid in emulsifying ointment |
|
03.01.01.01 |
Salmeterol |
- 50 mcg/puff breath actuated dry powdered inhaler (DPI) - Accuhaler®
- 25 mcg/puff metered dose inhaler (pMDI)
|
09.04.01 |
Sapropterin dihydrochloride Kuvan® |
- Approved for the treatment of hyperphenylalaninaemia in phenylketonuria in line with NICE
|
05.03.01 |
Saquinavir |
|
10.01.03 |
Sarilumab Kevzara® |
- 150mg/1.14mL & 200mg/1.14mL injection
- Approved as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) in line with NICE
|
06.01.02.03 |
Saxagliptin Onglyza® |
|
A2.04.01.02 |
Scandishake® Mix |
|
18.07.03 |
Scanpor® |
Permeable Non-woven Synthetic Adhesive Tape, BP 1988
|
18.04.02 |
Scar FX® |
Silicone gel sheet
- Burns Team and scar clinic initiation only
|
01.07.02 |
Scheriproct® |
|
18.10 |
Seal Tight® Wound Care Protector |
|
13.05.02 |
Sebco® scalp ointment |
|
09.08.01 |
Sebelipase alfa Kanuma® |
- 20mg/10ml concentrate for solution for infusion
- Approved for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency), only if people are aged 2 years or under when treatment starts, in line with NICE and NHSE Specialised Commissioning Policy.
- Services are only commissioned at:
- Birmingham Women and Childrens NHS Foundation Trust
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Manchester University Hospitals NHS Foundation Trust
|
10.01.03 |
Secukinumab Cosentyx® |
- Approved for active ankylosing spondylitis in line with NICE.
- Approved for psoriatic arthritis in line with NICE.
- Approved for the treatment of non-radiographic axial spondyloarthritis in line with NICE
|
13.05.03 |
Secukinumab Cosentyx® |
- Approved for the treatment of plaque psoriasis in line with NICE.
- Approved for the treatment of moderate to severe plaque psoriasis in children and young people in line with NICE
- Approved for treating moderate to severe hidradenitis suppurativa in line with NICE
|
04.09.01 |
Selegiline Hydrochloride |
|
09.05.05 |
Selenium |
|
13.09 |
Selenium Sulphide 2.5% shampoo Selsun® |
|
08.01.05 |
Selpercatinib |
- 40mg and 80mg capsules
- Approved for advanced thyroid cancer with RET alterations in people 12 years and older in line with NICE
- Approved for untreated RET fusion-positive advanced non-small-cell lung cancer in adults in line with NICE
|
08.01.05 |
Selumetinib Koselugo® |
- 10mg and 35mg hard capsules
- Approved treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over in line with NICE
|
06.01.02.03 |
Semaglutide |
- 0.25mg/0.19mL, 0.5mg/0.37mL and 1mg/0.7mL solution for injection pre-filled pen (Ozempic®)
- Approved for the treatment of type 2 diabetes in patients who require an intensification in treatment
- 3mg, 7mg & 14mg tablets (Rybelsus®) - BLACK TRIANGLE
- Approved as an option for patients with type 2 diabetes mellitus who require intensification of treatment, if use of a glucagon-like peptide 1 receptor agonist (GLP1RA) is clinically appropriate, in line with licensing and relevant guidance, and if an oral option is preferred.
- 0.25mg/0.37ml, 0.5mg/0.37ml, 1mg/0.75ml, 1.7mg/0.75ml & 2.4mg/0.75ml solution for injection pre-filled pens (Wegovy®)
- Approved for managing overweight and obesity in line with NICE guidance within a specialist weight management service (including but not limited to tiers 3 and 4)
- Also available via NHSE pilot sites involving primary care
- Note: As of 29th April 2024 there is an ICB weight management strategy in development which is seeking to review the arrangements and capacity of current service provision across the ICS
|
01.06.02 |
Senna |
- Avoid 15mg strength, this is an OTC product.
|
06.04.01.01 |
Sequential combined cyclical HRT patch Evorel® Sequi |
|
04.03.03 |
Sertraline |
- 25mg, 50mg, 100mg, 150mg & 200mg tablets
- 100mg/5ml concentrate for oral solution (Thame)
- Approved for patients who are unable to take a solid dose form or who require small doses
- Must be diluted prior to use. Please refer to SPC for list of specified drinks
|
09.05.02.02 |
Sevelamer Carbonate |
- 800mg f/c tablets.
- 2.4g powder for oral suspension
|
15.01.02 |
Sevoflurane |
|
13.09 |
Shampoo Cetrimide with undecanoic acid Ceanel Concentrate® |
|
13.09 |
Shampoos Dermax® |
|
13.05.02 |
Shampoos T/Gel® |
|
18.08.07 |
Short Stretch Compression Bandages |
|
02.05.01 |
Sildenafil |
- 25mg, 50mg & 100mg tablets
unlicensed indication
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
![Red](images/TrafficLightsRedV2.gif)
- Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
![Red](images/TrafficLightsRedV2.gif)
- Approved for secondary Raynaud's
![Green plus](../images/TrafficLightsGreenPlus.gif)
|
07.04.05 |
Sildenafil |
- Approved for the treatment of erectile dysfunction
- Also approved for specialist use in treating:
- Pulmonary hypertension (see section 2.5.1a)
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- Secondary Raynaud’s disease.
![Green plus](../images/TrafficLightsGreenPlus.gif)
|
18.04.02 |
Silgel® |
Silicone gel sheet
- Burns Team and scar clinic initiation only
|
13.11.06 |
Silver nitrate 0.5% Solution |
|
13.07 |
Silver Nitrate 75% & 95% applicators |
- 6 inch applicator
- 95% pencils
- 0.5% solution
|
13.10.01.01 |
Silver Sulfadiazine 1% cream Flamazine® |
|
01.01.01 |
Simeticone Infacol® Dentinox® |
|
03.09.02 |
Simple Linctus |
- Simple linctus and Paediatric simple linctus.
|
13.09 |
Simple shampoo |
|
02.12 |
Simvastatin |
- 10mg, 20mg. 40mg & 80mg tablets
|
08.02.04 |
Siponimod Mayzent® |
- 0.25mg and 2mg tablets
- approved for treating secondary progressive multiple sclerosis in adults in line with NICE
|
08.02.02 |
Sirolimus |
- Approved for renal transplantation in children and adolescents in line with NICE.
- For Transplant indications
unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes .
|
06.01.02.03 |
Sitagliptin |
|
09.05.03 |
Sodium Monofluorophosphate |
|
09.08.01 |
Sodium Benzoate |
|
09.02.01.03 |
Sodium Bicarbonate |
- 500mg capsules (500mg contains approx. 6 mmol each ofsodium and bicarbonate)
- 1mmol/ml oral solution
unlicensed
|
09.02.02.01 |
Sodium Bicarbonate |
- 1.26% IV infusion Polyfusor®
- 1.4% IV infusion Polyfusor®
- 2.74% IV infusion Polyfusor®
- 8.4% IV infusion Polyfusor®
- 8.4% injection (10ml & 50ml)
|
16 |
Sodium bicarbonate |
|
12.01.03 |
Sodium Bicarbonate ear drops |
|
16 |
Sodium calcium edetate |
|
09.02.01.02 |
Sodium Chloride |
- 600mg m/r tablets (Slow Sodium) - approx. 10 mmol sodium & chloride per tablet
- 1mmol/ml oral solution
- Treatment should only be initiated with the advice of a specialist.
- 5mmol/1ml oral solution
- Treatment should only be initiated with the advice of a specialist in accordance with NPPG/RCPCH Position Statement
|
09.02.02.01 |
Sodium Chloride |
- 0.9% injection (5ml, 10ml & 20ml)
- 0.9% IV infusion (100ml, 250ml, 500ml & 1000ml)
- 0.9% irrigation (1000ml & 3000ml)
- 0.45% IV infusion (500ml - Steriflex 2)
- 1.8%, 2.7% & 5% Polyfusor infusion (500ml)
- 30% injection (10ml)
|
11.08.01 |
Sodium Chloride |
- 0.9% eye drops and single dose unit eye drops.
- 5% eye drops and preservative-free eye drops.
- 5% eye ointment
unlicensed.
|
03.07 |
Sodium Chloride 0.9% |
|
12.02.02 |
Sodium Chloride 0.9% |
|
13.11.01 |
Sodium Chloride 0.9% |
- Sterile solution – bottles
- 25ml & 100ml sachets(Normasol®)
|
18.11.01 |
Sodium chloride 0.9% |
- Irrippod® (20mL & 100ml sachets)
- Miniversol® (45ml)
|
07.04.04 |
Sodium chloride 0.9% solution |
- Large volume solutions (up to 3 litres).
|
09.02.02.01 |
Sodium Chloride and Glucose |
- 0.9%/5% IV infusion (500ml - Sterfilex 3)
- 0.18%/4% IV infusion (500ml & 1000ml)
- 0.18%/10% IV infusion (500ml - Steriflex 19)
- 0.45%/5% IV infusion (500ml - Steriflex 45)
|
01.06.04 |
Sodium Citrate |
|
15.01.09 |
Sodium citrate |
- 0.3 molar peppermint falvoured solution.
|
11.08.02.04 |
Sodium Citrate 10.11% eye drops |
|
06.06.02 |
Sodium Clodronate |
|
09.05.01.02 |
Sodium Clodronate |
|
11.04.02 |
Sodium Cromoglicate 2% Eye drops |
- A 2% preservative free preparation is also approved
unlicensed - treatment to be imitated with the advice of an ophthalmologist only.
|
13.14 |
Sodium dichloroisocyanurate |
- 500mg & 5g tablets and granules
|
09.01.01.01 |
Sodium Feredetate Sodium ironedetate, Sytron® |
- 190mg in 5ml sugar-free elixir (27.5mg iron/5ml).
|
09.05.03 |
Sodium Fluoride |
- Sodium fluoride 0.619% (75ml) toothpaste (Duraphat® 2800 ppm)
![prescription only medicine](https://www.medicinescomplete.com/assets/images/content/pom.png)
- Sodium fluoride 1.1% (51g) toothpaste (Duraphat® 5000 ppm)
![prescription only medicine](https://www.medicinescomplete.com/assets/images/content/pom.png)
- Sodium fluoride 0.05% mouthwash - approved for use within the dental hospital.
- In line with NHS England’s guidance on conditions for which over the counter items should not be routinely prescribed, the ICB does not support the routine prescribing of medicines or preparations for dental conditions (including toothpastes such as Duraphat®, ulcer healing preparations, antibiotics and analgesics) on GP FP10 prescriptions except in the following circumstances:
- After head and neck cancer treatment on the recommendation of a Head & Neck or Restorative Dental Consultant.
- For patients receiving palliative care as part of ongoing symptom control.
Dentists must signpost patients to purchase products or issue prescriptions (NHS or private) for medicines to meet the identified dental needs of their patients. If a patient receives treatment as a private patient, they must always be given a private prescription.
|
05.01.07 |
Sodium fusidate |
- 250mg film coated tablets
- 250mg in 5ml suspension
|
09.05.02.01 |
Sodium glycerophosphate |
|
07.04.03 |
Sodium Hyaluronate Hyacyst® 120 |
- Prefilled syringe: 120mg/50ml
|
07.04.04 |
Sodium Hyaluronate Hyacyst® |
|
11.08.01 |
Sodium Hyaluronate |
- 0.1% eye drops & preservative-free eye drops
- 0.2% eye drops & preservative-free eye drops
- 0.4% unit dose vials (Clinitas) & 0.4% preservative-free eye drops (Clinitas Multi)
|
11.08.02 |
Sodium Hyaluronate |
- 10mg in 1ml bag (Z-Hyalin®, formerly Ophthalin Gelbag®)
- 14mg in 1ml syringe (Healon GV®)
|
07.04.04 |
Sodium hyaluronate (1.6%)/sodium chondroitinsulphate (2%) Ialuril® |
- Ialuril® is a 50ml solution for instillation into the bladder approved as second line treatment in patients who have failed Cystistat.
|
07.04.04 |
Sodium hyaluronate 40mg in 50ml solution Cystistat® |
- For instillation into the bladder.
|
09.02.01.03 |
Sodium hydrogen carbonate Nephrotrans |
Capsules: 500 mg |
01.06.02 |
Sodium hydrogen carbonate / sodium dihydrogen phosphate Lecicarbon A® Suppository |
Sodium hydrogen carbonate 500mg, sodium dihydrogen phosphate 680mg - Lecicarbon A® Suppository
- Pre-operative use for patients undergoing rectal surgery or diagnostic procedure
- 2nd/3rd line in spinal injuries after bisacodyl and glycerol rectal have been tried.
|
13.11.04 |
Sodium Hypochlorite Solution 1% |
|
09.02.02.01 |
Sodium Lactate IV infusion |
|
16 |
Sodium nitrite |
- 3% 10ml injection (30mg/ml)
unlicensed
|
02.05.01 |
Sodium nitroprusside |
unlicensed import
|
04.01.01 |
Sodium Oxybate 500mg/1ml oral solution Xyrem® |
- Approved for the treatment of narcolepsy with cataplexy in children age 7 years and above only in accordance with NHS England clinical commissioning policy.
- The Northern (NHS) Treatment Advisory Group recommends the use of sodium oxybate in adult patients who have received and benefited from treatment with sodium oxybate as commissioned by NHS England. i.e. continuing treatment for those >19 years old.
- The Northern (NHS) Treatment Advisory Group also recommends sodium oxybate for use in adults who have not received it as a child as per the RMOC criteria, noting that may sometimes be used in combination with other agents.
- The following criteria for use in adults who have not received sodium oxybate as child apply:
- Patients presenting with narcolepsy with cataplexy according to International Classification of sleep disorders 3 (ICSD) criteria for Narcolepsy Type 1 AND
- Patients ≥ 19 years old AND
- Where patients have co-morbidities, which are also affecting sleep, these should be managed and adequately treated (for example moderate to severe obstructive sleep apnoea or restless legs syndrome) AND
- Failure to respond to non-pharmacological treatments consisting of behavioural and environmental adaptations, for example planned naps AND
- Inadequate response (within 3 months) to, or intolerable adverse effects from, or contra-indicated use of, more than one stimulant for narcolepsy, and more than one anticataplectic agent AND
- Assessed as being able to benefit from sodium oxybate via a specialist sleep centre.
- Sodium oxybate is generally considered as a final treatment option for patient
|
09.08.01 |
Sodium Phenylbutyrate |
- 500mg tablets - Licensed formulation marketed as Ammonaps
- 1g in 5ml & 2g in 10ml injections
|
01.06.02 |
Sodium Picosulfate |
- For use as a second line agent in paediatric patients with constipation when Movicol, lactulose and senna are ineffective as single agent therapy.
|
01.06.05 |
Sodium Picosulfate with Magnesium Citrate Citrafleet® Picolax® |
|
05.04.05 |
Sodium Stibogluconate |
|
02.13 |
Sodium Tetradecyl Sulphate |
|
16 |
Sodium thiosulphate |
- 25% injection
unlicensed
- 50% injection
- Approved for the treatment of caliciphylaxis in patients with End Stage Renal Disease (ESRD)
|
04.07.04.02 |
Sodium valproate |
- Note: sodium valproate 500mg & 1000mg MR granules (Episenta®) are also approved for use in those who have difficulty swallowing sodium valproate tablets. MR granules may be more convenient to use than large volumes of liquid formulations.
Black Triangle in Females
Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP) ![Amber](images/TrafficLightsAmberV2.gif)
For information relating to alerts regarding valproate, including Drug Safety Updates and links to PPP materials, please use the following link:
MHRA Drug Safety Updates (valproate) |
04.08.01 |
Sodium Valproate |
- Note: sodium valproate 500mg & 1000mg MR granules (Episenta®) - for possible use in those who have difficulty swallowing sodium valproate tablets. May be more convenient to use than large volumes of liquid formulations.
- Valproate▼ must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP)
![Amber](images/TrafficLightsAmberV2.gif)
▼ BLACK TRIANGLE IN FEMALES
Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP)
For information relating to alerts regarding valproate, including Drug Safety Updates and links to PPP materials, please use the following link:
MHRA Drug Safety Updates (valproate) |
04.02.03 |
Sodium valproate 200mg, 300mg, and 500mg tablets Epilim Chrono® |
- Sodium valproate 200mg, 300mg, and 500mg (Epilim Chrono®) tablets are approved for the prevention and treatment of manic episodes associated with bipolar disorder (
unlicensed indication). May be useful in patients unresponsive to lithium.
Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP) ![Amber](images/TrafficLightsAmberV2.gif)
Black Triangle in females
For information relating to alerts regarding valproate, including Drug Safety Updates and links to PPP materials, please use the following link:
MHRA Drug Safety Updates (valproate) |
04.08.01 |
Sodium Valproate▼ Injection |
Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP)
For information relating to alerts regarding valproate, including Drug Safety Updates and links to PPP materials, please use the following link:
MHRA Drug Safety Updates (valproate) |
09.02.01.01 |
Sodium zirconium cyclosilicate Lokelma® |
- 5g and 10g oral powder
- Approved for the treatment of hyperkalaemia in adults in line with NICE
![Green plus](../images/TrafficLightsGreenPlus.gif)
- Approved for emergency acute treatment
![Red](../images/TrafficLightsRedV2.gif)
|
05.03.03.02 |
Sofosbuvir Sovaldi® |
- Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
|
05.03.03.02 |
Sofosbuvir & Ledipasvir Harvoni® |
- To be used in accordance with NHS England Commissiong Policy
|
05.03.03.02 |
Sofosbuvir & velpatasvir Epclusa® |
- Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
|
05.03.03.02 |
Sofosbuvir, Velpatasvir & Voxilaprevir Vosevi® |
- Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
|
18.07.01 |
Softdrape® Universal Dressing Pack |
Latex free; includes Vitrex gloves
|
07.04.02 |
Solifenacin |
|
04.04 |
Solriamfetol Sunosi® |
- 75mg and 150mg tablet
- Approved for treating excesive daytime sleepiness caused by narcolepsy in line with NICE
|
18.01.02 |
Solvaline N® |
Absorbent, Perforated Plastic Film Faced, Dressing
|
06.05.01 |
Somatrogon Ngenla® |
24mg and 60mg solution for injection in pre-filled pen |
06.05.01 |
Somatropin - adults |
- Genotropin® cartridges for use in Genotropin pens - 16 unit (5.3mg) & 36 unit (12mg) in 1ml.
- Genotropin Miniquick® syringes - 0.2mg (0.6 units), 0.8mg (2.4 units), 1.4mg (4.2 units) 0.4mg (1.2 units) 1mg (3 units) 1.6mg (4.8 units) 0.6mg (1.8 units) 1.2mg (3.6 units) 2mg (6 units) - to be used for patients when travelling.
|
06.05.01 |
Somatropin (children) |
- First line
- Omnitrope® 5-mg (15-unit) vial (powder with diluent) for use with Omnitrope Pen L® device, 3.3 mg (10 units)/ml, 1.5 ml (5-mg, 15-unit) cartridge & 6.7 mg (20 units)/ml, 1.5 ml (10-mg, 30-unit) cartridge - for use with Omnitrope Pen 5® & Omnitrope Pen 10® devices respectively.
- Note: Omnitrope is the least expensive formulation of somatropin and should be used in all de novo paediatric patients where possible.
- Second line
- Norditropin SimpleXx® 1.5ml cartridges for use in Nordipen® devices - 5mg (15 units), 10mg (30 units) and 15mg (45 units). Note: norditropin is the second least expensive alternative formulation for patients who cannot tolerate omnitrope.
- Saizen® 8mg vials (powder with diluent), Saizen® 5.83 mg/ml solution for injection (6mg cartridges), 8 mg/ml solution for injection (12mg and 20mg cartridges) - for use in EasyPod® device (to be used in patients with compliance issues).
- Third line
- Genotropin Miniquick® syringes - 0.2mg (0.6 units) 0.8mg (2.4 units) 1.4mg (4.2 units), 0.4mg (1.2 units) 1mg (3 units) 1.6mg (4.8 units) 0.6mg (1.8 units), 1.2mg (3.6 units) 2mg (6 units). To be used for patients when travelling.
- Zomacton® (needle free presentation) 12 unit (4mg) injection; 1st line: 75% to 85% of total mg usage; 2nd line: 15% to 25% of total mg usage; 3rd line: up to 5% of total mg usage.
|
08.01.05 |
Sorafenib Nexavar® |
- 200mg tablets
- Approved for treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment in line with NICE and NHS Commissioning Policy.
- Approved for the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE.
- Approved as maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) in line with NHS England Specialised Commissioning Policy
- Only available at The Newcastle upon Tyne Hospitals NHS Trust
|
13.02.02 |
Sorbaderm® cream |
- 2g, 28g & 92g barrier cream, 28ml pump spray, sterile 1ml no
sting barrier film foam applicator, sterile 3ml no sting barrier film foam applicator
|
18.02.06 |
Sorbsan ® Ribbon |
Calcium alginate fibre, highly absorbent |
06.01.02.03 |
Sotagliflozin |
- 200mg tablet
- Approved with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy in line with NICE
|
02.03.02 |
Sotalol |
|
02.04 |
Sotalol |
- Treatment should only be intiated on the advice of a cardiologist.
|
08.01.05 |
Sotorasib Lumykras |
|
05.03.06 |
Sotrovimab Xevudy® |
- 500mg concentrate for solution for infusion
|
03.01.05 |
Space Chamber Plus® |
|
05.01.04 |
Spectinomycin |
- Only approved for the treatment of gonorrhoea in adults.
|
02.02.03 |
Spironolactone |
Resistant Hypertension - Step 4 NICE NG 136 - consider seeking expert advice
Post-acute myocardial infarction patients and patients with heart failure treatment should be initiated on instructions from a cardiologist or GP with a specialist interest in cardiology. Spironolactone is first choice (ahead of eplerenone) for severe heart failure.
- Spironolactone 10mg and 50mg in 5ml suspension is also approved
unlicensed.
- 50mg/5ml - Recommended strength in children as per NPPG/RCPCH Position Statement: Using Standardised Strengths of Unlicensed Liquid Medicines in Children.
|
06.04.04 |
Spironolactone |
|
13.06.02 |
Spironolactone |
|
02.02.04 |
Spironolactone and chlorothiazide capsules |
- For use in paediatric cardiology.
- Capsules are manufactured to have 1:10 ratio of spironolactone to chlorothiazide - formulations available include:
- 1mg/10mg
- 2mg/20mg
- 3mg/30mg
- 5mg/50mg
- 10mg/100mg
|
09.02.01.02 |
St Marks solution |
- Specialist initiation for use in patients with a short bowel.
- Usually prepared at home
|
09.05.03 |
Stannous Fluoride |
|
19 |
Stanozolol 2mg tabs |
|
03.04.03 |
Stanozolol 50mg tablets |
- For use on the advice of an immunologist in the prophylaxis treatment hereditary angioedema associated with C1-esterase inhibitor deficiency.
|
05.03.01 |
Stavudine |
|
09.02.02 |
Steriflex 165® |
- Potassium chloride 0.3% (20mmol); sodium chloride 0.9%; and glucose 5% (500ml bag).
- Approved for diabetic ketoacidosis in paediatric patients
unlicensed.
|
18.07.01 |
Sterile Gloves |
|
18.11.07 |
Sterile Larvae Biobag® |
|
18.11.07 |
Sterile Larvae Larvae 300® |
|
13.11.07 |
Sterile Larvae (Maggots) LarvE® |
- Used for the management of sloughy wounds.
|
09.02.02.01 |
Sterile oral water |
|
04.08.01 |
Stiripentol |
- For use as adjunctive therapy of refractory generalised tonicclonic seizures in children with severe myoclonic epilepsy in infancy.
|
02.10.02 |
Streptokinase |
|
05.01.09 |
Streptomycin |
|
08.01.05 |
Streptozocin |
- Named patient supply only.
|
06.06.02 |
Strontium Ranelate |
- Treatment of severe osteoporosis
- in post menopausal women and adult men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
|
18.08.07 |
Sub-compression wadding bandage |
- Profore®
- Flexi-Ban®
- FormFlex natural (not on FP10)
|
01.03.03 |
Sucralfate 1g/5ml oral suspension |
- Approved for bile reflux and stomal ulceration.
![Green plus](images/TrafficLightsGreenPlus.gif)
- Approved for short term use post Radio Frequency Ablation (RFA) for Barret's Oesophagus and Endoscopic Mucosal Resection (EMR).
![Red](images/TrafficLightsRedV2.gif)
|
01.07 |
Sucralfate 2g/50ml enema |
Unlicensed
- For radiation proctitis; bowel inflammation following radiotherapy
|
13.02.02 |
Sucralfate cream |
- For limited use around gastrostomies when wound breakdown is thought to be aggravated by leakage of gastric acid.
|
09.05.02.02 |
Sucroferric oxyhydroxide Velphoro® |
- Approved for use by haemodialysis or peritoneal dialysis patients who cannot tolerate alternative phosphate binders or where these have been ineffective
|
19 |
Sucrose 24% solution |
|
15.01.06 |
Sugammadex Bridion® |
- 200mg in 2ml & 500mg in 5ml injections
- Approved for the emergency reversal of blockade in cases of failed intubation in patients who are undergoing rapid sequence induction anaesthesia with rocuronium because of contra-indications to suxamethonium.
- Approved for the reversal of rocuronium blockade in obstetric general anaesthesia for caesarean sections.
|
05.04.07 |
Sulfadiazine |
- Infectious diseases or microbiology advice only
|
01.05.01 |
Sulfasalazine |
|
10.01.03 |
Sulfasalazine E/C tablets |
|
10.01.04 |
Sulfinpyrazole |
Tablets: 100mg, 200mg |
19 |
Sulphur hexafluoride Sonovue ® |
- Sulphur hexafluoride. Available as a kit including one vial of gas, one vial of powder and one pre-filled syringe containing 5ml of solvent. On reconstitution, 1 ml of the resulting dispersion contains 8 microliters of sulphur hexafluoride in the microbubbles, equivalent to 45 microgrammes
- Approved for use in visualising blood vessels in liver and diagnosing cancer, and used for the diagnosis of pancreatic cancers, and also for use when echocardiography images are unsatisfactory for answering the clinical question due to poor definition.
|
04.02.01 |
Sulpiride |
|
04.07.04.01 |
Sumatriptan |
|
08.01.05 |
Sunitinib Sutent® |
- Approved for gastrointestinal stromal tumours (GISTs) in line with NICE.
- Approved for advanced and/or metastatic renal cell carcinoma in line with NICE.
- Sunitinib not approved for second line use in advanced and/or metastatic renal cell carcinoma NICE.
- Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
|
15.01.05 |
Suxamethonium Chloride |
|
07.03.01 |
Syreniring® |
- Ethinylestradiol 2.7 mg, Etonogestrel 11.7 mg vaginal ring
|
11.08.01 |
Systane® |
- 10ml multidose bottles 0.8ml preservative-free vials Contains hydroxypropyl guar, polyethylene glycol 400, propylene glycol (and other ingredients).
- Long-acting ocular lubricant used for the treatment of dry eye syndrome. Liquid formulation which turns into a gel on contact with eyes providing fast and long lasting relief. The multidose bottle may be used for up to six months after opening in primary care. In contact lens wearers, Systane should be applied before inserting lenses and after removal to extend comfortable wearing times.
|
11.09 |
Systane® |
|
13.10.05 |
TachoSil® |
- 4.8 & 9.5 cm 2 Haemostatic (collagen sponge coated with fibrinogen and thrombin) - for use in liver and renal surgery.
|
08.02.02 |
Tacrolimus |
Approved tacrolimus formulations include:
- 500 microgram, 1mg & 5mg capsules (Prograf® & Adoport®).
- 1mg in 1ml oral suspension (
unlicensed) - this replaces 0.5mg/ml oral suspension.
- 5mg in 1 ml concentrate for preparing IV infusion - approved for renal transplantation in children and adolescents in line with NICE.
- 500microgram, 1mg, 3mg & 5mg MR capsules (Advagraf®) approved for use for prophylaxis of organ rejection in kidney and liver transplantation. Advagraf® is also approved for use in patients who are currently prescribed Prograf®, and de novo patients should be prescribed Adoport®.
- 750microgram, 1 mg and 4 mg m/r tablets (Envarsus®)
- approved for the treatment of renal and liver transplant patients who are suffering from neurotoxicity with other formulations or for patients requiring large doses of tacrolimus.
- For Transplant indications
unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes .
|
13.05.03 |
Tacrolimus ointment Protopic® |
- Approved for moderate to severe disease atopic eczema in patients over 2 years in line with NICE.
|
02.05.01 |
Tadalafil |
- Approved for pulmonary hypertension in adults for whom treatment with sildenafil is not tolerated or effective (in accordance with NHS England Commissioning policy).
- Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
- Approved for secondary Raynaud's.
|
07.04.05 |
Tadalafil |
- 10mg and 20mg tablets
- Approved for the treatment of erectile dysfunction
- Also approved for specialist use in treating secondary Raynaud's disease.
![Red Traffic Light](images/TrafficLightsRedV2.gif)
- 5mg tablets (once daily)
- Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)
|
11.06 |
Tafluprost Saflutan® |
|
11.06 |
Tafluprost 15microg with timolol 0.5% eye drops |
|
08.01.05 |
Talazoparib Talzenna® |
- 0.25mg and 1mg capsule
- Approved or HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults in line with NICE
|
03.12 |
Talc (sterilised) BP |
- Pleurodesis. Intrapleural administration via chest drain
|
08.01.05 |
Talimogene laherparepvec |
- Approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy (SSC1679).
|
07.05.01.01 |
Tamoxifen |
|
08.03.04.01 |
Tamoxifen |
- Approved formulations include:
- 10mg and 20mg tablets;
- 10mg in 5ml sugar free oral solution.
|
07.04.01 |
Tamsulosin 400microgram MR capsules |
|
04.07.02 |
Tapentadol |
- Approved for use by chronic pain specialist in adults with severe pain who have been screened for a neuropathic element to their pain and are uncontrolled or experiencing GI side effects on existing therapy.
|
13.05.02 |
Tar Pomade (6% coal tar solution & 2% salycylic acid in emulsifying ointment) |
|
02.08.01 |
TauroHep® |
- Approved for use in the prevention of central intravenous line infections
in; haemodialysis patients, adult parenteral nutrition patients, patients with recurrent line infections, and immune deficiency unit patients.
|
19 |
Tauroldine 2% solution |
|
02.08.01 |
TauroLock® |
- Approved for use in the prevention of central intravenous line infections in; haemodialysis patients, adult parenteral nutrition patients, patients with recurrent line infections, and immune deficiency unit patients.
|
05.01.07 |
Tedizolid Sivextro® |
- 200mg tablet and 200mg powder for concentrate for solution for infusion
- Approved for thre treatment of bacterial skin and skin structure infections only on the advice of microbiologists/ID physicians
|
01.04.02 |
Teduglutide Revestive® |
- Approved for treating short bowel syndrome in people 1 year and above in line with NICE
|
18.02.02 |
Tegaderm Film |
- IV/sc dressing and podiatry use only
|
18.03.03 |
Tegaderm® Alginate Ag |
Calcium alginate and carboxymethylcellulose dressing with silver |
18.02.02 |
Tegaderm® with pad |
|
08.01.03 |
Tegafur with Gimeracil and Oteracil |
|
08.01.03 |
Tegafur with Uracil |
- Approved for metastatic colorectal cancer in line with NICE.
|
05.01.07 |
Teicoplanin |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
04.01.01 |
Temazepam |
|
15.01.04.01 |
Temazepam |
|
05.01.01.02 |
Temocillin |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
08.01.05 |
Temozolomide |
- Approved for the treatment of recurrent malignant glioma in line with NICE.
- Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
|
08.01.05 |
Temsirolimus Torisel® |
|
02.10.02 |
Tenecteplase Metalyse® |
|
05.03.01 |
Tenofovir Disoproxil |
|
05.03.03.01 |
Tenofovir Disproxil Viread® |
|
05.03.01 |
Tenofovir Disproxil & Cobicistat & Elvitegravir & Emtricitabine |
- To be used in accordance with NHS England Clinical Commissioning Policy.
|
05.03.01 |
Tenofovir Disproxil & Efavirenz & Emtricitabine |
|
08.02 |
Tepotinib Tepmetko® |
- Approved for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults in line with NICE.
|
05.02.05 |
Terbinafine |
|
13.10.02 |
Terbinafine 1% cream |
|
03.01.01.01 |
Terbutaline |
- Turbohaler® 500 mcg/puff (DPI)
|
07.01.03 |
Terbutaline |
- Ampoules: 500micrograms/ml
|
03.01.01.01 |
Terbutaline Injection |
|
03.01.01.01 |
Terbutaline Nebules |
- 2.5mg/ml nebuliser solution
|
08.02.04 |
Teriflunomide |
- Approved as a option for treating adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis NICE and NHS England Commissioning Policy.
|
06.06.01 |
Teriparatide 250microgram in 1ml prefilled pen Biosimilar brands - Movymia®,Terrosa® & Teva |
- Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.**All new patients**
- Approved for the treatment of osteoporosis in males and juveniles in line with NHSE Commissioning Policy
|
06.06.01 |
Teriparatide 250microgram in 1ml prefilled pen Forsteo® |
- Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE. **Exisiting patients only**
- Approved for the treatment of osteoporosis in males and juveniles in line with NHSE Commissioning Policy
|
06.05.02 |
Terlipressin 1mg injection |
|
06.04.02 |
Testosterone 1ml injection Sustanon 250® |
- Sustanon® 250 1ml injection contains testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg and testosterone decanoate 100mg.
|
06.04.04 |
Testosterone 1ml injection Sustanon® 250 |
- Sustanon® 250 1ml injection contains testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg and testosterone decanoate 100mg.
|
06.04.02 |
Testosterone Enantate |
- 250mg/ml solution for injection ampoules
|
06.04.02 |
Testosterone Gel |
Testogel®
- Gel pump dispenser 16.2mg/g (60 x 1.25g metered doses)
- Approved for hypogonadism on the advice of an endocrinologist
![Green plus](images/TrafficLightsGreenPlus.gif)
- 2.5g sachets (40.5mg/2.5g)
- Approved for hypogonadism on the advice of an endocrinologist
![Green plus](../images/TrafficLightsGreenPlus.gif)
- Management of low libido in menopausal (both natural and surgical) and post-menopausal women (unlicensed indication) in accordance with attached guidance
![Green](../images/TrafficLightsGreenV2.gif)
Tostran®
- 10mg in 0.5ml (2%)/metered dose
- Approved for hypogonadism on the advice of an endocrinologist
- Management of low libido in menopausal (both natural and surgical) and post-menopausal women (unlicensed indication) in accordance with attached guidance
![Green](../images/TrafficLightsGreenV2.gif)
Testavan®
- 20mg/g transdermal gel
- Approved for hypogonadism on the advice of an endocrinologist
|
06.04.04 |
Testosterone Gel |
- 23 mg/1.15 g (23 mg per actuation); 85.5 g (Testavan®)
- 50 mg/5 g (50 mg per tube); 30 tubes (Testim®)
- 16.2 mg/g (20.25 mg per actuation); 88 g (Testogel®)
- 50 mg/5 g sachet; 30 sachets (Testogel®)
- 20 mg/g (10 mg per actuation); 60 g (Tostran®)
|
06.04.04 |
Testosterone undecanoate 1gram in 4ml oily injection Nebido® |
1g in 4 mL (250 mg/ml oily injection) |
06.04.02 |
Testosterone undecanoate oily injection Nebido® |
- 1g in 4 mL injection (250 mg/mlL oily injection)
|
14.05.02 |
Tetanus immunoglobulin |
|
14.04 |
Tetanus vaccine |
|
04.09.03 |
Tetrabenazine |
- For use on the advice of neurologists.
|
15.02 |
Tetracaine (Amethocaine) Ametop® |
|
11.07 |
Tetracaine 1% Minims® |
|
06.05.01 |
Tetracosactide Synacthen® |
- Approved formulations include:
- 250microgram in 1ml injection;
- 1mg in 1ml depot injection.
|
09.02.02.02 |
Tetrastarch Volulyte® |
- 6% tetrastarch infusion in a balanced electrolyte solution containing Na+ 137 mmol, K+ 4 mmol, Mg2+ 1.5 mmol, Cl110 mmol, acetate 34 mmol/litre.
Contains calcium.
- Mainly for use in indications where calcium containing fluids are unsuitable
|
09.02.02.02 |
Tetrastarch Tetraspan® |
- 6% & 10% tetrastarch infusions in a balanced electrolyte solution containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 1 mmol, Cl- 118 mmol, Ca2+ 2.5 mmol, acetate 24 mmol, malate 5 mmol/litre.
Contains calcium
|
03.07 |
Tezacaftor and ivacaftor Symkevi® |
- Ivacaftor 75g/tezacaftor 50mg tablet & ivacaftor 100mg/tezacaftor 150mg tablet
- Approved for the treatment of cystic fibrosis in line with NHS England Commissioning Policy
- Only available from:
- South Tees Hopsitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
|
03.07 |
Tezacaftor with ivacaftor and elexacaftor Kaftrio® |
- Ivacaftor 75g/tezacaftor 50mg/elexacaftor 100mg & Ivacaftor 37.5mg/tezacaftor 25mg/elexacaftor 50mg tablet
- Approved for the treatment of cystic fibrosis in line with NHS England Commissioning Policy
- Only available from:
- South Tees Hopsitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
|
03.04.02 |
Tezepelumab Tezspire® |
- 210mg/1.91ml solution for injection (pre-filled devices)
- Approved for treating severe asthma in paeople 12 years and over in line with NICE and NHS England Specialised Commissioning Policy (SSC2536)
- Only available from:
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
- South Tyneside and Sunderland NHS Foundation Trust
- South Tees Hopsitals NHS Foundation Trust
|
08.02.04 |
Thalidomide |
- Approved in combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE.
- Approved for the treatment of bleeding from bowel angiodysplasia in patients with an inherited/acquired bleeding disorder on specialist advice only.
- Approved for the treatment of severe epistaxis as a result of hereditary haemorrhagic telangiectasia (HHT) who have failed all other treatments.
|
03.01.03 |
Theophylline Uniphyllin ® |
- 200mg, 300mg and 400mg MR tablet
Green plus50 mg/5 mL oral solution - unlicensed
|
09.06.02 |
Thiamine |
|
15.01.01 |
Thiopental Sodium 500mg/20ml injection |
|
08.01.01 |
Thiotepa |
|
04.08.01 |
Tiagabine |
|
06.04.01.01 |
Tibolone |
|
02.09 |
Ticagrelor |
- Only approved for use in accordance with NICE guidance.
|
14.04 |
Tick-borne encephalitis vaccine |
|
05.01.03 |
Tigecycline |
|
13.05.03 |
Tildrakizumab Ilumetri® |
- 100 mg solution for injection in pre-filled syringe
- Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
|
13.04 |
Timodine® |
|
11.06 |
Timolol |
- 0.25% and 0.5% eye drops.
0.25% and 0.5% unit dose eye drops.
|
05.04.02 |
Tinidazole |
- 500mg tablets
- Last line option for resistant Trichomonas vaginalis
unlicensed
|
02.08.01 |
Tinzaparin |
- Use during pregnancy and for pre-operative bridging therapy
.
|
08.01.03 |
Tioguanine |
- 50mg in 1ml suspension is also approved.
unlicensed
|
09.08.01 |
Tiopronin |
- 500mg tablets - for use as 2nd line treatment for cystinuria in
patients who fail to tolerate/respond to penicillamine unlicensed.
|
03.01.02 |
Tiotropium Respimat® |
- 2.5mg Respimat® inhaler
- Step 4 of the BTS/SIGN Asthma guidelines. Treatment should be stopped if not effective.
|
03.01.02 |
Tiotropium Handihaler® |
- 18 mcg inhalation powder capsule (Handihaler®) (DPI)
- For existing COPD patients only and those unable to use the other LAMA devices. Consideration should be given to switching at next review, providing adequate training / counselling is provided in device use.
|
03.01.04 |
Tiotropium & olodaterol Spiolto Respimat® |
- Tiotropium 2.5 microgram/dose & olodaterol 2.5 microgram/dose pressurised metered dose inhaler - (pMDI)
|
05.03.01 |
Tipranavir |
|
13.08.01 |
Tirbanibulin ▼ |
|
02.09 |
Tirofiban |
|
06.01.02.03 |
Tirzepatide Mounjaro® |
- 2.5mg/0.6ml & 5mg/0.6ml solution for injection (pre-filled pens)
- Approved for treating type 2 diabetes in line with NICE
|
08.01.05 |
Tisagenlecleucel |
- Approved for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under in line with NICE
|
08.01.05 |
Tivozanib Fotivda® |
- Capsules: 890 mg and 1340 mg
|
10.02.02 |
Tizanidine |
- Approved for use on advice from neurologists when other treatments are unsuitable.
|
05.01.04 |
Tobramycin |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
- 80mg in 2ml & 240mg in 6ml injections.
- 300mg in 4ml (Bramitob®).
- 300mg in 5ml (Tobi®).
- TOBI Podhaler.
- Inhaled preparations to be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.
|
10.01.03 |
Tocilizumab RoActemra® |
- IV preparations approved for:
- Systemic JIA in children and young people aged 2 years and older in line with NICE.
- People aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to previous therapy with methotrexate in line with NICE.
- An alternative treatment to anakinra for patients with systemic onset JIA who have already received treatment with etanercept and adalimumab (NETAG approval). Not recommended for polyarticular JIA.
- Rheumatoid arthritis in accordance with NICE.
- Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
- 162mg SC injection is approved for:
- Rheumatoid arthritis in accordance with NICE.
- Giant cell arteritis in adults only if:
- they have relapsing or refractory disease
- they have not already had tocilizumab
- tocilizumab is stopped after 1 year of uninterrupted treatment at most.
- Monitoring: monitoring of tocilizumab in adult patients can be undertaken by GPs under a shared care arrangement
![Amber](images/TrafficLightsAmberV2.gif)
|
01.05.03 |
Tofacitinib Xeljanz® |
- 5mg and 10mg tablets.
- Approved for the treatment of moderate to severe active ulcerative colitis in line with NICE
|
10.01.03 |
Tofacitinib Xeljanz® |
- 5mg and 10mg tablets.
- Approved for treating junveline idiopathic arthritis in line with NICE
- Approved for the treatment of active psoriatic arthritis after inadequate response to DMARDs in line with NICE.
- Approved for the treatment of moderate to severe rheumatoid arthritis in adults in line with NICE.
- Approved for for treating active ankylosing spondylitis in line with NICE
|
06.01.02.01 |
Tolbutamide |
|
04.09.01 |
Tolcapone |
|
07.04.02 |
Tolterodine 1mg and 2mg tablets |
|
06.05.02 |
Tolvaptan |
- 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc®) - approved for the treatment of autosomal dominant polycystic kidney disease in line with NICE.
- 15mg and 30mg tablets (Samsca®) - approved for the treatment of hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy in accordance with NHS England Policy.
|
04.07.04.02 |
Topiramate |
- MHRA Drug Safety Update (July 2022): Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
|
04.08.01 |
Topiramate |
|
08.01.05 |
Topotecan |
- Approved for relapsed NSCLC in line with NICE.
- Approved for recurrent or stage IVB cervical cancer in line with NICE.
- Approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE.
- Approved for the treatment of recurrent ovarian cancer in line with NICE.
|
02.02.02 |
Torasemide |
|
08.01.05 |
Trabectedin |
Approved for the treatment of recurrent ovarian cancer in line with NICE. |
13.05.03 |
Tralokinumab Adtralza® |
- Approved for the treatment of moderate to severe atopic dermatitis in line with NICE
|
04.07.02 |
Tramadol |
- 50mg capsules, 50mg dispersible tablets & 100mg/2ml injection
- Only approved for use as a second-line weak opioid analgesic for use in patients where treatment with possible alternatives such as paracetamol, NSAIDs, and codeine is insufficiently effective, not tolerated or considered unsuitable for other reasons.
- Note: modified release tramadol is not approved or recommended.
|
06.01.05 |
Tramadol |
- 50mg capsules, 50mg dispersible tablets & 100mg/2ml injection
|
08.01.05 |
Trametinib |
- Approved in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in line with NICE and NHS England Commissioning Policy.
- Approved for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC) in line with NHSE Specialised Commissioning Policy
|
02.11 |
Tranexamic Acid |
- Also available as a 500mg in 5ml syrup
unlicensed.
|
02.11 |
Tranexamic Acid Injection |
- 100mg/ml Solution for Injection
|
12.03.04 |
Tranexamic Acid Mouthwash |
|
18.07.03 |
Transpore® |
Permeable Non-woven Synthetic Adhesive Tape, BP 1988
|
19 |
Transvasin® Heat Rub Cream |
- Approved to arterialise earlobe capillary blood to facilitate capillary blood testing
|
08.01.05 |
Trastuzumab |
- Approved for metastatic or locally advanced inoperable gastric cancers in line with NICE.
- Approved for early stage HER2-positive breast cancer in line with NICE.
- Approved for advanced HER2-positive breast cancer in line with NICE.
- Note: trastuzumab is not recommended in combination with an aromatase inhibitor for the first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses HER2 - in line with NICE.
- Trastuzumab 600mg subcutaneous injection is approved by NHS England for HER2-positive breast cancer in line with NECN guidance.
|
08.01.05 |
Trastuzumab deruxtecan Enhertu |
Vial: powder for concentrate for infusion, 100 mg |
08.01.05 |
Trastuzumab emtansine Kadcyla® |
- 100mg & 160mg powder for concentrate for solution for infusion
- Approved for the treatment of HER2-positive advanced breast cancer after trastuzumab and a taxane in line with NICE and NHS England Commissioning Policy
- Approved for human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy in line with NICE
|
11.06 |
Travoprost |
Eye drops: 40 micrograms/1 mL |
11.06 |
Travoprost with Timolol |
Eye drops: travoprost 40 micrograms/1 mL, timolol 5 mg/1 mL (DuoTrav®) |
04.03.01 |
Trazodone |
- Trazodone is widely used off-license for night sedation and behavioural symptoms of dementia.
|
08.01.01 |
Treosulfan Trecondi® |
- Approved in combination with fludarabine for malignant disease before allogeneic stem cell transplant in line with NICE and NHS England Commissioning Policy
|
02.05.01 |
Treprostinil |
- Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
|
08.01.05 |
Tretinoin |
|
13.06.01 |
Tretinoin 0.025% with Clindamycin 1% gel Treclin® |
|
11.08.02.04 |
Tretinoin 0.05% eye drops |
|
13.06.01 |
Tretinoin with antibacterial Aknemycin® Plus |
|
10.01.02.02 |
Triamcinolone Acetonide |
- The following triamcinolone acetonide preparations are approved:
- Kenalog® - 40mg in 1ml and intramuscular/intra-articular injection.
- Adcortyl® - 50mg in 5ml intradermal/intra-articular injection.
|
11.04.02 |
Triamcinolone Acetonide Intracinol® |
- 40mg in 1ml ophthalmic suspension injection
- Approved for use in patients with pre-operative diabetic macular oedema (DMA) and epiretinal membrane undergoing vitreoretinal surgery
|
06.03.02 |
Triamcinolone acetonide 40 mg in 1ml |
|
12.02.01 |
Triamcinolone Acetonide 55microgram metered dose nasal spray Nasacort® |
|
10.01.02.02 |
Triamcinolone hexacetonide 20mg in 1ml |
- Only approved for paediatric use.
|
12.01.01 |
Triamcinolone with neomycin, gramicidin and nystatin Kenacomb Otic® |
- Triamcinolone acetonide 1mg, neomycin sulphate 2.5mg, gramicidin 0.25mg & nystatin 100,000iu/5g ointment
unlicensed
|
13.07 |
Trichloroacetic Acid |
|
09.08.01 |
Trientine Dihydrochloride |
- 300mg capsules
- Approved for the treatment of Wilsons disease in line with NHS England Commissioning Policy. NHS England will commission the treatment for patients who are currently being treated (April 2017)
|
04.02.01 |
Trifluoperazine |
|
11.03.03 |
Trifluorothymidine |
|
08.01.03 |
Trifluridine and tipiracil |
- Approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy (SSC1662).
|
04.09.02 |
Trihexyphenidyl |
|
05.01.08 |
Trimethoprim |
|
06.07.02 |
Triptorelin |
- The following formulations are approved for use in treating precocious puberty:
- Gonapeptyl Depot® 3.75mg injection;
- Decapeptyl SR®11.25mg injection.
- Refer to Chapter 8 - Gonadorelin analogues for the treatment of prostate cancer. The following strengths are approved:
|
08.03.04.02 |
Triptorelin |
- Approved formulations include triptorelin 3mg, 11.25mg and 22.5mg IM injection for the treatment of prostate cancer
- Please note for the treatment of precocious puberty please refer to Chapter 6 Drugs affecting gonadotrophins
|
06.04.04 |
Triptorelin Injection |
3 mg, 3.75 mg, 11.25 mg and 22.5 mg |
09.02.02 |
Trometamol (THAM) |
|
11.05 |
Tropicamide single use Minims® |
|
07.04.02 |
Trospium |
|
14.04 |
Tuberculin Purified Protein Derivative |
|
08.01.05 |
Tucatinib Tukysa® |
- Approved in combination with trastuzumab and capecitabine for HER2‑positive locally advanced or metastatic breast cancer in adults after 2 or more anti‑HER2 treatment therapies in line with NICE
|
14.04 |
Typhoid vaccine |
|
09.08 |
Ubidecarenone |
|
09.08.01 |
Ubiquinone Coenzyme Q10, Ubidecarenone |
- 10mg, 30mg, & 100mg capsules
- 50mg in 5ml & 30mg in 1ml (150mg in 5ml) oral solution
- nutritional supplement and antioxidant approved for use in the
management of mitochondrial disorders.
- Approved for use under specialist consultant supervision in the
management of patients with severe hyperlipidaemia who are not tolerating statins due to myopathy. Use in statin induced myopathy is subject to treatment being initiated by a consultant.
- Lipid clinic initiation only
|
18.05 |
UCS® Debridement |
|
06.04.01.02 |
Ulipristal Esmya® |
- 5mg tablets
- Approved for the pre-operative treatment of uterine fibroids for one 3 month course, as per its product licence.
- Approved for the medical treatment of uterine fibroids in women unsuitable for surgery, up to a maximum of four 3 month intermittent courses, as per its product licence and reviewed regularly.
- Contraindicated in women with underlying liver disorders.
- Requirements for liver function monitoring before, during, and after treatment
|
07.03.05 |
Ulipristal 30mg tablet ellaOne® |
- Recommended by NTAG as the preferred drug treatment option for post-coital contraception for patients who present between 72 and 120 hours following unprotected intercourse.
|
03.01.02 |
Umeclidinium Incruse Ellipta® |
- 55 microgram/dose (equivalent to umeclidinium bromide 65m microgram/dose) dry powder inhaler (DPI)
|
03.01.04 |
Umeclidinium & vilanterol Anoro Ellipta® |
- Umeclidinium55 microgram/dose & vilanterol 22 microgram/dose (equivalent to umeclidinium bromide 65 microgram/dose & vilanterol (as vilanterol trifenatate) 22 microgram/dose) dry powder inhaler (DPI)
|
01.05.03 |
Upadacitinib Rinvoq® |
- 15 and 30mg tablets
- Approved for the treatment of moderate to severe active ulcerative colitis in line with NICE
- Approved for previously treated moderately to severely active Crohn's disease in line with NICE
|
10.01.03 |
Upadacitinib Rinvoq® |
- Approved for the treatment of severe active rheumatoid arthritis in adults in line with NICE.
- Approved for the treatment of moderate rheumatoid arthritis in line with NICE.
- Approved for the treatment of active psoriatic arthritis after inadeqaute response to DMARDs in line with NICE.
|
13.05.03 |
Upadacitinib Rinvoq® |
- Approved for the treatment of moderate to severe atopic dermatitis in line with NICE
|
18.02.03 |
Urgotul® |
Non-adherent soft polymer wound contact dressing
|
17 |
Urografin 150® |
|
02.10.02 |
Urokinase |
|
01.09.01 |
Ursodeoxycholic acid |
|
01.05.03 |
Ustekinumab Stelara® |
- 130 mg concentrate for solution for infusion
- Approved for previously treated moderately to severely active Crohn’s disease in adults in line with NICE
- Approved for treating moderately to severely active ulcerative colitis in line with NICE
|
10.01.03 |
Ustekinumab Stelara® |
- Approved for psoriatic arthritis in accordance with NICE.
|
13.05.03 |
Ustekinumab Stelara® |
- 45mg & 90mg SC injections approved for psoriasis in line with NICE.
- Approved for the treatment of plaque psoriasis in children and young people in line with NICE
|
13.08.01 |
Uvistat Sun Cream® |
|
18.06.01 |
V.A.C.® Dressing |
|
07.04.02 |
Vaginal Devices |
- Vaginal Devices for female stress urinary incontinence (e.g. Diveen, Contiform, Efemia)
- Approved for use in line with NTAG / NICE
- Product should only be initiated by a specialist pelvic health physiotherapists and specialist nurses
|
05.03.02.01 |
Valaciclovir |
|
05.03.02.02 |
Valganciclovir |
|
04.02.03 |
Valproic Acid Depakote® |
- Licensed alternative to sodium valproate MR tablets.
Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP) ![Amber](images/TrafficLightsAmberV2.gif)
▼Black Triangle in females
For information relating to alerts regarding valproate, including Drug Safety Updates and links to PPP materials, please use the following link:
MHRA Drug Safety Updates (valproate) |
02.05.05.02 |
Valsartan |
- Only to be used in the treatment of existing patients.
|
11.03.01 |
Vancomycin |
|
05.01.07 |
Vancomycin Injection |
Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
- 20mg in 4ml intrathecal injection
unlicensed
- 500mg and 1g injections
|
05.01.07 |
Vancomycin Oral Preparations |
- Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
|
07.04.05 |
Vardenafil |
- 5mg, 10mg and 20mg tablets
- Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)
|
04.10.02 |
Varenicline |
- Only approved for use in accordance with NICE guidance.
- RAG status as per local commissioning arrangements.
|
14.04 |
Varicella Zoster vaccine Zostavax® |
|
14.05.02 |
Varicella-Zoster immunoglobulin VZIG |
|
14.04 |
Varicella-zoster vaccine |
|
15.01.05 |
Vecuronium Norcuron® |
|
01.05.03 |
Vedolizumab |
- Only approved for use in accordance with NICE guidance.
|
09.08.01 |
Velaglucerase |
|
09.08.01 |
Velmanase alfa Lamzede ® |
- 10mg powder for solution for infusion
- Approved for treating alpha-mannosidosis in line with NICE and NHS England Specialised Commissioning Policy
|
08.01.05 |
Vemurafenib |
- Approved melanoma (BRAF V600 mutation positive, unresectable metastatic) in line with NICE.
|
08.01.05 |
Venetoclax Venclyxto® |
- Approved in combination with rituximab for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy in line with NICE
- Approved in combination with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable in line with NICE
- Approved in combination with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable in line with NICE.
- Approved for the treatment of chronic lymphocytic leukaemia in adults:
- with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
- without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor in line with NICE
|
04.03.04 |
Venlafaxine |
- For patients on doses of 300mg/day or more.
![Green Traffic Light](images/TrafficLightsGreenplus.gif)
|
02.06.02 |
Verapamil |
- Tablets - 40mg, 80mg, 120mg, 160mg
- MR Tablets - 240mg
- Oral Solution - 40mg/5ml
|
02.06.02 |
Verapamil Injection |
- Injection: 5mg/2ml (2.5mg/1ml)
|
11.08.02 |
Verteporfin 15mg Injection Visudyne® |
Approved for photodynamic therapy in wet age-related macular degeneration in line NICE. |
04.08.01 |
Vigabatrin |
|
08.01.04 |
Vinblastine Sulphate |
|
08.01.04 |
Vincristine Sulphate |
|
08.01.04 |
Vindesine Sulphate |
|
08.01.04 |
Vinorelbine |
- The following formulations are approved for use:
- 20mg & 30mg capsules;
- 10mg in 1ml injections;
- 50mg in 5ml injections.
|
16 |
Viper Venom Antivenom |
|
09.06.01 |
Vitamin A |
- 20,000 unit injection - for the treatment of night blindness/ vitamin A deficiency as a result of malabsorption in patients with short bowel syndrome, ileal resection or pancreatic insufficiency
unlicensed.
|
09.06.02 |
Vitamin B & C injection Pabrinex® |
- IVHP injection (ascorbic acid 500mg, nicotinamide 160mg, pyridoxine
hydrochloride 50mg, riboflavin 4mg & thiamine hydrochloride 250mg & 1g anhydrous glucose / pair of ampoules)
- IMHP injection also used
|
09.06.02 |
Vitamin B Tablets, Compound Strong |
- Tablets (nicotinamide 20mg, pyridoxine hydrochloride 2mg, riboflavin 2mg & thiamine hydrochloride 5mg per tablet).
|
09.06.01 |
Vitamins A and D |
- Capsules containing vitamin A 4000 units, vitamin D 400 units
|
08.02.02 |
Voclosporin Lupkynis® |
- 7.9mg capsules
- Approved with mycophenolate mofetil for treating lupus nephritis in adults in line with NICE and NHSe Specialised Commissioning Policy (SSC2540)
- Only available from:
- North Cumbria University Hospital NHS Trust
- South Tyneside and Sunderland NHS Foundation Trust
- South Tees Hopsitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
|
19 |
Volanesorsen Waylivra® |
- Approved for treating familial chylomicronaemia syndrome in adults in line with NICE
|
03.01.05 |
Volumatic® |
|
05.02.01 |
Voriconazole |
|
11.03.02 |
Voriconazole |
- 100microgram in 0.1ml (0.1%) - preservative-free eye drops.
|
04.03.04 |
Vortioxetine |
- Only approved for use in accordance with NICE guidance.
|
04.12 |
Vutrisiran Amvuttra® |
- Approved as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy - in line with NICE TA868.
- Summer 2023 - Only one centre in London commissioned to provide this drug for patients in England.
|
02.08.02 |
Warfarin |
- 500 microgram, 1mg, 3mg & 5mg tablets
.
- 1mg/1ml oral suspension - - for use in paediatric patients on mechanical support using ventricular assistance devices, and for patients with mechanical heart valves or irregular heart rythms who have not been weaned
.
|
03.12 |
Water |
|
07.04.04 |
Water |
- Large volumes - up tp 3 litres.
|
09.02.02.01 |
Water for Injection Viaflo® - FE0304 |
- Approved for use by the North-East Assisted Ventilation Service (NEAVS)
- to be prescribed in boxes of 10
|
09.02.02.01 |
Water for Injection |
- 2ml, 5ml, 10ml, 20ml, 100ml & 500ml
|
09.02.02.01 |
Water for Irrigation |
|
13.11.01 |
Water for Irrigation |
|
03.04.02 |
White birch (Betula verrucosa) 12 SQ-Bet* per oral lyophilisate ITULAZAX® 12 SQ-Bet oral lyophilisate |
- For moderate to severe allergic rhinitis and/or conjunctivitis due to tree pollen (birch homologous group)
|
13.02.01 |
White Soft Paraffin BP |
|
07.04.04 |
Whitmore cocktail |
- Whitmore cocktail is a 60ml bladder installation containing hydrocortisone 100mg, heparin Sodium 10,000units, and bupivacaine 50mg in Sodium Chloride 0.9%.
|
11.08.01 |
Xailin Night |
White soft paraffin and mineral oil |
19 |
Xelma® |
|
12.02.02 |
Xylometazoline Otrivine® |
- 0.05% and 0.1% nasal drops.
- 0.1% nasal spray.
|
14.04 |
Yellow fever vaccine (Live) |
Only available from designated Yellow Fever Vaccination Centres. |
13.02.01 |
Yellow Soft Paraffin BP |
|
08.01.05 |
Zanabrutinib Brukinsa |
- 80mg capsule
- Approved for the treatment of chronic lymphocytic leukaemia in line with NICE and NHSE Specialised Commissioning guidance
|
05.03.04 |
Zanamivir Relenza® |
- 5mg inhalation powder blisters with Diskhaler
- Only approved for use in accordance with NICE guidance.
|
05.03.04 |
Zanamivir Injection Dectova® |
- 200mg/20mL solution for infusion
- Approved on the advice of virology/microbiology/ID physician only
|
08.01.05 |
Zanubrutinib Brukinsa 80mg capsules® |
|
13.02.01 |
ZeroAQS® |
- SLS free alternative to Aqueous Cream.
|
13.02.01 |
Zerobase® |
|
13.02.01 |
Zerocream® |
- Alternative to E45® Cream.
|
13.02.01 |
Zerodouble® Gel |
- Alternative to Doublebase gel.
|
13.02.01 |
Zeroveen® cream |
|
18.01.02 |
Zetuvit Plus® |
Super absorbent cellulose primary dressing
|
18.01.02 |
Zetuvit® E |
Absorbent Cellulose Dressing with Fluid Repellent Backing
|
05.03.01 |
Zidovudine |
|
05.03.01 |
Zidovudine & Lamivudine |
|
09.08.01 |
Zinc Acetate Wilzin® |
|
13.05.02 |
Zinc and Coal Tar Paste White's Tar Paste |
|
13.05.02 |
Zinc and Salicylic Acid Compound Paste Half Strength Lassar's Paste |
|
13.05.01 |
Zinc oxide bandage Viscopaste® |
|
18.08.09 |
Zinc Paste and Ichthammol Bandage, BP 1993 Ichthopaste® |
|
18.08.09 |
Zinc Paste Bandage, BP 1993 Viscopaste® PB7 |
|
09.05.04 |
Zinc Sulphate Solvazinc® |
|
09.05.04 |
Zinc Sulphate 220mg capsules |
|
09.05.01.02 |
Zoledronic Acid Zometa® |
- 4mg injection
For hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer. Prescribe by brand name (Zometa®) to avoid confusion with a different strength product used to treat osteoporosis and Paget’s disease
|
06.06.02 |
Zoledronic Acid 4mg injection |
- Approved for use in treating hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer.
- Approved for the adjuvant treatment of post-menopausal women with early breast cancer (subject to agreement with the CCGs and provider trusts regarding the extra activity).
- Not approved for preventing skeletal events in patients with prostate cancer.
- To avoid confusion it is recommended that this product is prescribed by brand name i.e. Zometa®
|
06.06.02 |
Zoledronic Acid 5mg injection |
- Prescribe by brand name
- Approved for the treatment of osteoporosis in line with NICE
|
04.07.04.01 |
Zolmitriptan 2.5mg tablets |
|
04.01.01 |
Zolpidem |
|
04.08.01 |
Zonisamide |
- For use only in patients that are refractory to treatment with other drugs on the recommendation of a specialist
- Use in children is
unlicensed.
|
04.01.01 |
Zopiclone |
- To be used in accordance with NICE criteria
|
04.02.01 |
Zuclopenthixol |
|
04.02.02 |
Zuclopenthixol Acetate Clopixol Acuphase® |
- For short-term use by NTW.
|
04.02.02 |
Zuclopenthixol Decanoate |
CNTW
TEWV
|